Categories
Report

BRAND NEW PROFILE: USAU

OUR NEW PROFILE IS:  (NASDAQ: USAU)

ALLIANCE GLOBAL PARTNERS ANALYST, JAKE SEKELSKY, PUT A $25.00 TARGET ON USAU

ELECTRIC VEHICLES USE MORE THAN DOUBLE THE COPPER OF AN INTERNAL COMBUSTION ENGINE AUTOMOBILE, AND THE METAL IS ALSO USED HEAVILY IN EV INFRASTRUCTURE. COPPER IS KEY TO ELECTRIC VEHICLES, WIND, AND SOLAR POWER, AS WELL AS THE INFRASTRUCTURE THAT TRANSPORTS AND STORES RENEWABLE ENERGY

U.S. FOCUSED GOLD EXPLORATION AND DEVELOPMENT COMPANY ADVANCING HIGH POTENTIAL PROJECTS IN WY, NV AND ID

VIEW THE INVESTOR PRESENTATION HERE

_________________

Hello Everyone,

2

We have another profile for tomorrow’s session that we want you to take a look at and research.

Pull up USAU immediately.

Let’s take a look at some of the major catalysts:

  • Promising portfolio, instable and mining friendly
    U.S. jurisdictions. The portfolio offers investors both potential near- term production and sizeable blue-sky exploration
  • Team of accomplished explorers and proven company builders, who have made, and financed, the discovery and development of numerous world class gold assets
  • CK Gold Project offers potential exposure to compelling value, and potential near-term production in mining friendly Wyoming
  • Keystone offers exposure to significant potential exploration upside– entire districts on Nevada’s prolific Cortez Trend. We believe Challis Gold to be a high potential exploration project located in Idaho
  • The company has a tight share structure (9.3M shares out standing), with a large audience – listed on NASDAQ

With centuries of history as a store of value in uncertain times, gold is experiencing high levels of demand. (53)

Right now, gold is hovering in record-high territory. Demand for the asset jumped 12% year over year for the first half of 2022, according to a World Gold Council report. (53)

IN FACT, OVER THE PAST YEAR, GOLD IS ALREADY QUIETLY OUTPERFORMING THE S&P 500…(78)

…And even the Tech Heavy Nasdaq (78)

…And even the Tech Heavy Nasdaq (78)

Image Source (78)

The Dow…

The Dow…

…And even the Tech Heavy Nasdaq (78)

…And even the Tech Heavy Nasdaq (78)
Image Source (78)

Some believe the price of gold is set to skyrocket even higher in the weeks and months to come….(78)

Image Source (78)
Image Source (78)
Image Source (78)
Image Source (78)
Image Source (78)
Image Source (78)
Image Source (78)
Image Source (78)
Image Source (78)
Image Source (78)

SOME OF THE WORLD’S SMARTEST INVESTORS ARE JUMPING IN, TOO.(78) DAVID EINHORN, FOUNDER OF GREENLIGHT CAPITAL, OWNS A GOLD POSITION WORTH $40 MILLION. BILLIONAIRE BOND KING JEFFREY GUNDLACH TOLD YAHOO FINANCE: “GOLD IS GOING TO GO A LOT HIGHER.”(78)

EGYPTIAN BILLIONAIRE NAGUIB SAWIRIS SAYS A QUARTER OF YOUR PORTFOLIO SHOULD BE IN GOLD AS INFLATION CREEPS HIGHER… WHILE LEGENDARY HEDGE-FUND MANAGER JOHN PAULSON HAS INVESTED MORE THAN $200 MILLION INTO THIS SPACE. BUT PERHAPS THE MOST SURPRISING WAS WHEN REAL ESTATE BILLIONAIRE SAM ZELL, WHO SPENT HIS CAREER ARGUING AGAINST GOLD… IS NOW BUYING GOLD AS A HEDGE AGAINST INFLATION.
BUT IT DOESN’T STOP THERE…

Billionaire hedge-fund founder Ray Dalio told readers not long ago he sees a paradigm shift happening in the gold market. He compared today’s price movements with historical turning points like: Gold’s historic 2,300% leap in the 1970s from $35 to $850 per ounce after President Nixon took the U.S. off the gold standard…

AND IN THE EARLY 2000S, WHEN GOLD TRIPLED IN VALUE – SOARING FROM UNDER $300 PER OUNCE IN 2000 TO $1,000 BY 2008.(78)

BUT SOME ARE SAYING GOLD COULD GO MUCH HIGHER…

8

Gold surges to 6-month high, and analysts expect records in 2023.(75)

According to commentary published on CNBC.com, Gold prices could surge to $4,000 an ounce in 2023 as recession fears persist, said Juerg Kiener, managing director and chief investment officer of Swiss Asia Capital.

Gold prices could surge to $4,000 per ounce in 2023 as interest rate hikes and recession fears keep markets volatile, said Juerg Kiener, managing director, and chief investment officer of Swiss Asia Capital. (74)

The price of the precious metal could reach between $2,500 and $4,000 sometime next year, Kiener told CNBC’s “Street Signs Asia.”(74)

There is a good chance the gold market sees a major move, he said, adding “it’s not going to be just 10% or 20%,” but a move that will “really make new highs.”(74)

Kiener explained that many economies could face “a little bit of a recession” in the first quarter, which would lead to many central banks slowing their pace of interest rate hikes and make gold instantly more attractive. He said gold is also the only asset that every central bank owns. (74)

According to the World Gold Council, central banks bought 400 tonnes of gold in the third quarter, almost doubling the previous record of 241 tonnes during the same period in 2018. (74)

Driving Demand For Gold(53)

10

There are several factors that have created an almost perfect storm for gold.

Gold’s Role in Electric Vehicles: Gold is a metal that has been used in batteries for electric vehicles (EVs) for many years. While gold is not the most abundant metal on Earth, it is one of the most conductive. It makes gold an ideal material for use in EV batteries, as it helps to ensure that electricity can flow freely and efficiently throughout the battery.(59)

Gold is also non-reactive, meaning it won’t rust or degrade over time, making it a perfect material for long-term use in EVs. While gold is not the most abundant metal on Earth, it is still a very valuable resource essential for producing electric vehicles. (59)

Record High Inflation: Inflation is at a 40-year high. Conflict in eastern Europe snarled supply chains and China’s strict CV-19 response continue to create incredible inflationary pressures. Gold has been a traditional hedge against inflation. When inflation rises, the value of the dollar goes down. Since gold holds its value, it costs more dollars per ounce to purchase. Therefore, the investor can preserve their total wealth. (53)

Aggressive Interest Rate Hikes: With rising prices hurting every American, the Federal Reserve has made taming inflation its priority. To do so, they began a series of increasingly higher interest rate hikes in March. The hikes quickly grew steeper as inflation remained at historic heights.
The price of gold is thought to go down as interest rates go up because higher-yielding investments become more appealing. Yet, there is little evidence that gold is consistently weakened by federal funds rate hikes. (53)

Looming Recession: The Federal Reserve hopes to achieve a “soft landing,” contracting the economy just enough to tame inflation but not cause a recession. Major banks don’t share the Fed’s optimism. Their analysts currently predict that there is a 1 in 3 chance of a recession hitting. Historically, gold increases in value during a recession. (53)

AN ALL-ELECTRIC FUTURE DEPENDS HEAVILY ON COPPER, GOLD, AND OTHER PRECIOUS METALS. (54)

4

Source (62)

An all-electric future depends heavily on copper, gold, and other metals. (54) Looming supply shortfalls could hamper the nations’ goals of reaching net-zero emissions by 2050. (54) Electric vehicles, solar and wind power, and batteries for energy storage all run on copper. An EV requires 2.5 times as much copper as an internal combustion engine vehicle. (54) Copper is used throughout electric vehicles, charging stations, and supporting infrastructure because of the metal’s durability, high conductivity, and efficiency. (72)

Meanwhile, solar and offshore wind need two times and five times, respectively, more copper per megawatt of installed capacity than power generated using natural gas or coal. (54)

Copper is also key to the infrastructure that transports renewable energy, thanks in part to its electrical conductivity and low reactivity. Its uses include cables, transistors, and inverters. (54)

Demand for metals and minerals that fuel our future will ultimately create new world orders, as countries rush to secure supplies of copper, lithium, nickel, and other vital raw materials. (54)

Unless a significant new supply of copper and gold becomes available, climate goals will be short-circuited and remain out of reach.(54)

Recent Reports indicate the potential of over 1,00,000 ounces of Gold and over 240,000,000 million pounds of Copper at U.S. Gold Corp. (NASDAQ: USAU)’s CK Gold Project. (50)

HOW THE INFLATION REDUCTION ACT WILL SPUR A REVOLUTION IN ELECTRIC VEHICLE BATTERY SUPPLY CHAINS (63)

6

Batteries are an essential part of the clean energy transition. The International Energy Agency estimates that demand for battery minerals, including aluminum, copper, cobalt, and lithium, will grow sevenfold by 2030. Domestic mineral supply chains will need to catch up. The United States alone will need 500,000 metric tons per year of unrefined lithium by 2034 just to power EVs, but it currently accounts for only 1 percent of global lithium production. (63)

In the same period, a rapidly industrializing China has created a near-monopoly on many of these minerals. Although it mines around 1 percent of the world’s cobalt, China is responsible for refining and exporting roughly 80 percent of the world’s supply. (63)

To catch up, the United States will need to invest $175 billion in battery production in the next three years.(63)

RECENT REPORTS INDICATE THE POTENTIAL OF OVER 1,000,000 OUNCES OF GOLD AND OVER 240,000,000 MILLION POUNDS OF COPPER AT U.S. GOLD CORP.’S CK GOLD PROJECT. (50)

https://youtube.com/watch?v=TxmuuxNyLrY

The CK Gold Project was reportedly discovered in 1881, was high-graded and saw limited mining. The first exploration work reported was drilling by ASARCO in 1938. Several additional rounds of drilling have been conducted since that time. In 1972 Henrietta Mines Ltd. acquired the property and completed a comprehensive program of exploration and development. (50)

The CK Gold Project property is located in the Silver Crown mining district of southeast Wyoming, approximately 20 miles west of the city of Cheyenne, on the southeastern margin of the Laramie Range. (50)

The property comprises about 1,120 acres (2 square miles) and is 100% owned by U.S. Gold Corp. (50)

The project offers the company near-term, open-pit production potential as well as compelling value. (50)

https://youtube.com/watch?v=AejjzpNcXbY

The CK Gold Project deposit is a development stage, large-tonnage, gold-copper deposit with high-grade mineralization exposed at the surface surrounded by a large, low-grade zone with the potential for expanding resources. The project’s main zone deposit provides a SK-1300 compliant Proven and Probable (P1+P2) reserve and shows the highlights as follows*:(50)

PREFEASIBILITY STUDY HIGHLIGHTS: (50)

Mineral Resources – 1.58 million gold equivalent (“AuEq”) ounces of Measured and Indicated (M+I) Resources (50)
– An additional 0.357 million AuEq ounces of inferred resource
– M+I includes: Gold – 1.110 million ounces and Copper – 280 million lbs
Mineral Reserves – 1.44 million AuEq ounces of Proven and Probable (P1 and P2) Reserves (50)
– P1 and P2 include: Gold – 1.010 million ounces and Copper – 248 million lbs
10-year Mine Life at 20,000 short tons per day process rate(50)
– Average AuEq production: 108,500 ounces per year
– First 3 years: 135,300 AuEq ounces per year
Initial Capital: $221 million (50)
– Potential attractive financing terms from equipment suppliers and development capital sources
– 2-year Payback
Robust Economics – 39.4% IRR before tax and 33.7% IRR after tax (50)
– NPV (5%): $323 million and $266 million, before and after tax, respectively
– All in Sustaining Cost (“AISC”) at $800 per AuEq ounce
– Assumes $1,625/ounce gold price and $3.25/lb copper price
– Highly leveraged to increase metals prices

Upside Potential(50)

– Aggregate sales from mine waste rock, proven to be excellent quality
– FS-level value engineering and plant optimization
– Ongoing metallurgical testing to enhance recovery of gold and copper<
– Resource expansion potential at depth and to the south-east

Permitting and Development (50)

– Project footprint under the jurisdiction of Wyoming agencies
– Potential to submit mine permit in 2022 and receive approval in 2023

The CK Gold Project resource is based upon 160 drill holes totaling 28,500m and contains an oxide, mixed oxide-sulfide, and sulfide rock types. The CK Gold Project mineralization is characterized by an extraordinarily even distribution of metal grades occurring as a large body of disseminated and vein / stockwork gold, silver, and copper mineralization. (50)

The SK-1300 PFS study using base case prices of $1625/oz gold and $3.25/lb copper indicates a 10-year project with a manageable capital requirement of $221 million. (50)

Over the project life, a total of 248.8 million pounds of copper and 1,017,000 ounces of gold are projected to be produced based on the PFS throughput assumptions. The project shows a pre-tax NPV (5%) of $323.3 million and an IRR of 39.4%. The project enjoys an ideal geopolitical location in Wyoming; the State has been very supportive of efforts to advance the project. (50)

U.S. Gold Corp. has assembled a team to both continue expanding CK Gold Project’s current gold and copper resource and to advance the project towards production. In addition, the company is developing effective community and government relations programs in order to minimize any future social challenges. (50)

https://youtube.com/watch?v=bVhgfoQZKZk

U.S. GOLD CORP. ANNOUNCES THE SALE OF ITS INTEREST IN THE MAGGIE CREEK PROPERTY FOR $2.75 MILLION TO TWO OF THE WORLD’S LARGEST MINING COMPANIES.(65)

7

Nevada Gold Mines is a joint venture between Barrick (61.5%) and Newmont (38.5%) that combined our significant assets across Nevada in 2019 to create the single largest gold-producing complex in the world.

Nevada Gold Mines is operated by Barrick.

On November 10, 2022, U.S. Gold Corp. (NASDAQ: USAU) announced the execution on November 9, 2022, of a transaction related to the Maggie Creek Property among Nevada Gold Mines LLC. (65)

The Transaction

Renaissance Exploration, Inc., which is an indirect wholly-owned subsidiary of Orogen, and the Company’s wholly-owned subsidiary, Orevada Metals, Inc., are parties to an Exploration Earn-In Agreement dated February 19, 2019, pursuant to which Orevada, by making certain payments and incurring certain exploration expenditures, has the right to earn at least a 50% interest and up to a 70% interest in the Maggie Creek Property, owned by RenEx, in Eureka County, Nevada. (65)

Pursuant to an Assignment and Assumption Agreement dated November 9, 2022, among NGM, Orogen, RenEx, U.S. Gold, and Orevada, U.S. Gold caused Orevada to assign its interest in the Original Earn-In Agreement to NGM. (65)

Simultaneous with that assignment, NGM and RenEx entered into an Amended and Restated Exploration Earn-In Agreement, pursuant to which NGM can earn a 100% interest in the Maggie Creek Property. (65)

As consideration for the assignment of the Original Earn-In Agreement to NGM, U.S. Gold received an upfront cash payment of $2.75 million dollars from NGM, and NGM agreed that if it exercises the NGM Option and acquires the Maggie Creek Property, it will grant to U.S. Gold a 0.5% Net Smelter Returns royalty on all gold and other recovered and saleable minerals from the Maggie Creek Property, pursuant to a separate royalty agreement between NGM and U.S. Gold, the terms of which have been fully agreed as part of the Transaction. (65)

Under the U.S. Gold Royalty Agreement, NGM will have the right to buy back one-half of the U.S. Gold Royalty (reducing the royalty to 0.25% of Net Smelter Returns) for a fixed price of $500,000.(65)

In addition, the U.S. Gold Royalty Agreement will provide that U.S. Gold waives the first $800,000 of production royalty payments owed to it, regardless of whether NGM exercises its buy-back rights.(65)

Under the U.S. Gold Royalty Agreement, NGM will also have a right of first refusal to purchase the U.S. Gold Royalty if U.S. Gold decides to sell that royalty.(65)

Commenting on the transaction, George Bee, President and CEO of U.S. Gold, said,(65)

“While we have spent the last two years with a laser focus on moving our CK Gold Project along the path to development, we have not lost sight of the excellent exploration portfolio the Company holds. In 2021, we drilled two holes at the south end of our Maggie Creek exploration project. While we knew that we had potential along the entire length of the claims, we followed the reasoning of our then Chief Geologist, Ken Coleman, that the geologic horizon hosting the large gold endowment was a stone’s throw away at NGM’s Gold Quarry Mine and might be within reach on the Maggie Creek Project. Previously, the consensus was that structures along the Carlin Trend had put important gold-bearing host horizons beyond reasonable reach. The holes drilled by U.S. Gold intersected the Popovich Formation, the primary host of Carlin-style gold mineralization, and returned anomalous gold and significant elemental anomalies known to be associated with the most enriched gold deposits in the area. We believe all that remains is to vector into what could be significant occurrences of gold mineralization, judging the extent of the alteration and pathfinder elements, through further exploration.”(65)

Mr. Bee went on to say, “Such exploration is very costly and, for U.S. Gold, drilling Maggie Creek comes at a time when there is not a great deal of appetite in the capital markets to fund the resource sector and exploration in particular. We believe that pursuing deeper high-grade mineralization is best conducted by NGM, who have decades of experience on the Carlin Trend and understand the gold occurrences in the target horizons. We are content to have played a part in what we believe will be another extension to the prolific Carlin Trend, to have recovered more than our investment in the Maggie Creek property, and retained an interest, via a production royalty, for our shareholders in what we hope will be future exploration success. Furthermore, we can now focus exploration efforts on our Keystone property, a 100% owned 20-square mile land package on the Battle Mountain Eureka/Cortez Trend, a highly prospective area just 10 miles on trend from the NGM Cortez Complex.”(65)

U.S. GOLD CORP. – Q1 2023 UPDATE, CK GOLD PROJECT ON TRACK

APRIL 26, 2023

CHEYENNE, Wyo., April 26, 2023 /PRNewswire/ — As U.S. Gold Corp. (“U.S. Gold,” the “Company,” “we,” “our” or “us”) (NASDAQ: USAU) begins the second quarter of calendar year 2023, we would like to inform our shareholders and investors that we remain on track with our objectives. Despite the uncertainty of the financial markets and our banking system, precious metals continue to be primed for a bright future, with gold, silver and copper leading the charge. Precious metal equities continue to outperform on Wall Street and trend towards historic highs. In fact, a Kitco News’ online survey, recently projected that gold’s value could top out the year at a record $2,100 per ounce. This makes us extremely excited about the future of U.S. Gold. Earlier this month we closed a $5 million registered direct offering, to be used for general working capital which puts us in a solid position fiscally.

CK Gold Mine Operating Permit and Reclamation and Closure Plan documents filed with the WY Department of Environmental Quality on September 13, 2022

Those that have been following us closely are aware that in 2020 we pivoted toward the development of our CK Gold Project in Wyoming, lowering priority, for now, on our outstanding exploration assets in Nevada and Idaho. Let there be no mistake, permitting and developing a new mine are not easy tasks. We appreciate the support of our shareholders as we advance through the rigorous steps that are necessary to take our CK Gold Project from a resource with potential, to a wealth and opportunity-generating mine. We believe we are on track.

Update on activities and major milestones for the CK Gold Project

Following the Prefeasibility Study (PFS) published in December 2021, work continued toward a Feasibility Study (FS) which was largely completed in 2022.  The PFS contemplated a gold price of $1625 per ounce and $3.25 per pound of copper. While inflation will likely push up some of the costs identified in the PFS, the revenue side of the equation will be positively impacted by, among other things, the projection of higher gold and copper prices. It is anticipated that the CK Gold Project revenues will count on approximately 70% of its revenue from gold, but of increasing importance is the 30% from copper sales in the concentrate that we plan to ship.

As things now stand, the Company plans to have the FS available in Q3 2023.  Finalization rests on certain aspects that needed further clarity.

  • Energy Prices. In the runup to the winter months, oil and fuel prices were surging for a number of reasons, principally, geopolitics and the Ukraine conflict. We now see prices stabilizing and have a better view of energy prices in general, which will affect both capital and operating costs associated with the project.
  • Supply Chain. Supply chain uncertainty resulted in equipment manufacturers providing quotations and lead times on equipment that were overly conservative. As COVID-19 has been largely dealt with, manufacturing has ramped up and there is once again competitive tension in the market, resulting in more options and better prices for the project.
  • Inflation and Economic uncertainty. Inflation pressure and higher interest rates still give rise to caution. While interest rates are high, it does appear that inflation is beginning to come under control, allowing more confidence in estimates.
  • Project Royalty Rate. The project royalty rate is payable to the Office of State Lands and Investment (OSLI), from whom project mineral leases are granted. A recommendation was made by OSLI staff to the OSLI Board of Directors on April 6, 2023 and adopted that same day. The rate, set at 2.1% of the net receipts from the CK Gold Project, gives the Company certainty on this important parameter, which can now be reliably incorporated into our assessment of project economics. This royalty is earmarked for K-12 education in Wyoming, an important benefit supporting project development.
  • Water Supply. Water in the western United States is a contentious issue after many years of drought and the paucity of water in the Colorado river system. U.S. Gold has been aware of this from the outset and sought to reduce the water necessary for the project with plans to install filter presses to capture water and reuse it, rather than implement a conventional tailings storage system. Having defined the water needed for the project, options for a water supply were investigated. A win-win scenario was chosen for the supply, wherein the City of Cheyenne through its Board of Public Utilities (BOPU) would supply the water needed. After mining and reclamation, the water that BOPU will sell to the Company will be needed to cater to the growing water use in the city and its surroundings. In the interim and for the life of the mine, there is surplus water, and the sale of that water will provide funding for the development of the BOPU system for future regional water needs. To firm up the water supply the following events/steps have been taken.
    • At a City of Cheyenne council meeting in November 2022, the City Council approved an “Outside Water Users Agreement” that could be entered into between U.S. Gold and BOPU.
    • In February, a Water Development and Purchase Agreement was ratified and signed between U.S. Gold and BOPU, contemplating the firm supply of up to 600 gallons per minute for the life of the project.
  • Mine Operating Permit (MOP) and Closure Plan. On September 13, 2022, the permit application was submitted to the Wyoming Department of Environmental Quality’s Land Division. The submission was subject to a completeness review, which it passed, and went on to the technical review stage. The first round of comments from the technical review have now been received. The process is proceeding as anticipated and we do not see any issues in responding to the first round of technical commentary from the authority. As a reminder, the project falls under the jurisdiction of the state since the project lies within state and private ground. The Company anticipates that the permitting will continue through the balance of 2023 and most likely into early 2024.
  • Industrial Siting Commission (ISC) Permit. Depending on the magnitude of capital expenditure, the State of Wyoming has a mechanism to cushion the impact of large investment projects on the local community, freeing up state funds for infrastructure and city and county service enhancements. The ISC permit cycle is shorter than the MOP cycle, and the Company should have concluded the proceedings ahead of U.S. Gold having a determination on the MOP. The steps on the ISC permit application are as follows:
    • November 28, 2022 – mailed project description to 126 agencies and organizations, including projected impacts. Set date for and invited public to project open houses in Cheyenne and Laramie.
    • December 14 and 15, 2022 – held open houses to discuss project with interested parties.
    • February 21, 2023 – submitted ISC permit application.
    • March 2023 – passed ISC completeness review and received initial comments.
    • May 10, 2023 – scheduled hearing, followed by 90-day review (August 2023), leading up to a decision by the ISC.
  • Updating the CK Gold Project Resource and Mine Plan. The PFS was based on the 2020 drilling and exploration program. The PFS plan was scheduled at 20,000 short tons per day (stpd) and 20-ft bench height cuts in the mine plan. The following enhancements are anticipated in the FS:
    • Resource to incorporate 2021 drilling, capturing some of the additional mineralization we know to extend beyond the PFS-defined open pit.
    • Switch to +/-30-ft bench heights to ease mine planning and help productivity and mine costs, maintaining the 20,000 stpd mill feed rate.
    • Incorporate an ore stockpile strategy that allows the mine to present higher grade material to the mill sooner, resulting in better economic performance.
    • Conclude mining sooner and reclaim stockpiled ore in the latter years of the project, allowing tailings to be deposited into the base of the mined-out pit, thereby reducing the size of the tailings facility and improving project economics in the final years.
  • Repricing Capital Equipment. With the majority of the FS complete and all major equipment identified, the equipment needed for the project will be repriced. Factors that will affect the price include inflation, a new view on availability and supply, and interest and foreign exchange rates.
  • Other Opportunities. While the project economics revolve around revenues from copper and gold, with copper and gold extraction into a concentrate for sale to smelters, there is a whole new revenue opportunity from the CK Gold Project that is being evaluated. In order to extract the gold and copper from the open pit, not only the ore containing the copper and gold must be moved but also other rock, normally referred to as waste rock. Some of this rock will be used to stabilize the dry stacked tailings pile and for reclamation; however, there will be over 30 million tons stacked and eventually reclaimed in a separate pile. This material has been tested and constitutes an excellent source of aggregate and ballast. While our plans and permit applications do not contemplate the commercialization of this material, the FS will identify the opportunity for later consideration.
  • Other Activities. While the majority of the Company’s resources are aimed at the CK Gold Project, we continue to look for opportunities to advance our exploration assets. Having sold Maggie Creek to Nevada Gold Mines, our attention turns to Keystone, a phenomenal land package on the Eureka/Battle Mountain and Cortez gold trend, and our Challis property in Idaho.

On behalf of the entire team at U.S. Gold, we thank you for your interest in our Company and look forward to an exciting year ahead. Please do not hesitate to contact us through our website.

George Bee
President and CEO, Director
U.S. Gold Corp.

NEWS

U.S. GOLD CORP. TO PARTICIPATE AT SME’S 2023 ANNUAL CURRENT TRENDS IN MINE FINANCE CONFERENCE IN MAY

MAY 3, 2023

U.S. GOLD CORP. – Q1 2023 UPDATE, CK GOLD PROJECT ON TRACK

APR 26, 2023

U.S. GOLD CORP. ANNOUNCES ROYALTY CONDITIONS OF CK GOLD PROJECT TO BENEFIT WYOMING’S EDUCATION COMMON SCHOOL FUND

APR 19, 2023

U.S. GOLD CORP. CLOSES $5 MILLION DIRECT REGISTERED OFFERING

APR 12, 2023

U.S. GOLD CORP. ANNOUNCES $5 MILLION REGISTERED DIRECT OFFERING

APR 5, 2023

U.S. GOLD CORP ANTICIPATES COPPER AND GOLD SULFIDE CONCENTRATE FROM ITS CK GOLD PROJECT TO BE READILY MARKETABLE

MAR 22, 2023

U.S. GOLD CORP. TO ATTEND PDAC 2023: THE WORLD’S PREMIER MINERAL EXPLORATION & MINING CONVENTION IN TORONTO ON MARCH 5-8, 2023

FEB 28, 2023

U.S. GOLD CORP. TO PARTICIPATE AT 2023 MINES AND MONEY CONFERENCE IN MIAMI

FEB 14, 2023

U.S. GOLD CORP. ISSUES 2023 SHAREHOLDER LETTER

FEB 7, 2023

U.S. GOLD CORP. ANNOUNCES RESULTS OF ITS 2022 ANNUAL MEETING OF STOCKHOLDERS

DEC 20, 2022

U.S. GOLD CORP. ANNOUNCES THE RESIGNATION OF RYAN ZINKE FROM ITS BOARD OF DIRECTORS

NOV 22, 2022

U.S. GOLD CORP. ANNOUNCES THE SALE OF ITS INTEREST IN THE MAGGIE CREEK PROPERTY FOR $2.75 MILLION TO NEVADA GOLD MINES LLC (BARRICK (61.5%) AND NEWMONT (38.5%) AND RETAINS A POTENTIAL ROYALTY

NOV 10, 2022

U.S. GOLD CORP. TO PARTICIPATE IN THREE UPCOMING NOVEMBER INVESTOR CONFERENCES

NOV 7, 2022

U.S. GOLD CORP. ISSUES CEO UPDATE ON ITS MINING ASSETS AND OPERATIONS

OCT 5, 2022

U.S. GOLD CORP. SUBMITS KEY PERMIT APPLICATION FOR THE CK GOLD PROJECT

SEP 14, 2022

MANAGEMENT

bee

GEORGE BEE

PRESIDENT AND CEO

Mr. Bee is a senior mining industry executive, with deep mine development and operational experience.  He has an extensive career advancing world-class gold mining projects in eight countries on three continents for both major and junior mining companies.  Most recently in 2018 Mr. Bee concluded a third term with Barrick Gold as Senior VP Frontera District in Chile and Argentina to advance Pascua Lama feasibility as an underground mine. This capped a 16-year history with Barrick Gold with positions that included Mine Manager at Goldstrike during early development and operations, Operations Manager at Pierina Mine taking Pierina from construction to operations, and General Manager of Veladero developing the project from advanced exploration through permitting, feasibility and into production.

With his Barrick experience and having had eight years in South Africa working underground gold with Anglo American and open pit copper with Rio Tinto at Palabora Mine, Mr. Bee was well placed to advance projects internationally and domestically as a senior executive. This led to his appointment to various board and leadership positions at various companies. As COO of Aurelian Resources in 2007, he was in charge of project development for Fruta del Norte in Ecuador until Aurelian was acquired by Kinross Gold in 2008. Post-acquisition, moving on from Kinross, where he had also previously worked from 1996 to 1998 advancing projects in El Salvador and Nevada, he joined Andina Minerals as CEO in 2009. Andina and its 6 million-ounce Volcan Gold Project in Chile was acquired by Hochschild in 2013. By this time Mr. Bee had been appointed to the boards of Peregrine Metals and later Stillwater Mining and Jaguar Mining. In 2014, he also assumed the role of Chief Executive Officer of Jaguar Mining, operating mines in Brazil, as the company emerged from a financial restructuring process.

Mr. Bee is a graduate of the Camborne School of Mines in Cornwall, United Kingdom and is a member of the Institute of Corporate Directors with an ICD.D designation.

eric

ERIC ALEXANDER

CHIEF FINANCIAL OFFICER AND CORPORATE SECRETARY

Mr. Eric Alexander has over 30 years of corporate, operational and business experience, and over 15 years of mining industry experience. Previously he served as Corporate Controller of Helix Technologies, Inc., a publicly traded software and technology company from April 2019 to September 2020. Prior to that, he served as the Vice President Finance and Controller of Pershing Gold Corporation, a mining company (formerly NASDAQ: PGLC), from September 2012 until April 2019. Prior to that, Mr. Alexander was the Corporate Controller for Sunshine Silver Mines Corporation, a privately held mining company with exploration and pre-development properties in Idaho and Mexico, from March 2011 to August 2012. He was a consultant to Hein & Associates LLP from August 2012 to September 2012 and a Manager with Hein & Associates LLP from July 2010 to March 2011. He served from July 2007 to May 2010 as the Corporate Controller for Golden Minerals Company (and its predecessor, Apex Silver Mines Limited), a publicly traded mining company with operations and exploration activities in South America and Mexico. In addition to his direct experience in the mining industry, he has also held the position of Senior Manager with the public accounting firm KPMG LLP, focusing on mining and energy clients. Mr. Alexander has a B.S. in Business Administration (concentrations in Accounting and Finance) from the State University of New York at Buffalo and is also a licensed CPA.

KEVIN FRANCIS

VICE PRESIDENT – EXPLORATION & TECHNICAL SERVICES

Mr. Francis has held many senior roles within the mining industry, including VP of Project Development for Aurcana Corporation, VP of Technical Services for Oracle Mining Corporation, VP of Resources for NovaGold Resources and Principal Geologist for AMEC Mining and Metals. Most recently, he consulted to U.S. Gold Corp. as Principal of Mineral Resource Management LLC, a consultancy providing technical leadership to the mining industry, as well as the CK Gold Project through his association with Gustavson Associates (a member of WSP) since September 2020. Mr. Francis is a member of the Board of Directors of Texas Mineral Resources Corporation. Mr. Francis is a “Qualified Person” as defined by SEC S-K 1300 and Canadian NI 43-101 reporting standards and holds both an M.S. degree and a B.A. in geology from the University of Colorado.


Source 1: https://www.investopedia.com/ask/answers/09/gold-standard.asp

Source 2: https://www.investopedia.com/terms/s/safe-haven.asp

Source 3: https://goldprice.org/spot-gold.htm

Source 4: https://d1io3yog0oux5.cloudfront.net/usgoldcorp/files/video/U.S.+Gold+Corp.+I+CK+Gold+Project.mp4

Source 5: https://www.cnbc.com/2021/05/06/copper-is-the-new-oil-and-could-hit-20000-per-ton-analysts-say.html
Source 6: https://www.visualcapitalist.com/why-gold-mining-stocks-outperform-gold-bull-markets/

Source 7: https://sprott.com/insights/sprott-gold-report-gold-the-simple-math/#

Source 8: https://www.prnewswire.com/news-releases/us-gold-corp-announces-the-appointment-of-senior-mining-industry-executive-mr-george-bee-as-president-301111513.html

Source 9: https://youtu.be/QO1d5tUdE5Q

Source 10: https://sciencing.com/open-pit-mining-pros-cons-12083240.html

Source 11: https://www.intechopen.com/chapters/71931

Source 12: https://finance.yahoo.com/news/healthy-correction-bear-market-silver-141406103.html

Source 13: https://www.barchart.com/stocks/quotes/USAU/performance

Source 14: https://www.investing.com/equities/dataram-corp-technical

Source 15: https://www.vaneck.com/us/en/investments/junior-gold-miners-etf-gdxj/

Source 16: https://www.barchart.com/etfs-funds/quotes/GDXJ/performance

Source 17: https://www.reviewjournal.com/business/2-new-major-finds-may-extend-nevadas-gold-boom-for-years-1972010/

Source 18: https://www.usgoldcorp.gold/properties/challis-gold/overview

Source 19: https://goldbull.ca/big-balds/

Source 20: https://investingnews.com/innspired/cortez-trend-nevada/

Source 21: https://d1io3yog0oux5.cloudfront.net/_99cb187746de0507d7057beee5eadd57/usgoldcorp/db/280/795/pdf/USAU+Corporate+Presentation+May+2021.pdf

Source 22: https://www.usgoldcorp.gold/news-media/press-releases/detail/125/u-s-gold-corp-receives-bureau-of-land-management-approval Source 23: https://www.mining-technology.com/projects/carlin/

Source 24: https://www.prnewswire.com/news-releases/us-gold-corp-highlights-progress-on-challis-gold-project-as-it-moves-toward-plan-of-operations-301299634.html

Source 25: https://www.usgoldcorp.gold/properties/challis-gold/overview

Source 26: https://finance.yahoo.com/news/u-gold-corp-amplifies-potential-130919049.html

Source 27: https://www.foxbusiness.com/economy/yellen-says-americans-havent-experienced-current-inflation-rate-in-a-long-time

Source 28: https://d1io3yog0oux5.cloudfront.net/_f5ca51969ee43abae80b0d958cd37587/usgoldcorp/db/280/795/pdf/USAU+Corporate+Presentation+Oct+2021.pdf

Source 29: https://bit.ly/3mlsA0o

Source 30: https://www.cnbc.com/2021/10/25/economists-expect-shipping-problems-to-linger-well-into-2022.html

Source 31: https://www.thebalance.com/gold-prices-and-the-u-s-economy-3305656

Source 32: https://stockcharts.com/h-sc/ui?s=%24GOLD&p=D&yr=0&mn=0&dy=15&id=p23897033209&a=1042871741&listNum=3

Source 33: https://county17.com/2021/10/14/tcs-cheyenne-gold-mine/

Source 34: https://www.wyomingnews.com/news/local_news/potential-gold-copper-mine-could-generate-millions-for-state/article_5ff26327-d9f5-5af0-8762-a26fed274d66.html

Source 35: https://www.cnn.com/2021/10/25/investing/tesla-stock-trillion-dollar-market-cap/index.html

Source 36: https://alphaomegarecycling.com/electric-cars-role-may-increase-demand-base-metals/#:~:text=A%20fully%20electric%20car%20uses,upside%20in%20other%20green%20technologies.

Source 37: https://www.yahoo.com/now/u-gold-corp-amplifies-potential-130919049.html

Source 38: https://www.usgoldcorp.gold/news-media/press-releases/detail/137/u-s-gold-corp-outlines-2021-field-season-activities-and

Source 39: https://www.usgoldcorp.gold/news-media/press-releases/detail/129/u-s-gold-corp-successfully-completes-2021-drilling-at

Source 40: https://schrts.co/ApjTJDre

Source 41: https://schrts.co/eManmckD

Source 42: https://schrts.co/niFycXVH

Source 43: https://schrts.co/urgMpVjn

Source 44: https://www.barchart.com/stocks/quotes/usau/opinion

Source 45: https://money.com/gold-vs-gold-miner-stocks/

Source 46: https://www.foxbusiness.com/economy/producer-inflation-set-record-for-sixth-straight-month

Source 47: https://www.etftrends.com/gold-silver-investing-channel/gold-hits-1800-as-yields-take-a-dip/

Source 48: https://www.mining-technology.com/analysis/whats-in-the-inflation-reduction-act-for-miners/

Source 49: https://www.cnbc.com/2022/07/14/copper-is-key-to-electric-vehicles-wind-and-solar-power-were-short-supply.html

Source 50: https://www.usgoldcorp.gold/overview

Source 51: https://www.barchart.com/stocks/quotes/USAU/price-history/historical

Source 52: https://fortune.com/2022/04/28/global-gold-demand-soared-first-quarter-safe-haven-assets-inflation/

Source 53: https://www.forbes.com/sites/forbesfinancecouncil/2022/10/11/understanding-todays-gold-market/?sh=289e27664885

Source 54: https://www.cnbc.com/2022/07/14/copper-is-key-to-electric-vehicles-wind-and-solar-power-were-short-supply.html

Source 55: https://www.marketwatch.com/investing/stock/gold?mod=search_symbol

Source 56: https://www.marketwatch.com/investing/stock/nem?mod=mw_quote_recentlyviewed

Source 57: https://schrts.co/ZtfQnrgZ

Source 58: https://media.istockphoto.com/photos/gold-barssilvercopperplatinum1000-grams-pure-metalbusiness-investment-picture-id1366606966?k=20&m=1366606966&s=170667a&w=0&h=O0RuqQ4HVQ0bkJQhrehWMQ3SgiUqqXryk0F49c-KVO0=

Source 59: https://sebangsanetwork.com/en/ev-battery-components-what-precious-metals-are-used-in-electric-cars-batteries/#:~:text=Gold%20is%20a%20metal%20that,one%20of%20the%20most%20conductive.

Source 60: https://www.marketwatch.com/investing/stock/usau?mod=search_symbol

Source 61: https://stockstotrade.com/low-float-stocks/

Source 62: https://www.greenbiz.com/sites/default/files/2022-09/shutterstock_751358878.jpg

Source 63: https://rmi.org/how-the-inflation-reduction-act-will-spur-a-revolution-in-ev-battery-supply-chains/

Source 64: https://www.generalkinematics.com/wp-content/uploads/2018/04/New-GK-2018-Size-2.png

Source 65: https://finance.yahoo.com/news/u-gold-corp-announces-sale-133000818.html

Source 66: https://www.usgoldcorp.gold/properties/ck-gold-project/photo-video-gallery#ck-gold-project-wyoming

Source 67: https://d1io3yog0oux5.cloudfront.net/usgoldcorp/files/docs/USAU_Maggie_Creek_Presentation+November+2019.pdf

Source 68:https://www.usgoldcorp.gold/about/management-team

Source 69: https://bloximages.chicago2.vip.townnews.com/wyomingnews.com/content/tncms/assets/v3/editorial/d/01/d01f6b6e-39e0-11ed-a9e7-ef8479b61334/632b61756f168.image.jpg?resize=333%2C500

Source 70: https://media-exp1.licdn.com/dms/image/C5603AQHvW_GRHsDCfw/profile-displayphoto-shrink_800_800/0/1601400190676?e=2147483647&v=beta&t=gy21S0NecEO0d8WPxuDDei0fbnCJudX6vmOtmpVjWrk

Source 71: https://www.linkedin.com/in/kevin-francis-73197631/

Source 72: https://www.copper.org/publications/pub_list/pdf/A6191-ElectricVehicles-Factsheet.pdf

Source 73: https://d1io3yog0oux5.cloudfront.net/_d6663809cff93591bd32368521d5438a/usgoldcorp/db/280/2223/pdf/USAU+Corporate+Presentation+January+2023.pdf

Source 74: https://www.cnbc.com/2022/12/22/gold-at-4000-analysts-share-their-2023-outlook-for-prices.html

Source 75: https://www.cnbc.com/2023/01/03/gold-surges-to-6-month-high-and-analysts-expect-new-records-in-2023.html

Source 76: https://www.cmegroup.com/openmarkets/commodities/2021/copper-role-in-electric-vehicle-production.html

Source 77: https://schrts.co/kHvbgZfk

Source 78: https://secure.commoditysupercycles.com/?cid=MKT701037&eid=MKT705139&assetId=AST275780&page=1

Source 79: https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372085619/image_1372085619.jpg?io=getty-c-crop-16-9

Source 80: https://investmentu.com/low-float-stocks/

Source 81: https://www.sofi.com/learn/content/understanding-low-float-stocks/

Source 82: https://www.investopedia.com/terms/n/nanocap.asp

Source 83: https://www.benzinga.com/money/best-nano-cap-stocks

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, SICA MEDIA LLC FOR A ONE DAY USAU AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

SYTA BRAND NEW PROFILE!

Siyata Mobile Inc.

OUR NEW PROFILE IS:  (NASDAQ: SYTA)

(TSXV: SIM)

SYTA OPERATES IN THE UNITED STATES, CANADA, EUROPE, AUSTRALIA, MIDDLE EAST

SIYATA MOBILE RECEIVES $1.2 MILLION ORDER TO PROVIDE IN-VEHICLE DEVICES AND VIDEO MONITORING FOR EMS ORGANIZATION

COULD SYTA BE CURRENTLY UNDERVALUED AFTER A $2.50 TARGET SET BY ZACKS SMALL CAP RESEARCH? (1)

SIYATA MOBILE REPORTED A 9% INCREASE IN Q4 REVENUE, REACHING $2.1 MILLION. REVENUES FOR THE 12 MONTHS ENDED DECEMBER 31, 2022, WERE $6.5 MILLION COMPARED TO $7.5 MILLION IN THE PRIOR YEAR

CHECK OUT THE INVESTOR PRESENTATION HERE

_____________________________________________

Hello Everyone,

We have another exciting Nasdaq profile for Tomorrow’s session.

It is not often that we see a company trading on a National exchange at this price point.

Pull up SYTA immediately.

Siyata Mobile Inc. (NASDAQ: SYTA) (TSXV: SIM) is a leading global developer and provider of Push-to-Talk Over Cellular (“PTT/PoC”) systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world’s first 3G connected vehicle device as well as the world’s first 4G/LTE vehicle-mounted smartphone for First Responders and commercial fleets and vehicles, thereby creating a new category in the cellular device market with a dedicated smartphone tailor-made for the commercial vehicle market.

Siyata’s suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company’s flagship product, the Uniden UV350, is the world’s first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada’s largest LTE network and PTT community, as well as AT&T in the U.S. Further expanding its availability, Siyata is completing network approval with another U.S. Tier 1 operator to launch the UV350 in Q3 2019.

1

Image Source (36)

The telecommunications landscape is constantly evolving, giving rise to new technologies and communication solutions that are shaping the way we connect and interact. Among these emerging trends, the Push-to-Talk (PTT) market stands out as a segment with immense growth potential.

For those looking for market opportunities and actively exploring the growing Push-to-Talk (PTT) industry, it is essential to understand its size, the factors driving its growth, and the key players in the industry.

In this report, we’ll delve into the potential of the Push-to-Talk (PTT) market and highlight Siyata Mobile Inc. (Nasdaq: SYTA)—a company leading the way in PTT innovation.

The Push-to-Talk (PTT) Market: An Overview of Size and Growth Potential(9)

According to a report by Adroit Market Research, the global PTT market is anticipated to achieve a remarkable value of USD 59.81 billion by 2030, growing at a positive compound annual growth rate (CAGR) of 8.9%. The market’s rapid expansion can be attributed to various factors, including the introduction of 5G networks, which are expected to revolutionize PTT operations by offering enhanced speed, reliability, and connectivity. (9)

One of the primary growth drivers of the PTT market is the increasing popularity of Push-to-Talk over Cellular (PoC) solutions. PoC technology enables two-way wireless device communication and allows users to use their mobile phones as walkie-talkies with unlimited range. It offers advanced features such as GPS, auto-pairing, mobile workforce management, and IP-based interoperability, making it a preferred choice for businesses and organizations.

Large corporations are increasingly adopting cloud-based PTT solutions that offer multimedia features, real-time security, and greater use of wireless PTT services. These solutions provide improved call management, cost control, and convenience, fueling the expansion of the global PTT market.

Another significant factor contributing to market growth is the expanding use of PTT in public safety organizations and the increased demand for rugged and ultra-rugged cell phones. The development of advanced communication technologies, such as the LTE network and 5G infrastructure, has spurred the rapid adoption of PTT solutions. Additionally, the integration of emerging technologies such as the Internet of Things (IoT), artificial intelligence (AI), and natural language processing (NLP) presents a myriad of opportunities for the PTT market. (9)

PTT solutions offer instant communication capabilities that are crucial in various industries and sectors, particularly for public safety and law enforcement authorities. PTT technology provides robust network coverage, high-quality audio support, and reliability, making it ideal for emergency response and mission-critical operations. Moreover, PTT solutions eliminate the need for extensive infrastructure, such as radio towers and repeaters, reducing capital expenditure.

Welcome to Siyata Mobile Inc. (Nasdaq: SYTA).

Siyata Mobile Inc. (Nasdaq: SYTA) is a global provider of innovative PoC devices and cellular signal booster systems, making it a key player in the PTT market. Siyata Mobile’s rugged SD7 device is an Android-based, Push-to-Talk solution with excellent sound quality that operates over high-bandwidth 4G LTE networks. Its IP68 rating, resistance to water and dust, drop protection, and robust battery make it well-suited for use in harsh environments. (32)

The company has established partnerships with major wireless carriers, including T-Mobile, AT&T, Verizon, and UScellular™, expanding its reach and market penetration. Siyata Mobile aims to disrupt the traditional Land Mobile Radio (LMR) industry by offering superior PoC solutions that meet the demands of first responders, enterprise personnel, and various industries. (22),(23),(33)

Keep reading to see why you should keep a close eye on Siyata Mobile Inc. (Nasdaq: SYTA).

SIYATA MOBILE INC. (NASDAQ: SYTA) LEVERAGES PARTNERSHIPS WITH T-MOBILE, VERIZON, AT&T, AND KPN TO DELIVER CUTTING-EDGE PUSH-TO-TALK TECHNOLOGIES ( 33, 22, 23, 38)

3

Image Source (34)

Siyata Mobile Inc. (Nasdaq: SYTA) is making significant strides in expanding its reach and partnerships. The company has recently announced a distribution agreement with KPN Royal Dutch Telecom (“KPN”), a leading telecommunications and IT provider in the Netherlands. (38)

“This distribution agreement expands the reach of our SD7 handset through wireless carriers to a new geographic region and opens new opportunities for growth,” said Marc Seelenfreund, Siyata CEO.“Aligning with quality wireless carriers is an important aspect of our growth strategy. As an innovator and telecommunications leader in the Netherlands and one of the largest wireless carriers in Europe, KPN has extensive experience in the push-to-talk technology space and is highly focused on offering the best solutions for its customers. We are eager to leverage their established channels to provide more end users with our powerful MCPTT solution.” (38)

The SD7 enables push-to-talk communications for first responders and enterprise clients in a simple easy-to-use rugged Android based Push-To-Talk (PTT) handset with excellent sound quality that operates over the high bandwidth 4G LTE network, providing consistent connectivity across the nation and internationally. Its IP68 rating, resistance to water and dust, drop protection, and robust battery make it well suited for use in harsh environments. Importantly, there is no need to invest in infrastructure such as radio towers or repeaters, and the SD7 handset allows first responders as well as secondary support personnel to quickly connect and coordinate on unified public cellular networks in international markets as well as in North America. (38)

On January 9, 2023, Siyata Mobile also made an exciting announcement. T-Mobile US, Inc., the second-largest wireless carrier in the U.S. with a customer base of over 111.7 million, is set to launch Siyata’s rugged SD7 device onto its Internet of Things (IoT) data network. This move will significantly expand Siyata’s reach to a broader customer base. The SD7 is designed to disrupt and replace the multi-billion-dollar Land Mobile Radio (LMR) industry. (33)

“We are thrilled to add T-Mobile to our growing list of partners, significantly expanding our addressable market and entering 2023 with a strong position, as all major U.S. wireless carriers are now offering the SD7, along with additional partnerships globally,” said Marc Seelenfreund, Siyata CEO. “Our relationship with T-Mobile solidifies our network compatibility and further broadens our ability to provide first responders and enterprise personnel with a dependable PoC device designed to perform optimally in challenging work environments.” (33)

Additionally, Siyata Mobile has established a channel partnership with Verizon Communications Inc., the largest mobile operator in the U.S. with 143 million total retail connections as of Q1 2022. Verizon has fully integrated Siyata’s rugged SD7 device into their network and will offer it to their broad enterprise customer base as well as their first responder network of 4.5 million connections with over 30,000 public-safety agencies. This collaboration opens up extensive opportunities for Siyata Mobile to reach more first responders and enterprise personnel with a reliable and rugged device that can operate effectively in tough working environments. (22)

The SD7, at the core of Siyata Mobile’s offerings, is a game-changer in communications technology. It brings push-to-talk communications into the 21st century, offering first responders and enterprise clients a user-friendly, rugged, Android-based Push-To-Talk (PTT) device with outstanding sound quality. The SD7 operates over the high-bandwidth 4G LTE network, ensuring consistent connectivity nationwide. Its IP68 rating for water and dust resistance, drop protection, and long-lasting battery make it well-suited for use in harsh environments. Importantly, the SD7 eliminates the need for infrastructure investments such as radio towers or repeaters, providing seamless communication capabilities for a modern workforce. (33)

With the addition of KPN as a distribution partner, Siyata Mobile expands its global distribution of the SD7 device to the Netherlands. The partnership with KPN, a leading telecommunications provider in the region, will enable Siyata to offer the SD7 to medium and large government and enterprise clients in the Netherlands. This marks another significant step in Siyata Mobile’s growth strategy and opens up new opportunities for market expansion. (38)

As Siyata Mobile continues to make advancements in the push-to-talk communications market, it remains committed to delivering cutting-edge solutions that address the unique needs of first responders, enterprise clients, and various industries. (38)

In addition to its partnerships with T-Mobile and Verizon, Siyata Mobile’s collaboration with KPN in the Netherlands strengthens its presence in the European market (33)(38). KPN’s extensive experience in the telecommunications industry and focus on offering the best solutions to its customers make them an ideal distribution partner for Siyata Mobile. The availability of the SD7 handset and related accessories through KPN’s network will provide medium and large government and enterprise clients in the Netherlands with reliable and efficient communication tools. (33)(38)

The SD7 handset, with its push-to-talk functionality, rugged design, and excellent sound quality, caters to the needs of first responders and enterprise clients alike. Its compatibility with high-bandwidth 4G LTE networks ensures consistent connectivity both nationally and internationally. The SD7’s IP68 rating for water and dust resistance, along with its durability and long-lasting battery, make it a reliable choice for use in challenging work environments. (33)

Siyata Mobile’s focus on innovation and its ability to disrupt the traditional Land Mobile Radio (LMR) industry positions it as a key player in the evolving communication technology landscape. The SD7 handset’s superior coverage, functionality, and cost-effectiveness make it an attractive alternative to outdated land-based radio technologies (22). With the support of major wireless carriers like T-Mobile and Verizon, Siyata Mobile can reach a wide range of customers, including first responders, enterprise personnel, and various industries such as construction, energy, transportation, and more. (22)

As Siyata Mobile expands its global distribution and strengthens its partnerships, the company is poised for significant growth in the coming years. The increasing demand for reliable communication solutions and the shift towards modernized communication technologies create a favorable market environment for Siyata Mobile and its game-changing SD7 device. By leveraging its network compatibility, strong partnerships, and innovative product offerings, Siyata Mobile is well-equipped to meet the evolving needs of customers and seize new opportunities in the push-to-talk communications market. (38)

Image Source(26)

Siyata Mobile Inc. (Nasdaq: SYTA) aims to be the global leader in the rapidly growing Push-to-Talk Over Cellular (PoC) industry by disrupting the legacy Land Mobile Radio (LMR) industry with Next Generation Cellular Technology.

Siyata will be competing with companies that have $10b – $40B Market Values.

But this is not a “David vs Goliath” situation…

In fact, Siyata is in a “Goliath vs Goliath” situation as they already have 2 of the largest mobile carriers (AT&T and Verizon) as their channel partners.

Could you imagine what this could mean for a company with a market cap of less than $2.5 million dollars as of 12/8/22(4)?

AT&T, Verizon, and other cellular carriers are competing for the lucrative Land Mobile Radio (LMR) market and Siyata Mobile Inc. (Nasdaq: SYTA) and its technology could be the secret ingredient…

This is similar to when the Intel Corporation started its now famous “Intel Inside” marketing campaign.

Before the “Intel Inside” campaign, Intel had been largely unknown to consumers. The company had a reputation for its technical prowess and quality among original equipment manufacturers, but it had not seen much need to cultivate a similar renown among end users. (26)

That began to change in the late 1980s — the PC market was creating a huge demand for central processing units, and with that came a new imperative for Intel to explain the desirability of its products to lay consumers.(26)

Intel’s response to that imperative, the “Intel Inside” campaign, would make advertising history, turn Intel into a household brand name and create a valuable shortcut through which OEMs could signal the quality of their products to customers.(26)

Siyata could potentially be the “Siyata Inside” that the Push-to-Talk Over Cellular market is missing.

With a combined existing base of over 343 million subscribers, having AT&T and Verizon as channel partners could prove to be a monumental catalyst for Siyata Mobile Inc. (Nasdaq: SYTA) as they roll out their game-changing Push-to-Talk Over Cellular devices. (22)(23)

IS SIYATA MOBILE INC. (NASDAQ: SYTA) THE NEXT MARKET DISRUPTOR?

2

Siyata Mobile Inc. (Nasdaq: SYTA) is a B2B global vendor of next generation Push-To-Talk over Cellular devices and cellular booster systems. (11)

Its portfolio of in-vehicle and rugged devices enable first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to increase situational awareness and save lives.(11)

Its portfolio of enterprise-grade and consumer cellular booster systems enables first responders and enterprise workers to amplify cellular signals in remote areas, inside structural buildings where signals are weak, and within vehicles for the maximum cellular signal strength possible.(11)

Since developing the world’s first 3G-connected vehicle device back in 2012,
Siyata has been a pioneer in the industry, launching the world’s first 4G LTE all-in-one fleet communications device.(11)

Incorporating voice, push-to-talk over cellular, data, and fleet management solutions into a single device, the company aims to become the connected vehicle communications device of choice for commercial vehicles and fleets around the world.(11)

SIYATA MOBILE INC. (NASDAQ: SYTA) IS DEVELOPING THE NEXT GENERATION OF CELLULAR COMMUNICATION

INTRODUCING THE SIYATA SD7…

The New Way To Two Way! The Siyata SD7 has all the benefits of the push to talk over cellular with the same usability as your traditional two-way radio. (13)
• Easy Adoption to Push to talk over cellular (PoC)
• Nationwide Coverage
• Cost Effective
• Enterprise Quality
• Dedicated PTT button, long-lasting battery, loud audio, rotary knob for PTT channels
• Optional Siyata VK7 Vehicle Kit for the ultimate two-way vehicle solution (not pictured)

STRONG POSITION IN PUBLIC SAFETY AND EMERGENCY RESPONSE (30)

4

Image Source(37)

On March 6, 2023, Siyata Mobile Inc. (Nasdaq: SYTA) announced the successful deployment of its mission critical push-to-talk (MCPTT) solution for security and other communications at the 2023 Special Olympics New York Winter Games. (30)

“For the second year in a row, our devices were donated to and used at the Special Olympics Winter Games in Syracuse, New York to equip certain security personnel and event volunteers with the communications tools they need to help keep athletes, coaches, volunteers and spectators safe,” said Marc Seelenfreund, Siyata CEO. (30)

“We are pleased to support this worthy cause and to be providing more solutions in support of the Games. Our SD7 MCPTT solution is well-suited for the severe weather conditions that can occur in Syracuse, the site for this year’s event.”

“We are pleased to once again be using Siyata’s SD7 solution at our Winter Games,” said David Burgess, Volunteer Director of Emergency Services for Special Olympics New York. “The SD7 is a robust cellular solution that is ideal for meeting our public safety needs and once again worked flawlessly during the Games.” (30)

The SD7 enables push-to-talk communications for first responders and enterprise clients in a simple easy-to-use rugged Android based Push-To-Talk (PTT) device with excellent sound quality that operates over the high bandwidth 4G LTE network, providing consistent connectivity across the nation and internationally. Its IP68 rating, resistance to water and dust, drop protection, and robust battery make it well suited for use in harsh environments.

Importantly, there is no need to invest in infrastructure such as radio towers or repeaters, and the SD7 allows first responders as well as secondary support personnel to quickly connect and coordinate on unified public cellular networks in North American and international markets. (30)

Users of the SD7 can initiate and receive talk-group calls, receive private calls, notify others of emergencies, and report locations, all actions ideally tailored for mission critical purposes.

SIYATA MOBILE INC. (NASDAQ: SYTA) EXPANDS INTO INTERNATIONAL MARKETS (31)

5

Image Source(38)

AUSTRALIA’S LARGEST WIRELESS CARRIER EXPECTED TO COMMENCE SALES OF THE SD7 IN Q2 2023. (31)

On March 20, 2023, Siyata Mobile Inc. (Nasdaq: SYTA) announced the successful certification and approval of its mission-critical PoC (MCPTT) SD7 solution by Telstra, Australia’s largest wireless carrier. Telstra is anticipated to begin sales of the SD7 in the second quarter of 2023 to its enterprise and government customers.

“We are pleased to work with Telstra on their planned sales of the SD7,” commented Siyata CEO Marc Seelenfreund.

“Telstra’s network includes 18.8 million retail mobile services, 3.8 million retail fixed bundles and standalone data services, and 960,000 retail fixed standalone voice services. We continue to believe that the SD7 is the most unique upgrade from legacy two-way radio devices currently on the market, offering expanded coverage, high functionality and low startup and operating costs.”(31)

SIYATA MOBILE INC. (NASDAQ: SYTA) GETS $2.50 VALUATION FROM ZACKS SMALL CAP RESEARCH

8

Thomas Kerr, CFA is a Senior Equity Research Analyst at Zacks Small-Cap Research with over 25 years of securities industry experience in Technology, Consumer, Industrials, Med-Tech, Healthcare & Biotechnology sectors recently assigned a $2.50 valuation on Siyata Mobile Inc. (Nasdaq: SYTA) on November 14th, 2022. (1)

SIYATA MOBILE INC. (NASDAQ: SYTA) SHOWS PROMISING FINANCIAL RESULTS IN Q4 AND SETS STAGE FOR POTENTIAL GROWTH IN 2023 (40)

On 5/16/2023, Siyata Mobile Inc. (Nasdaq: SYTA) announced its financial results for the fourth quarter and full-year 2022. The company reported a fourth-quarter revenue of $2.1 million, representing a 9% increase compared to the previous year. These results demonstrate the continued growth of Siyata’s mission-critical PoC (MCPTT) SD7 solution.

Marc Seelenfreund, Founder and CEO of Siyata, expressed satisfaction with the company’s performance. He stated, “We delivered top-line growth of 9% in the fourth quarter of 2022 on strengthening sales of our mission-critical PoC (MCPTT) SD7 solution.” Seelenfreund highlighted the successful launch of the SD7, which contributed to total sales exceeding $3 million in the second half of 2022. He also emphasized the growing adoption of Siyata’s solutions in various verticals, particularly in the education sector. (40)

Seelenfreund further discussed Siyata’s expansion into new markets beyond first responders and emergency personnel, with a focus on establishing distribution channels in North America. The company has forged partnerships with leading North American cellular carriers such as AT&T, FirstNet, Verizon, Bell, and US Cellular. Additionally, Siyata has added T-Mobile and a leading two-way radio distributor to its list of channel partners. These strategic collaborations are expected to drive growth in 2023 and beyond.

To support its anticipated growth, Siyata secured $3.6 million in additional financing through the sale of warrants and entered into an accounts receivable factoring facility. Seelenfreund highlighted the multi-billion-dollar market opportunity that Siyata is pursuing and expressed confidence in the company’s position to become a market leader in the Push to Talk Over Cellular arena.

In terms of financial highlights, Siyata reported revenues of $6.5 million for the full-year 2022, compared to $7.5 million in 2021. The net loss for 2022 was $15.3 million, which includes $5.6 million of impairment of goodwill and intangibles. The company’s adjusted EBITDA for 2022 was ($12.6) million, slightly higher than the prior year.(40)

For the three months ended December 31, 2022, Siyata recorded revenues of $2.1 million, a 9% increase from the same period in the previous year. This growth was primarily driven by sales of the SD7 handset. The net loss for the quarter was $6.6 million, compared to $5.0 million in the previous year. The adjusted EBITDA for the quarter was negative $5.0 million.

Regarding liquidity and capital resources, as of December 31, 2022, Siyata had a cash balance of $1.9 million and working capital of $1.6 million. Importantly, the company had no debt, a significant improvement compared to the previous year.

Siyata Mobile Inc. plans to report its results for the first quarter of 2023 after the market close on May 24, 2023. Furthermore, the company will host a conference call at 8 a.m. ET on May 25, 2023, providing an opportunity to discuss the financial results and address any inquiries.

These financial results demonstrate Siyata’s continued growth and momentum in the PoC devices and cellular signal booster systems market. The company’s expansion into new markets, establishment of key partnerships, and focus on innovative solutions position it for further success in the coming years. (40)

HIGHLIGHTS (40)

  • The company’s total sales for the SD7 devices and related accessories exceeded $3 million in the second half of 2022.
  • Siyata Mobile is expanding its distribution platform with partnerships with leading North American cellular carriers, including AT&T, FirstNet, Verizon, Bell, US Cellular, and T-Mobile.
  • The company secured $3.6 million in additional financing and entered into an accounts receivable factoring facility to support anticipated growth.
  • Siyata Mobile aims to become a market leader in the Push to Talk Over Cellular arena, targeting a multi-billion dollar market opportunity.
  • Revenues for the 12 months ended December 31, 2022, were $6.5 million compared to $7.5 million in the prior year.
  • The net loss for the same period was $15.3 million, including a $5.6 million impairment of goodwill and intangibles.
  • Revenues for the three months ended December 31, 2022, were $2.1 million, representing a 9% increase compared to the same period in the prior year.
  • The company had a cash balance of $1.9 million and zero debt as of December 31, 2022.=Will “Push-To-Talk” Fuel the 4th Industrial Revolution?(7)
1

Image Source (8)

Enterprises are going through another industrial revolution known under different names, including Industry 4.0, Digital Transformation, and the Industrial Internet of Things (IIoT). The goal of the implementation of this revolution is to improve efficiency, value, and innovation.(7)
Push-to-talk over cellular or PoC solutions is becoming increasingly popular, which is increasing the growth of the global push-to-talk market.(9)

Large corporations are putting in place cloud-based push-to-talk solutions that offer multimedia features, real-time security, and greater use of wireless Push-to-Talk services. (9)

Likewise, it offers improved call management, cost control, and greater convenience, fueling the expansion of the global push-to-talk market.(9)

Other significant factors are the expanding use of push-to-talk in public safety organizations and the increased demand for rugged and ultra-rugged cell phones.(9)

A rapid increase in the push-to-talk market is also projected as a result of the introduction of cutting-edge technologies like the LTE network and the development of 5G infrastructure.(9)

There will be a range of changes coming for the push to speak market as a result of the Internet of Things (IoT), AI, NLP, and the rising use of online applications.(9)

Thus, there is enormous potential for growth in the industry.

The global push-to-talk market is projected to grow at a positive CAGR of 8.9%, reaching $59.81 billion by 2030.(9)

NEWS

Siyata Mobile to Showcase Mission Critical PPT Solution with CrisisGo at National School Safety Conference June 28-29

Vancouver, BC – June 21, 2023 — Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced that it will host exhibitor’s booth #105…

Read More

Posted on June 21, 2023

Siyata Mobile Teams with Mobile Tornado to Offer Leading Push-to-Talk Over Cellular Application on SD7 Handset

Vancouver, BC – June 20, 2023 — Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced that Mobile Tornado Group Plc (AIM: MBT)…

Read More

Posted on June 20, 2023

Siyata Mobile to Showcase SD7 Handset and VK7 Vehicle Kit at Minnesota School Bus Operators Association’s Annual Summer Conference June 19 – 21

Vancouver, BC – June 15, 2023 – Siyata Mobile Inc. (NASDAQ:SYTA, SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced that it will showcase its SD7 Handset and its VK7…

Read More

Posted on June 15, 2023

Siyata Mobile Launches New Mobile Command Center Unit

Secures First Order from EMS Organization Vancouver, BC – June 14, 2023 – Siyata Mobile Inc. (Nasdaq:SYTA, SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today launched its latest product, the…

Read More

Posted on June 14, 2023

Siyata Mobile Improving Fleet Communications at Minnesota Coaches

Enabling unlimited push-to-talk, two-way communication across North America for transportation fleet Vancouver, BC – June 12, 2023 – Siyata Mobile Inc. (Nasdaq:SYTA)(Nasdaq:SYTAW)(“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced…

Read More

Posted on June 12, 2023

Siyata Mobile Announces $400,000 in New Orders

Increases Market Penetration in Healthcare, Education and Construction Verticals VANCOUVER, BC — June 5, 2023 — Siyata Mobile Inc. (Nasdaq:SYTA)(Nasdaq:SYTAW)(“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced that it…

Read More

Posted on June 5, 2023

Siyata Mobile Receives $1.2 Million Order to Provide In-Vehicle Devices and Video Monitoring for EMS Organization

Video Monitoring Service Enabled by New Product Creates Recurring Revenue Stream  Vancouver, BC – June 1, 2023 — Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal…

Read More

Posted on June 1, 2023

Siyata to Present at LD Micro Invitational XIII

Presentation on Tuesday, June 6, 2023 at 3:30 p.m. PT  VANCOUVER, British Columbia – May 31, 2023 – Siyata Mobile Inc. (Nasdaq: SYTA/SYTAW) (“Siyata” or the “Company”), a global provider of innovative Push-to-Talk over Cellular (“PoC”) and cellular signal booster…

Read More

Posted on May 31, 2023

Siyata Mobile Announces First Quarter 2023 Financial Results

Revenue of $1.8 million, up 116% year-over-year Company to host conference call at 8 a.m. ET on Thursday, May 25 Vancouver, BC – May 24, 2023 — Siyata Mobile Inc. (Nasdaq: SYTA/SYTAW) (“Siyata” or the “Company”), a global vendor of…

Read More

Posted on May 24, 2023

Siyata Mobile to Participate in Critical Communications World 2023 in Helsinki, Finland May 23 to 25

Visit Booth F65 in the Exhibition Hall to Experience Siyata’s Solutions  Vancouver, BC – May 22, 2023 – Siyata Mobile Inc. (Nasdaq: SYTA/SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (“PoC”) devices and cellular signal booster…

Read More

Posted on May 22, 2023

Siyata Expands Global Distribution of Next-Generation Push-to-Talk Mobile Device in the Netherlands

Signs Distribution Agreement with KPN  VANCOUVER, British Columbia – May 17, 2023 – Siyata Mobile Inc. (Nasdaq: SYTA/SYTAW) (“Siyata” or the “Company”), a global provider of innovative Push-to-Talk over Cellular (“PoC”) and cellular signal booster solutions, today announced it has…

Read More

Posted on May 17, 2023

Siyata Mobile Announces Fourth Quarter and Full-Year 2022 Financial Results

Q4 Revenue of $2.1M million, up 9% year-over-year Q1 2023 results to be reported after the Nasdaq close on May 24 Company to host conference call at 8 a.m. ET on Thursday, May 25 VANCOUVER, BC – May 16, 2023…

Read More

Posted on May 16, 2023

Siyata Mobile Announces Upcoming Earnings Release and Conference Call Schedule

Q4 and Full Year 2022 results to be reported after the close on May 15 Q1 2023 results to be reported after the close on May 24 Plans to host conference call at 8 a.m. ET on May 25  Vancouver,…

Read More

Posted on May 11, 2023

Siyata Mobile Expands Footprint in Education Vertical with over $900,000 Order to Supply a U.S. School District with SD7 Handsets

Vancouver, BC – May 3, 2023 – Siyata Mobile Inc. (Nasdaq: SYTA/SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (“PoC”) devices and cellular signal booster systems, has received a purchase order for over $900,000 to supply…

Read More

Posted on May 3, 2023

Siyata Mobile to Participate in 1×1 Meetings at The Inaugural EF Hutton Global Conference

Vancouver, BC – April 25, 2023 – Siyata Mobile Inc. (Nasdaq: SYTA/SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (“PoC”) devices and cellular signal booster systems, announced today that Glenn Kennedy, its VP of International Sales,…

Read More

Posted on April 25, 2023

Siyata Mobile Expands Reseller Network for SD7 with Addition of Leading US Distributor Serving the Two-Way Radio Market

Two Way Direct offers SD7 nationally  Vancouver, BC – April 24, 2023 – Siyata Mobile Inc. (Nasdaq: SYTA/SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (“PoC”) devices and cellular signal booster systems, announces Two Way Direct,…

Read More

______________________________

MANAGEMENT TEAM

MARC SEELENFREUND – CEO

Founder and CEO of Siyata . Prior to establishing Siyata Mr. Seelenfreund was a VP at Sunrise Corporation in New York focusing on financing publicly traded technology companies. Mr. Seelenfreund has a law degree and is a board member at a leading private university.

GERALD BERNSTEIN – CFO

Mr. Bernstein spend 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. Mr. Bernstein holds a Bachelor of Commerce as well as a Graduate Diploma in Public Accountancy- both from McGill University. Member of the Canadian Institute of Chartered Accountants since 1987 and a professional chartered accountant.

GLENN KENNEDY – VP SALES

Mr. Kennedy has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Mr. Kennedy has managed sales nationally for Motorola Canada, HTC Communications Canada and Sonim Technologies. Mr. Kennedy holds an Bachelor of Arts in Honors Business Administration from the Richard Ivey School of Business at the University of Western Ontario.

DIRECTORS

PETER GOLDSTEIN, CHAIRMAN OF THE BOARD

With over 30 years of diverse and global entrepreneurial, client advisory and capital market experience, Mr. Goldstein has a successful track record in leading and building companies in the capital markets. Mr. Goldstein has achieved capital market objectives by drawing on his strengths in M&A, strategic planning and transaction structuring, as well as his own entrepreneurial success. He has steered and completed initial public offerings (IPO), uplisting and reverse merger transactions, secured private placements and designed successful crowdfunding campaigns. Mr. Goldstein advised the Company on its recently upsized $12.6 Million U.S. Initial Public Offering and listing on the NASDAQ.

STEPHEN OSPALAK, BOARD MEMBER

Over 20 years in telecom, currently SVP Marketing & Operations at BMG Inc. Served as interim CEO for AiTelecom; Global Integration Officer for Virgin Management Inc.; Canadian VP & Board Advisor for Brightstar, and as SVP Operations at Iusacell. Served as VP of Products & Services at Telus Communications Inc. responsible for an annual spend > $US 1billion in wireless & wireline equipment. Led the planning and execution of Clearnet’s market debut and nationwide launch of the iDEN and PCS Cellular services, setting the North American PCS launch record. Held management positions at AT&T.

MICHAEL KRON, BOARD MEMBER

Mr. Kron has over 20 years of experience in investment and corporate finance, currently chairman and CFO at AnywhereCommerce Inc. He also co-founded Zellers Optical Centers and played a key role in the sale to Vision Associates of Atlanta. He was the co-founder and CFO of Miazzi Ventures where he founded Mamma.com Inc and later sold to Intasys Corporation at a $44M valuation. Mr. Kron holds a Bcomm from Concordia University as well as a Graduate Diploma in Public Accountancy from McGill University. He has been a member of the Canadian Institute of Chartered Accountants since 1987.

LOURDES FELIX, BOARD MEMBER

Lourdes Felix is a corporate finance executive offering over fifteen years of combined experience in public accounting and in the private sector in building, leading, and advising corporations through complex restructurings. Ms. Felix was previously the controller for a mid-size public accounting firm for over seven years and was responsible for the operations and financial management of regional offices. Ms. Felix has been a Director of BioCorRx Inc. since March 7, 2013. Ms. Felix was appointed Chief Executive Officer of BioCorRx on November 9, 2020 and became Chief Financial Officer of BioCorRx on October 1, 2012. Ms. Felix was President of BioCorRx from February 26, 2020 until she resigned upon her appointment as CEO on November 9, 2020. Ms. Felix holds a Bachelor of Science degree in Business Management and Accounting from University of Phoenix.

Source 1: https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_11142022_SYTA_Kerr.pdf
Source 2: https://www.barchart.com/stocks/quotes/SYTA/price-history/historical
Source 3: https://www.finweb.com/investing/4-reasons-to-invest-in-a-nano-cap.html
Source 4: https://www.marketwatch.com/investing/stock/syta?mod=search_symbol
Source 5: https://www.siyatamobile.com/wp-content/uploads/2022/08/Siyata-Mobile-Investor-Presentation-Q3-2022-2022-08.pdf
Source 6: https://www.siyatamobile.com/wp-content/uploads/2021/11/SYTA-One-Pager_Nov-23-2021.pdf
Source 7: https://www.securitymagazine.com/articles/97324-private-mobile-networks-will-fuel-the-4th-industrial-revolution
Source 8: https://www.commercient.com/wp-content/uploads/2019/03/The-Fourth-Industrial-Revolution-The-Rise-Of-The-Intelligent-Era-2.jpg
Source 9: https://www.globenewswire.com/news-release/2022/10/21/2538979/0/en/Push-To-Talk-PTT-Market-Size-to-Reach-USD-59-81-Billion-by-2030-Future-Projections-Emerging-Technical-Advancements-Recent-Initiatives-and-Growth-Opportunities-Adroit-Market-Researc.html
Source 10: https://s27.q4cdn.com/906368049/files/design/zacks_scr.svg
Source 11: https://finance.yahoo.com/news/siyata-mobile-adds-uk-ireland-130000242.html
Source 12: https://www.siyatamobile.com/wp-content/uploads/2022/02/homepage-SD7-Front-v2.png
Source 13: https://www.siyatamobile.com/
Source 14: https://www.siyatamobile.com/wp-content/uploads/2020/09/booster_img.png
Source 15: https://www.amazon.com/Uniden-Cradle-Signal-Booster-Carriers/dp/B09MTY562X
Source 16: https://www.siyatamobile.com/uniden-uv350/
Source 17: https://www.siyatamobile.com/uniden-cp250/
Source 18: https://www.siyatamobile.com/uniden-ur5/
Source 19: https://schrts.co/iHhbBcPk
Source 20: https://tradesmith.com/educational/this-market-cap-strategy-is-crushing-the-nasdaq/
Source 21: https://www.siyatamobile.com/directors-officers/
Source 22: https://www.siyatamobile.com/siyata-launches-next-generation-push-to-talk-over-cellular-sd7-device-on-verizon-global-network/
Source 23: https://www.siyatamobile.com/siyatas-next-generation-push-to-talk-over-cellular-sd7-device-is-now-commercially-available-and-sold-through-firstnet-and-att-inc/

Source 24: https://www.cnet.com/a/img/resize/409f3c87a1c14d4edc95e1b423fd14061df0c9d7/hub/2014/10/31/64b38597-6e50-4566-8786-9d5e8cd2da52/att-verizon.jpg?auto=webp&width=1200

Source 25: https://blog.nuovoteam.com/what-is-push-to-talk-over-cellular-poc/
Source 26: https://www.intel.com/content/www/us/en/history/virtual-vault/articles/end-user-marketing-intel-inside.html
Source 27: https://www.t-mobile.com/news/business/t-mobile-preliminary-customer-results-2022
Source 28: https://finance.yahoo.com/news/siyata-mobile-welcomes-industry-veteran-120000679.html
Source 29: https://www.siyatamobile.com/siyata-launches-t600-cellular-booster-for-t-mobile-5g-enterprise-customers/
Source 30: https://finance.yahoo.com/news/siyata-provides-mission-critical-broadband-130000546.html
Source 31:https://www.accesswire.com/744624/Siyata-Announces-Certification-and-Approval-of-Next-Generation-SD7-Solution-by-Telstra
Source 32: https://www.siyatamobile.com/wp-content/uploads/2023/02/Siyata-Mobile-Investor-Presentation-Q1-2023.pdf
Source 33: https://www.siyatamobile.com/siyatas-next-generation-push-to-talk-over-cellular-sd7-device-to-be-launched-across-t-mobile-iot-data-network/
Source 34: https://res.cloudinary.com/equities-com/image/upload/v1/contributor_46890/AT_T_VZ_TMUS_x7d8v4
Source 35: https://schrts.co/WbyhNDHK
Source 36: https://info.infovision.com/hubfs/AI%20ML%20Smart%20City.jpg
Source 37: https://media.licdn.com/dms/image/C4E12AQFlZbp3YyI4TA/article-cover_image-shrink_600_2000/0/1644243336092?e=2147483647&v=beta&t=fXJeIHVkTxlOzac_UmPztdJmoPoJ5J-Y_s3b0agBi1I
Source 38: https://static.stocktitan.net/company-logo/syta-tmb.png
Source 39: https://finance.yahoo.com/news/siyata-expands-global-distribution-next-120000498.html
Source 40: https://finance.yahoo.com/news/siyata-mobile-expands-footprint-education-123000476.html
Source 41: https://finance.yahoo.com/news/siyata-mobile-announces-fourth-quarter-120000965.html
Source 42: https://schrts.co/snQuwcYX

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, TD MEDIA LLC  FOR A ONE DAY SYTA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: NCPL) Profile

OUR NEW PROFILE IS:   (NASDAQ: NCPL)

REVENUE GROWTH OF 48% YEAR-OVER-YEAR TO $5.4 MILLION IN THE FIRST 9 MONTHS OF 2023

OVER THE PAST NINE MONTHS NETCAPITAL HAS GENERATED SUBSTANTIAL REVENUE GROWTH WHILE GENERATING POSITIVE OPERATING AND NET INCOME

THE COMPANY BOASTS MORE THAN 100,000 USERS ALREADY WITH OVER $5O MILLION RAISED SO FAR

THIS ONE HAS AN EXTREMELY SMALL FLOAT OF JUST 4.56 MILLION ACCORDING TO YAHOO

READ THE INVESTOR PRESENTATION HERE

NCPL EXPLODED OVER 50% IN WEEK THE LAST TIME WE PUT IT IN FRONT OF YOU

Hello Everyone,

We have a profile back on our radar from lsat month that you are definitely gong to remember if you have. been subscribed since then.

When we brought it to you we saw it opened at 1.68 and hit an average trade of 1.79 on the session.

In just a few days we saw it explode and hit 2.77 on huge interest.  We even got up to 2.88 in the premarket that day.

This was a massive 50%+ move on huge interest.

The implementation of the Title III of the JOBS Act enabled early-stage companies to offer and sell securities to the general public for the first time.

The SEC followed with Reg CF, changing the landscape for private capital raising and investment. This allows general public to invest in private companies and enables private companies to advertise their security offerings.  This conditionally exempts securities sold under Section4(a)(6) from the registration requirements of the Securities and Exchange Act of 1934.

Enter Netcapital, Inc. (Nasdaq: NCPL)

They are disrupting the private capital markets and fundamentally altering the traditional private capital markets by. giving entrepreneurs greater access to investors.

Netcapital makes it possible for more businesses to help grow the economy, create jobs, and start making things that people love.  This gives any investor, not just the connected ones access to early-stage investments.

Low investment minimums and steady deal flow empower the average person to own shares in private companies they believe in.

Netcapital’s management consulting group, Netcapital Advisors, helps companies at all stages to raise capital. Netcapital Advisors provides strategic advice, technology consulting and online marketing services to assist with fundraising campaigns on the Netcapital platform. It also acts as an incubator and accelerator, taking equity stakes in select disruptive start-ups.

THE CEO OF NCPL TALKS TO JIM CRAMER ON MAD MONEY:

Take a look at some of the catalysts: 

  • Incubate, accelerate, and empower private companies to grow
  • Provide access to online private markets
  • Market offerings to investors using digital technology
  • Connect clients with our deep network of institutional and accredited investors
  • Empowers private companies to raise capital online
  • Democratizing access to capital and investments’
  • More than 100,000 users
  • Provides both accredited and non-accredited investors with access to new investment opportunities in private companies
  • They provide marketing and strategic advice and takes equity positions in select companies with disruptive technologies
  • Multi-trillion-dollar market opportunity
  • Pandemic and regulatory changes enhancing growth
  • Proven scalability
  • Established track record enabling companies to raise capital
  • Equity stakes provide upside optionality through possible exits (sale or IPO)

INVESTMENT HIGHLIGHTS

  • Private capital markets reached $7.4 trillion at year-end 2020, $13 trillion expected over the next five years*
  • Within this market, private equity represents the largest share, with assets of +$3 trillion and a 10-year CAGR of 10%
  • $42 trillion held in retail investment accounts representing a large pool of potential account holders** Multiple industry tailwinds driving growth in digital capital markets
  • Pandemic accelerating push to bring processes online
  • Regulatory changes increasing digital funding opportunities
  • Private equity outperformance drives growing investor demand for private investments
    Robust business model of fee income (Netcapital Funding Portal) plus equity stakes (Netcapital Advisors). Management team comprised of experienced institutional investors, angel investors and entrepreneurs.* Morgan Stanley
    **Boston Consulting Group

THE 3 MONTH CHART SHOWS THAT NCPL HAS BEEN MOVING NORTH ON LIGHT INTEREST AFTER BOUNCING OFF OF RECENT LOWS.  THIS CHART IS LOOKING EXTREMELY BULLISH

PORTFOLIO

Kingscrowd

Trusted by over 100,000 investors to vet startup investments, KingsCrowd is the leader in ratings and analytics for online private markets. The company aggregates, analyzes, and rates companies raising on platforms like Netcapital to help investors make more informed decisions.

Deuce Drone

Deuce Drone solves the last mile delivery problem for “brick and mortar” retailers. The company designs, builds, and operates drone delivery systems, transforming retail stores into customer fulfillment centers. Deuce Drone provides a cost-effective, technology-driven solution for same-day delivery that allows retailers to compete with major e-commerce players.

Zelgor

Backed by famous venture capitalist Tim Draper, napster founder, Shawn Fanning, and co-creator of Guitar Hero, Kai Huang, Zelgor is an interactive entertainment company aiming to take over the universe with a new species of rambunctious alien characters called The Noobs. Noobs are a unique and original IP, introduced to the world through mobile games, multimedia content, and strategic partnerships.

ChipBrain

Effective communicators close more deals. ChipBrain’s emotionally intelligent AI assistant provides real-time emotion, tone, and facial expression feedback in live conversations across text, voice, and video. Taking the guesswork out of identifying conversational cues, the company’s technology enables sales professionals to see at a glance how they are coming across to customers.

MustWatch

MustWatch brings your friends and favorite shows together all in one place. The Watch Party app makes it easy to find new shows, see what your friends are watching, and recommend great shows to each other. The company’s platform delivers targeted show recommendations based on the TV viewing tastes of users’ friends and family. It’s not a single streaming platform’s media catalog, but a cross-platform TV guide, crowdsourced from your friends and family.

C-Reveal

C-Reveal’s proprietary technology, developed at Massachusetts General Hospital and Harvard University, helps the body’s immune system to identify and destroy cancer cells by inhibiting key enzymes that conceal the disease. This patent pending approach is designed to improve the efficacy of treating a broad range of cancers.

________________

“NETCAPITAL APPEALS TO ME BECAUSE I’VE HAD FIRSTHAND EXPERIENCE WITH THE PASSION AND SUPPORT THAT COMES FROM AN ENGAGED USER BASE, AND I’VE SEEN HOW THAT EXCITEMENT TRANSLATES INTO FUNDING.”  

——-JASON ROBINS  CO-FOUNDER AND CEO OF DRAFTKINGS

DraftKings Sportsbook Review

__________________________________

NETCAPITAL ANNOUNCES THIRD QUARTER FISCAL 2023 FINANCIAL RESULTS INCLUDING YEAR-TO-DATE REVENUE GROWTH OF 48%

BOSTON, MA – March 16, 2023 – Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, today announced financial results for the third quarter and first nine months of fiscal year 2023 ended January 31, 2023.

“Over the past nine months, Netcapital has generated substantial revenue growth while generating positive operating and net income,” said Martin Kay, CEO of Netcapital Inc. “We have established a number of important strategic partnerships designed to create opportunities for clients and investors, while scaling and advancing our operating platform for continuing growth. Netcapital is executing on the vision for our brand – to break down traditional barriers and offer opportunities for anyone to invest in private companies. Along the way, we are turning customers and communities into owners and brand ambassadors for the businesses they love. We believe this is a powerful symbiotic relationship.”

Third Quarter Fiscal 2023 Financial Highlights

●  Revenue growth of 25% year-over-year to $2.3 million

●  Positive operating income of $571,000 compared to an operating loss of $135,000 in the year-ago quarter

●  Diluted earnings per share of $0.33

First Nine Months of Fiscal 2023 Highlights

●  Revenue growth of 48% year-over-year to $5.4 million

●  Positive operating income of $912,000 compared to an operating loss of $1.5 million in the first nine months of fiscal year 2022

●  Diluted earnings per share of $0.46

●  Paid down $1 million in debt, closed a $5 million underwritten public offering, and uplisted to Nasdaq in July 2022

For additional disclosure regarding Netcapital’s operating results, please refer to the Quarterly Report on Form 10-Q for the period ended January 31, 2023, which has been filed with the Securities and Exchange Commission.

NEWS

05/25/2023

Netcapital Inc. Announces Closing of Registered Direct OfferingBOSTON, May 25, 2023 — Netcapital Inc. (Nasdaq: NCPL, NCPLW), (“Netcapital” or the “Company”), a digital private capital markets ecosystem, today announced the closing of the purchase and sale of an aggregate of 1,100,000 shares of its common stock, at a purchase price of $1.55 per share, in a regi…

Continue Reading

05/24/2023

Netcapital to Present at Singular Research’s Spring Select Webinar on May 25, 2023BOSTON, MA – May 24, 2023 – Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, announced today that the Company’s founder Jason Frishman will present at Singular Research’s Spring Select Webinar on Thursday, May 25, 2023 at 8:30 am PDT / 11:30 am ET.

Continue Reading

05/23/2023

Netcapital Inc. Announces Registered Direct OfferingBOSTON, May 23, 2023 — Netcapital Inc. (Nasdaq: NCPL, NCPLW), (“Netcapital” or the “Company”), a digital private capital markets ecosystem, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,100,000 shares of its common stock, at a purchase…

Continue Reading

05/03/2023

Netcapital to Present at the Sidoti Micro-Cap Virtual Conference on May 10, 2023BOSTON, MA – May 3, 2023 – Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, today announced that Company Founder Jason Frishman will present at the Sidoti Micro-Cap Virtual Conference being held May 10-11, 2023.

Continue Reading

03/23/2023

Netcapital Named “Best Crowdfunding Platform” at FinTech Breakthrough Awards for Second Consecutive YearBOSTON, MA – March 23, 2023 – Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, today was named “Best Crowdfunding Platform” for the funding portal netcapital.com at the 7th Annual 2023 FinTech Breakthrough Awards, a premier awards program founded to…

Continue Reading

03/16/2023

Netcapital Announces Third Quarter Fiscal 2023 Financial Results Including Year-to-Date Revenue Growth of 48%BOSTON, MA – March 16, 2023 – Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, today announced financial results for the third quarter and first nine months of fiscal year 2023 ended January 31, 2023.

Continue Reading

03/06/2023

Netcapital to Report Third Quarter Fiscal 2023 Results on March 16thBOSTON, MA – March 6, 2023 – Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, announced today that it will report financial results for the third quarter of fiscal year 2023, ended January 31, 2023, after the U.S. equity markets close on Thursday, M…

Continue Reading

02/09/2023

Netcapital Establishes Referral Program with JD Merit SecuritiesBOSTON, MA – February 9, 2023 – Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, today announced that it has formed a referral agreement with JD Merit Securities, LLC, a leading boutique investment bank focused on serving middle-market technology-fo…

Continue Reading

01/11/2023

Netcapital to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023BOSTON, MA – January 11, 2023 – Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, today announced that Founder Jason Frishman will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023. Date: Wednesday, January 18, 2023 Locatio…

Continue Reading

01/06/2023

Netcapital Announces Alternative Trading System (ATS) Partnership with Templum Markets LLCBOSTON, MA – January 6, 2023 – Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, today announced a new partnership between Netcapital Systems LLC, a Utah limited liability company and wholly owned subsidiary of the Company, and Templum Markets LLC, o…

Continue Reading

01/04/2023

Martin Kay Named CEO of Netcapital Inc.BOSTON, MA – January 4, 2023 – Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, today announced the appointment of Company director Martin Kay as Chief Executive Officer, effective January 3, 2023. In addition, the Company also announced that Dr. Ce…

Continue Reading

12/16/2022

Netcapital Inc. Announces Closing of Public OfferingBOSTON, MA – December 16, 2022 / Netcapital Inc. (Nasdaq: NCPL, NCPLW) (“Netcapital” or the “Company”), a digital private capital markets ecosystem, today announced the closing of its previously announced public offering of 1,247,000 shares of its common stock at a public offering price of $1.40 per…

Continue Reading

12/14/2022

Netcapital Inc. Announces Pricing of Public OfferingBOSTON, MA – December 13, 2022 / Netcapital Inc. (Nasdaq: NCPL, NCPLW) (“Netcapital” or the “Company”), a digital private capital markets ecosystem, today announced the pricing of an underwritten public offering of 1,247,000 shares of its common stock at a public offering price of $1.40 per share, f…

Continue Reading

MANAGEMENT TEAM

Martin Kay

MARTIN KAY

CHIEF EXECUTIVE OFFICER

Martin Kay began his career at Bain & Company, where he filled roles of increasing responsibility to become a Partner and lead the global Telecom, Media, and Technology practice. Most recently Mr. Kay was a Managing Director with Accenture Strategy, where he led growth engagements for corporate clients and private equity firms. He is a co-founder of Accenture BLOOM, a digital strategy practice that invents, incubates, and scales new growth opportunities in partnership with clients. He was also the global Strategy lead for Accenture’s “Cloud First” program, driving innovation, growth, and digital transformation with cloud technologies. He joined the Netcapital’s board of directors in May 2022, after three decades as a successful leader, investor, advisor, and operator in early-stage digital ventures, including the original napster. Mr. Kay holds an MA in Physics from Oxford University and an MBA from the Stanford Graduate School of Business.

Coreen Kraysler, CFA

COREEN KRAYSLER, CFA

CHIEF FINANCIAL OFFICER

Coreen is a Chartered Financial Analyst, with over 30 years of investment experience. Formerly a Senior Vice President and Principal at Independence Investments, she managed several 5-star rated mutual funds as well as institutional accounts and served on the Investment Committee. She also worked at Eaton Vance, as a Vice President, Equity Analyst on the Large and Midcap Value teams. A specialist in financial services, household and consumer products, she guest lectures at local colleges and universities. Coreen received a B.A. in Economics and French, Cum Laude, from Wellesley College and a Master of Science in Management from MIT Sloan.

Jason Frishman

JASON FRISHMAN

FOUNDER

Jason Frishman is the Founder of Netcapital Funding Portal Inc. and serves as a mentor and advisor for early stage companies. He currently holds advisory positions at leading organizations in the financial technology ecosystem and has spoken as an external expert at Morgan Stanley, University of Michigan, YPO, and others. Jason has a background in the life sciences and previously conducted research in medical oncology at the Dana Farber Cancer Institute and cognitive neuroscience at the University of Miami, where he graduated summa cum laude with a B.S. in Neuroscience.

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, SICA MEDIA LLC  FOR A ONE DAY NCPL AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: DFLI) Profile

OUR NEW PROFILE IS: (NASDAQ: DFLI)

ANALYSTS AT CANACCORD GENUITY LLC (US) HAVE INITIATED COVERAGE ON DRAGONFLY ENERGY HOLDINGS CORP. (NASDAQ: DFLI) WITH A BULLISH RATING AND A TARGET OF $15

READ THE INVESTOR PRESENTATION HERE

Hello Everyone,

Our last profile took off fast and saw strong interest on the session after hitting 1.40.

We have another profile we want you to research for tomorrow’s session that boasts several strong catalysts.

The transition to a sustainable and clean energy future is underway, and green energy storage is set to play a pivotal role in this transformation. As the world embraces renewable energy sources like solar and wind power, the need for efficient and reliable energy storage systems is more pronounced than ever before. (7)

This report explores the outlook and growth opportunities in the green energy storage sector, the benefits of discovering under-the-radar companies ahead of Wall Street, and introduces Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) as an emerging player in this dynamic industry.

Upside Potential:

According to Barchart.com, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) has a 52-week low of $2.61 and 52-week high of $28.75.

After bouncing off of its 52-week low of $2.61 on 3/17/2023, could Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) demonstrate the potential for a 1,001.53% move back to its 52-week high of $28.75 while creating a strong research opportunity for readers? A 1,001.53% move is not expected but the potential needs to be noted. (1)

Strong Analyst Ratings:

Analysts at Canaccord Genuity LLC (US) have initiated coverage on Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) with a bullish rating and a target of $15.

This rating reflects their confidence in the company’s growth potential and strategic positioning in the energy storage market. DFLI opened at $4.10 on 3/27/2023, indicating a potential upside of approximately 265.85% if the stock reaches the target of $15.

Low Float and High Insider Ownership:

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) has less than 9.5 million shares in its float with insiders owning 62.00% of shares. (3)

This concentrated ownership may suggest confidence in the company’s prospects by those with deep knowledge of its operations.

Pioneering Technology:

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is at the forefront of developing cleaner and more efficient lithium-ion battery manufacturing processes, positioning the company as an innovator in the energy storage industry with its focus on next-generation non-flammable solid-state batteries.(4)

Sustainable and Reliable Energy:

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is committed to delivering energy storage solutions that enable a sustainable and reliable smart grid, thereby contributing to the global transition to green, renewable energy sources through the deployment of its solid-state cell technology. (4)

Robust Intellectual Property:

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) has developed and filed patent applications on commercially relevant aspects of their business, including chemical composition systems and production processes.

To date, they have processed 24 issued patents, with an additional 20 patent applications pending, in the United States, China, Europe, Australia, Canada, and other regions. (4)

Diverse Market Focus:

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) manufactures and supplies deep-cycle lithium-ion batteries for various applications, including recreational vehicles, marine vessels, and off-grid installations.

This diverse market focus provides multiple revenue streams and growth opportunities. (4)

Addressing Grid Storage Challenges:

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is working to revolutionize grid storage with its non-flammable solid-state battery technology,  which is crucial for grid stability and resilience in a world increasingly reliant on renewables. (4)

Potential Market Disruption:

Solid-state batteries have the potential to disrupt the energy storage market, and Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is positioning itself as an early mover in this space.

Readers may want to research the company to assess its potential for market leadership in this emerging technology segment. (4)

Strong Management Team:

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is led by an experienced and dedicated management team that is committed to driving profitable growth and building the smart grid of the future.

11

THE OUTLOOK FOR GREEN ENERGY STORAGE

The global green energy storage market is poised for remarkable growth, driven by the increasing adoption of renewable energy, advancements in battery technology, and supportive government policies to combat climate change. Energy storage sysTems address the intermittency challenges inherent in renewable energy sources, enabling the integration of renewables into the grid and ensuring a stable supply of electricity regardless of weather conditions or time of day. (7)

The electrification of transportation and the rapid adoption of electric vehicles (EVs) also contribute to the growing demand for energy storage solutions. Lithium-ion batteries, in particular, have emerged as the leading technology for both stationary storage applications and EVs due to their high energy density, long cycle life, and declining costs. (7)

GROWTH OPPORTUNITY IN THE ENERGY STORAGE SECTOR

As the energy transition accelerates, the demand for green energy storage solutions is expected to increase exponentially, creating significant growth opportunities for companies in the sector. According to market research, the global energy storage market size is projected to reach USD $435.32 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.4% from 2022 to 2030. (8)

The market presents opportunities for innovation in battery technology, grid integration, distributed energy resources, and microgrids. In addition, the race to secure raw materials for battery production has intensified, with a focus on establishing sustainable and responsible supply chains. (9)

THE BENEFITS OF DISCOVERING LITTLE-KNOWN COMPANIES

For those seeking to capitalize on the growth in the green energy storage market, identifying little-known companies ahead of the rest of Wall Street can offer significant advantages. These undiscovered gems may possess innovative technologies, unique business models, and strong growth potential that is not yet reflected in their stock prices. (9)

22

One such emerging company in the green energy storage space is Dragonfly Energy Holdings Corp. (Nasdaq: DFLI). Headquartered in Reno, Nevada, Dragonfly Energy is a manufacturer and supplier of deep cycle lithium-ion batteries for various applications, including RVs, marine vessels, off-grid installations, and more. (4)

The company focuses on delivering sustainable energy storage solutions to enable a smart grid through the deployment of its solid-state cell technology. In addition to manufacturing lithium-ion batteries, Dragonfly Energy is actively engaged in the research and development of next-generation non-flammable solid-state batteries, aiming to address future energy storage needs.

Dragonfly Energy’s commitment to innovation, its robust patent portfolio, and its dedication to cleaner and more efficient battery manufacturing processes make it a compelling choice for readers seeking exposure to the booming green energy storage market. (4)

As the world continues on its path to a cleaner and more sustainable future, green energy storage will be a critical enabler of the energy transition. The growth opportunities in this sector are vast, and readers who identify and research these innovative companies ahead of the broader market may reap significant advantages.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) stands out as a promising company in this space and deserves your immediate attention.

SIGNIFICANT UPSIDE POTENTIAL: AFTER BOUNCING OFF ITS 52-WEEK LOW OF $2.61, COULD DRAGONFLY ENERGY HOLDINGS CORP. (NASDAQ: DFLI) MOVE 1,001.53% BACK TO ITS 52-WEEK HIGH OF $28.75?

Image Source (10)

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) has demonstrated the potential for significant upside potential with a 52-week range of $2.61 – $28.75. (1) Not that any moves are certain, but the potential for a 1,000.51% upside, after bouncing off its 52-week low, suggests a strong reason to begin your research on this company.

In fact, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) has already made a 91.57% move in less than 4 days when it bounced off its 52-week low of $2.61 on 3/17/2023 and reached $5.00 on 3/22/2023, according to the price history on Barchart.com. (1)

While the company’s stock price has seen fluctuations, it’s important to note that Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s focus is on pioneering next-generation solid-state battery technology, robust intellectual property portfolio, and strategic partnerships which could provide a strong foundation for future growth.

Additionally, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s commitment to addressing grid storage challenges and enabling a more sustainable and reliable energy ecosystem is aligned with global efforts to transition to renewable energy sources.

Readers should consider Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s significant upside potential in the context of the broader industry dynamics, technological advancements, and the company’s strategic initiatives.

Several analysts believe that Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) offers a robust opportunity for upside potential for those seeking exposure to the transformative potential of the energy storage industry.

CANACCORD GENUITY SLAPS $15 TARGET ON DRAGONFLY ENERGY HOLDINGS CORP. (NASDAQ: DFLI)(2)

44

Image Source (2)

STRONG ANALYST RATINGS

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) received a bullish rating from Canaccord Genuity when a report surfaced on 1/11/2023 showing the firm placed a $15 target on shares of the battery technology company. (2)

From the Canaccord Genuity Report:

Dragonfly Energy: premium unleaded

Deleading the world, one segment at a time. Dragonfly is a manufacturer of non-toxic deep cycle li-ion batteries designed as a “drop-in” replacement for lead acid batteries in several markets, including recreational vehicles (RVs), marine vessels, and off-grid applications. The company uses li-ion with LFP (lithium iron phosphate) chemistry cells from outside suppliers to build its batteries. Dragonfly was founded in 2012 and came public via a SPAC merger in 2022.

The company’s products are equipped with a battery management system (BMS) and internal heating capabilities designed for cold weather temperatures. Additionally, Dragonfly is developing a “battery communication system” – designed to monitor battery system performance through real-time data and monitoring tools that are accessible via phone or tablet.

Importantly, Dragonfly is in the process of developing its chemistry-agnostic solid-state state dry electrode/electrolyte deposition technology. The company is uniquely focused on developing a solution for the energy storage market, which has different technology priorities relative to markets like EVs.

Li-ion batteries offer several relative benefits including a more sustainable option with better ROI. Dragonfly’ li-lion batteries with LFP chemistry are available as a “drop-in” replacement to lead-acid. These batteries also offer several benefits – particularly in Dragonfly’s key markets, including RVs, marine vessels, and off-grid applications – which include: 1) better power and performance, 2) longer lifespan, 3) maintenance-free, 4) cheaper “cost per usable energy” over battery lifetime, 5) faster charging time, and 6) safer.

From batteries to system integration… In addition to eight core products, Dragonfly offers bundled solutions for its key markets (RVs, marine vessels, off-grid solar installations), as well as charging components (inverter chargers, converter charges, solar charge controllers) and a variety of accessories that simplify the installation process and ensure performance and reliability. This wide range of products allows Dragonfly to assist customers with system design and the installation process, which can result in deeper relationships with customers as their system requirements change. Management estimates that the transition to becoming a “systems integrator” is a natural path for the company as the li-ion supply chain evolves.

… to vertical integration. Dragonfly’s long-term vision is to become a vertically integrated “battery technology provider” serving multiple market verticals. To that end, in 2020, Dragonfly signed an MOU with Ioneer USA Corporation to develop a domestic battery supply chain – particularly for its solid-state cells in development.

Established partnership with an RV champion. Dragonfly’s RV OEM relationship with Thor Industries is groundbreaking. Thor, together with its subsidiaries, is the world’s largest manufacturer of RVs (~40-50% share). To date, Dragonfly has a relationship with three of 17 Thor brands: Keystone, Tiffin, and Airstream. In July 2022, Thor also made a $15M strategic investment in the company and 2) Dragonfly agreed to enter a future, mutually agreed distribution arrangement and joint IP development arrangement.

Solid-state technology development adds future optionality. Dragonfly is developing solid-state batteries (SSB) and expects to launch a pilot line in 2023. CEO Dr. Phares has been working on this proprietary technology for ~10 years. Unlike other manufacturers focused on the EV market – which requires batteries with high energy density and fast charging time – Dragonfly is focused on energy storage, which has a different set of priorities. Energy storage is less focused on charging time and energy density – but more on low-cost, long-life cycle, and safety/non-flammability (achieved through using a stable and proven LFP cathode chemistry).

Initiating coverage with a bullish rating and $15 target. Using our DCF analysis, we generate a $15 price target. Dragonfly has created a strong niche leading traditional lead-acid markets into the li-ion age with its premium offering. We expect the company to continue gaining traction in RVs and penetrate additional markets – including marine – to supplement growth. Longer term, Dragonfly’s solid-state efforts add optionality to the equity as the company looks to develop into a vertically integrated leader in energy storage markets. Dragonfly must now prove it can sustain its premium pricing, penetrate new verticals, and make its solid-state offering a reality. (2)

But Canaccord Genuity isn’t the only firm to see the potential of Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)…

In fact, they weren’t even first…

55

Image Source (20)

Back on 11/17/2022, Stifel announced that it was initiating coverage on Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) with a $12 target.(20)

6

Image Source (11)

Then the next, on 11/18/2023, Benzinga.com reported that Chardan Capital had initiated coverage on Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) with a $15 target…

Just to put things into perspective… On 3/27/2023, shares of (DFLI) opened at $4.10 according to Barchart.com. (1) Meaning that from (DFLI)’s opening price of $4.10, to Stifel’s $12 target, would be a 192% move…

And from (DFLI)’s opening price of $4.10, to Canaccord Genuity(2)and Chardan’s (11)original target of $15, presents the opportunity for a 265% move…

But remember, it was just a few short months ago when Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) was trading at much higher prices.

On 12/20/2022, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) reached an intraday high of $28.75 which would indicate a 1,001.53% upside potential from its $2.61 52-week price according to Barchart.com price history. (1)It’s not certain that a move like this (or a move to these targets above) could happen, but the potential needs to be noted.

One thing to consider is that Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is a low-float stock.

Low float stocks refer to the securities that remain after a company’s stock has been issued to its controlling investors — meaning there are relatively few shares for the public to buy. (12)

Market participants typically consider a float of 10-to-20 million shares as a low float. Some larger corporations have very high floats in the billions. (12)

Companies with a low float frequently have a large portion of their equity held by controlling investors such as directors and employees, which leaves only a tiny percentage of the stock available for public trading. (12)

That limited supply can cause dramatic valuation swings if demand changes quickly. (12)

According to Finviz.com, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) only has around 9.3 million shares in its float… And has a staggering 62% of its shares owned by insiders. (3) This concentrated ownership suggests confidence in the company’s prospects by those with deep knowledge of its operations.

Which is why things could get very interesting and also why you need to start your research on Dragonfly Energy Holdings Corp. (Nasdaq: DFLI).

DRAGONFLY ENERGY HOLDINGS CORP. (NASDAQ: DFLI): AT THE FOREFRONT OF LITHIUM-ION TECHNOLOGY FOR RENEWABLE ENERGY STORAGE. (13)

Harnessing the power of the sun, utilizing the strength of the wind, and turning the movement of water into power—renewable energy is all around us. But what happens if the water dries up, when the sun sets, and when the wind dies down? We lose power. But what if we didn’t have to? What if we could ensure that we use every ounce of that energy, whether it’s intermittent or not? The solution is storage. (13)

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) has been at the forefront of integrating lithium-ion technology to deliver environmentally impactful solutions for energy storage. Their batteries have powered RVs, marine vessels, industrial applications, and off-grid properties for years, and now is the time for a bigger, brighter future. As our world makes the shift, living off green energy is possible, no matter how intermittent that source is. Through manufacturing and advanced research and development, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is putting Americans to work and developing technology for our future.

Powering life on the water, on the road, at home, or at work, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)is here to harness the unlimited potential of renewable energy. They’re increasing the adoption of energy sources, reducing emissions, and furthering the energy transition from being tied to the grid to being free and sustainable. As the industry leader in green energy storage, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)is powering lives with products that are safe, reliable, and powerful—products that are revolutionary. (13)

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) —solving intermittency today for smarter energy storage tomorrow, and developing a cleaner, brighter future for generations to come.

(13)

DRAGONFLY ENERGY HOLDINGS CORP. (NASDAQ: DFLI): WHAT’S NEXT IN GRID-LEVEL STORAGE & HARNESSING RENEWABLE ENERGY (14)

The transition to renewable energy storage represents a pivotal and essential shift towards a brighter, more sustainable future. At the forefront of this transformation is Dragonfly Energy Holdings Corp. (Nasdaq: DFLI), a company that is revolutionizing how we store power and paving the way for innovative energy solutions.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s role extends far beyond that of a typical battery company. In fact, it is a trailblazer in the field of technology and innovation. The company’s primary focus is on developing and enhancing battery technology, including the creation of new battery packs, innovative battery cell manufacturing processes, and related products. Dragonfly Energy’s mission is to address and solve key challenges in energy and electricity production, both in the United States and around the world.

The critical challenge facing renewable energy is not cost, but rather intermittency—the fluctuating availability of sources like sunlight and wind. This is where Dragonfly Energy’s expertise in battery technology becomes vital. As a cutting-edge technology company, Dragonfly Energy is dedicated to developing energy storage solutions that allow renewable sources like wind and solar to effectively compete with traditional energy sources such as coal, oil, and gas. The company empowers individuals and communities to enjoy extended periods of independence from the grid—a capability that has become increasingly crucial.

With traditional lead acid batteries having remained relatively unchanged for 150 years, Dragonfly Energy, along with its consumer brand Battle Born Batteries, has introduced game-changing solutions. The company provides ideal replacements for conventional lead acid batteries, leading to a transformative shift in how recreational vehicles (RVs), marine vessels, and off-grid customers power their lifestyles.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s approach involves the assembly and marketing of battery packs to consumers and original equipment manufacturers (OEMs) for a range of applications. This is done through both the Battle Born Batteries and Dragonfly brands. In addition to batteries, Dragonfly Energy offers complete energy systems, including inverters, solar charge controllers, and solar panels. By offering these comprehensive solutions, the company gains valuable insights into the evolving energy industry, enabling it to drive conversations and innovations in larger-scale applications such as emergency backup power and industrial power.

For those at Dragonfly Energy with a scientific background, the opportunity to deploy and develop cutting-edge technology for solving real-world problems is a driving passion. The company is committed to making a positive and lasting impact on the world through its research and development efforts.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s pioneering work extends to the realm of solid-state battery technology—a field in which the company is introducing unprecedented innovations. While many other companies in the solid-state technology space are primarily focused on the electric vehicle market, Dragonfly Energy has chosen to concentrate on the energy storage market—an area with vast potential and unique challenges.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s solid-state battery technology is distinctive and groundbreaking. It addresses critical concerns, such as the flammability of liquid electrolytes, by using solid electrolytes that are inherently safe. The company’s solid-state batteries will be manufactured in the United States, offering cost-effective and non-flammable solutions that can be safely deployed in a wide range of settings, from individual buildings to entire communities.

DRAGONFLY ENERGY HOLDINGS CORP. (NASDAQ: DFLI) BRINGS YOU BATTLE BORN BATTERIES: POWERFUL, RELIABLE LITHIUM-ION BATTERIES (15)

The growth of Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) can largely be attributed to the company’s ability to deliver a product that met the pressing needs of a wide range of consumers. In particular, Dragonfly Energy made its mark in the recreational vehicle (RV) industry by addressing the shortcomings of traditional lead acid batteries, which were widely disliked by RV owners. (15)

By combining a high-quality product with a rapidly growing industry like the RV market, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) set itself on a trajectory of remarkable success.

What set Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) apart from its competitors was the company’s strategy of identifying a problem in the market and then developing a solution that was not only powerful but also safe and reliable. Through forming relationships with influential customers, industry-leading OEMs, and grassroots campaigns, Dragonfly Energy was able to raise awareness about the dangers and limitations of lead-acid batteries, thereby revolutionizing the industry.

Since 2018, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) has sold over 175,000 of the most popular deep-cycle lithium-ion batteries on the market, leading to rapid growth of both the Dragonfly Energy and Battle Born Batteries brands. The company’s products have been well received, not only for their superior quality but also for the exceptional customer service and support provided by the company. (15)

Dragonfly Energy’s Battle Born Batteries brand was an early mover in the transition from lead acid to lithium-ion batteries in the RV industry. These new batteries were non-toxic, lighter weight, longer-lasting, and safer than their lead-acid counterparts. As a result, they not only improved customer experiences but also enhanced and powered their lifestyles.

The company’s commitment to understanding its customers’ needs and designing products to meet those needs has been a driving factor in its success. Dragonfly Energy started small, selling just one or two batteries per day, but it now sells thousands per month. This growth has been fueled by the company’s unwavering dedication to its customers.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s impact extends beyond the RV industry. Customers from various verticals and markets have sought out the company’s products to power their lives and activities. The ability to provide solutions to an increasingly diverse range of applications is a testament to Dragonfly Energy’s expertise and innovation. (15)

 For years, the RV industry was limited by outdated and dangerous technology. However, Dragonfly Energy’s introduction of lithium-ion batteries has been a game-changer, offering customers the freedom to power their lives in new and exciting ways. The company’s unique position as a battery technology company, rather than just a battery importer, allows it to take customer feedback and turn it into meaningful product development. (15)

Dragonfly Energy’s approach to the RV industry was carefully planned. The company sought to educate early adopters about the benefits of its technology and drive business back to dealerships while simultaneously educating OEMs. This dual branding strategy positioned Dragonfly Energy on both sides of the market, resulting in widespread success and full market penetration.

As the market leader in RV batteries, Dragonfly Energy has no intention of resting on its laurels. The company plans to continue expanding, automating, and advancing its technology. This includes capturing adjacent markets and becoming a leader in the lead acid battery replacement market, which represents an enormous opportunity. (15)

DRAGONFLY ENERGY HOLDINGS CORP. (NASDAQ: DFLI) REVOLUTIONIZING THE ENERGY STORAGE MARKET THROUGH INNOVATIVE LITHIUM-ION TECHNOLOGY AND STRATEGIC OEM PARTNERSHIPS (16)

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) has built a reputation for trust and reliability with DIY enthusiasts, sailing enthusiasts, and on- and off-road adventurers. This track record in the aftermarket has opened the door to partnerships with leading original equipment manufacturers (OEMs) in the industry. Through strategic OEM partnerships, Dragonfly Energy and its Battle Born Batteries brand have made their products widely available to consumers across the country via dealerships and as factory-standard and installed equipment. (16)

The Battle Born brand played a significant role in rejuvenating the industry by focusing on the aftermarket and introducing lithium-ion batteries to recreational vehicles (RVs). This move caught the attention of OEMs, who realized that customers wanted lithium-ion batteries installed directly from the factory. As the company’s customer base embraced the benefits of lithium-ion technology over traditional lead acid batteries, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) attracted the attention of major OEMs.

One such OEM partnership was with Airstream, the iconic RV brand. Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s success with Airstream led to other notable partnerships, including Keystone RV and Tiffin Motorhomes, which contributed to the company’s growing footprint in the OEM market.

Innovation and industry leadership characterized Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s partnership with Keystone RV. Keystone RV became the first company to put batteries on the assembly line and ship RVs to dealerships with batteries already installed. This groundbreaking move, which utilized Dragonfly Energy batteries, challenged preconceived notions in the industry and positioned Keystone RV as a leader in innovation. (16) 

The collaboration with Keystone RV has grown substantially, with Dragonfly Energy now serving as Keystone RV’s exclusive lithium battery supplier. This partnership not only speaks to the quality of Dragonfly Energy’s products but also to the company’s ability to meet high demand. (16)

While Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s OEM business is crucial for credibility and growth, the company continues to pursue other verticals, including material handling, the rail market, and the marine market. In essence, any application where a lead acid deep cycle battery is used today presents an opportunity for Dragonfly Energy’s lithium-ion batteries.

The company’s success in cultivating strong OEM partnerships has not gone unnoticed. Thor Industries, the parent company of Keystone RV and Airstream, recognized Dragonfly Energy’s potential to change the industry and the course of the planet. As a result, Thor Industries made a $15 million investment in Dragonfly Energy, further solidifying the relationship and expressing confidence in the company’s future. (16)

DRAGONFLY ENERGY HOLDINGS CORP. (NASDAQ: DFLI) DISRUPTS ENERGY STORAGE: LEAD ACID BATTERIES OUT, ADVANCED LITHIUM-ION TECHNOLOGY IN (17)

For decades, lead acid batteries have served as the primary technology for energy storage across various industries. Despite their widespread use, technological advancements have been limited, causing industries to struggle with the need for safe, efficient, and cost-effective energy storage. Enter Dragonfly Energy Holdings Corp. (Nasdaq: DFLI), the company that’s already elevating energy storage technology to new heights. (17)

The market is dominated by lead acid batteries, which are currently the go-to technology for deep-cycle storage. However, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) aims to disrupt this status quo by targeting a wide range of markets including data centers, railroads, forklifts, emergency vehicles, and more. The company’s mission is to replace lead acid batteries with its advanced lithium-ion technology, opening up a potential market worth tens of billions of dollars.

Dragonfly Energy’s ETL-Listed lithium-ion batteries address the limitations of lead-acid batteries, which suffer from poor shelf life and toxicity. For example, in material handling and forklift industries, lead-acid batteries have traditionally been installed after the manufacturing process due to these deficiencies. However, lithium-ion batteries enable original equipment manufacturers (OEMs) to install the batteries directly during manufacturing, eliminating post-production hassles.

Security and industrial solar applications also stand to benefit from Dragonfly Energy’s lithium-ion technology. Whether it’s powering cameras in the sky or solar panels for license plate readers and radar detectors, lithium-ion batteries offer an improved return on investment and performance. Dragonfly Energy’s engineering team is innovating and developing custom solutions for OEMs, enabling them to shine in a variety of applications. (17)

The possibilities for Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) are limitless, and the future looks bright for this trailblazing company. With its advanced technology, Dragonfly Energy is poised to enter new markets and revolutionize energy storage. From powering lives to changing the way energy storage is perceived, Dragonfly Energy is at the forefront of industry innovation. (17)

The company’s rapid growth and success to date have laid the groundwork for further expansion. As Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) continues to displace lead-acid batteries in various markets, it is also setting its sights on revolutionizing the energy grid—a monumental opportunity. Ultimately, Dragonfly Energy envisions its batteries being present in every home, marking a transformative shift in the energy storage landscape. (17)

NEVADA-BASED DRAGONFLY ENERGY HOLDINGS CORP. (NASDAQ: DFLI) LEADS THE WAY IN US-MADE SOLID-STATE BATTERIES FOR A SUSTAINABLE FUTURE (18)

For years, electric vehicles have been the primary driver behind the development of solid-state batteries. However, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is charting a different path by focusing on energy storage. The company’s unique solid-state technology is centered on safety and longevity, with the goal of producing a non-flammable battery that can last thousands of cycles, making renewable energy storage more cost-effective. (18)

The energy storage market is dominated by applications dependent on lead-acid batteries, a technology that has struggled to keep up with modern advancements. Dragonfly Energy is addressing this challenge by targeting various markets, including data centers, railroads, forklifts, emergency vehicles, and more. They aim to replace traditional lead acid batteries with their cutting-edge lithium-ion technology, opening up a massive potential market worth tens of billions of dollars.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s solid-state technology is uniquely positioned to solve the problem of intermittency in renewable energy. The company envisions a resilient energy grid that relies on distributed energy storage at homes, businesses, and buildings. Lithium-ion batteries enable this vision by offering safety, cost-effectiveness, and long-lasting performance. By enhancing energy storage capabilities, Dragonfly Energy is allowing for greater integration of solar and wind power into the grid.

To achieve this vision, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is in the process of building a pilot production line for solid-state batteries at its headquarters in Reno, Nevada. The pilot line is a critical step in scaling up the manufacturing process and producing saleable battery cells. The company has assembled a team of automation and robotics experts to develop the necessary equipment for the pilot line. They are also focused on producing cost-effective products through low-yield, low-operating-cost, and low-capital-equipment-cost methods. (18)

Notably, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is committed to onshoring lithium-ion battery cell production to the United States, with a goal of vertical integration within the state of Nevada. The company is partnering with mining companies and has signed an MOU with ioneer to secure a lithium source for cell production. By harnessing Nevada’s rich lithium resources, Dragonfly Energy is creating jobs, lowering costs, and contributing to a more sustainable world.

Ultimately, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s mission is to revolutionize the energy storage industry by delivering non-flammable, US-made solid-state batteries. As the company moves closer to achieving this goal through its public market debut, it is poised to make a lasting impact on the way renewable energy is stored and used.

The potential of this technology is vast, and Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is at the forefront of innovation and sustainability in the energy storage market. (18)

DRAGONFLY ENERGY HOLDINGS CORP. (NASDAQ: DFLI)’S VISION FOR A RESILIENT GRID: DISTRIBUTED ENERGY STORAGE TO STABILIZE RENEWABLES (19)

Power is all around us—be it from the sun, wind, or water—and Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is on a mission to ensure that using this renewable power is possible, even long after it has stopped producing. With a vision of a bright and sustainable future, Dragonfly Energy is working to revolutionize the energy grid by harnessing the power of renewables. (19)

As part of its strategy, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is investing in new infrastructure and tools to advance its mission. The company is building new labs and bringing prototype and pilot lines online to develop safe, high-energy-density storage solutions. These solutions are designed to open up new possibilities for cleaner energy production and level out the energy grid, addressing longstanding energy challenges.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) envisions a future with a distributed network of energy storage across the country and the world, helping to stabilize the grid. By providing reliable and safe storage solutions, the company can bridge the gap during times when solar and wind energy are less available, ensuring that power remains accessible.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s approach goes beyond just designing and assembling batteries; the company aims to be fully vertically integrated. This commitment to innovation is part of Dragonfly Energy’s larger goal of displacing lead-acid batteries and replacing coal as an energy source.

The future at Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is powerful, and the company is poised to make a significant impact on climate change. With a dedicated team focused on making a difference, Dragonfly Energy has the potential to change the course of the planet and usher in a new era of clean, renewable energy. (19)

NEWS

JUNE 12, 2023

Dragonfly Energy Set to Join Russell 3000® Index

JUNE 7, 2023

Dragonfly Energy Speaks at Rho Motion Seminar Series

MAY 24, 2023

Dragonfly Energy Lithium Batteries to be Installed on all New Leisure Travel Vans

MAY 15, 2023

Dragonfly Energy Reports First Quarter 2023 Financial Results

MAY 9, 2023

Dragonfly Energy and Ioneer Sign Lithium Supply Agreement

MAY 1, 2023

Dragonfly Energy to Report First Quarter 2023 Earnings Call on May 15, 2023

APRIL 18, 2023

Dragonfly Energy and Airstream Announce Battery Partnership

APRIL 17, 2023

Dragonfly Energy Files Annual Report on Form 10-K and Updates Operating Results for the Fourth Quarter and Year ended December 31, 2022

APRIL 6, 2023

Dragonfly Energy’s CEO to Speak on Grid Storage at IEEE’s Grid Edge Technologies Conference

MARCH 29, 2023

Dragonfly Energy Reports Fourth Quarter and Full Year 2022 Financial Results

DOWNLOAD(OPENS IN NEW WINDOW)

MARCH 17, 2023

Dragonfly Energy Reschedules Fourth Quarter and Year End 2022 Earnings Call for March 29, 2023

MARCH 1, 2023

Dragonfly Energy Launches the Li-MITLESS ENERGY Podcast

FEBRUARY 27, 2023

Dragonfly Energy to Hold Fourth Quarter and Year End 2022 Earnings Call on March 20, 2023

FEBRUARY 15, 2023

ABYC Compliant Lithium Power Systems Made Possible with New Products from Battle Born Batteries

JANUARY 17, 2023

Dragonfly Energy Launches Smart Lithium-Ion Battery Technology Dragonfly IntelLigence™

MANAGEMENT

DR. DENIS PHARES

Dr. Denis Phares leads with a passion for making the planet more sustainable. As the President and Chief Executive Officer of Dragonfly Energy Corp., he focuses on developing revolutionary technologies that will change the way we store and harness renewable energy. As a visionary leader, Phares has helped grow Dragonfly Energy and its consumer brand, Battle Born Batteries, into one of the leading Li-Ion products on the market while also leading a world class R&D team in the advancement of groundbreaking technologies and manufacturing processes. After establishing himself as a tenured professor of Aerospace & Mechanical Engineering at the University of Southern California, Phares left academia to found Dragonfly Energy in 2012. With three decades of extensive experience in the fields of Energy, Nanotechnology, Fluid Mechanics, and Powder Processing, Phares has positioned himself as a leading expert in Green Energy Storage and has spent the last 15 years focused on advancing lithium-ion battery technology. He holds a number of patents, some of which are key in fundamental battery cell manufacturing. Phares received a B.S. in Physics from Villanova University, an M.S. and Ph.D. in Environmental Engineering Science from California Institute of Technology, and an MBA from the University of Nevada, Reno.

DFE Headshot - John Marchetti

JOHN MARCHETTI

John Marchetti is the Chief Financial Officer of Dragonfly Energy Corp. and leads the corporate finance and investor relations of the company. Bringing over 20 years of experience in the technology and financial services industries, John Marchetti serves as a key member of the leadership team of Dragonfly Energy. Prior to joining Dragonfly Energy, Marchetti was most recently a Managing Director and senior research analyst at Stifel, focused on applied technologies, including advanced battery technologies. He previously served as the Chief Strategy Officer of Fabrinet, where Marchetti enabled growth and diversification through innovative go-to-market strategies and developed effective investor relations, as well as also served as a Senior Equity Analyst at Cowen & Co. and Morgan Stanley. As CFO of Dragonfly Energy, Marchetti focuses on the data and financials that will ultimately lead the company into future successful markets and opportunities.

DFE Headshot - Wade Seaburg

WADE SEABURG

As the Chief Revenue Officer, Wade Seaburg leads Dragonfly Energy’s sales, business development and revenue growth & diversification efforts. Wade’s career and long-term success in business progression and B2B sales originated from his education at Purdue University where he earned a B.S. in Industrial Engineering and then through Eaton Corporation (ETN) where Seaburg completed their distinguished Technical Sales Training Program. Following 12 years as a Senior Account Representative within the WESCO (WCC) Distribution Manufactured Structures Division, Wade began his 5-year career as Founder and President at Structure Sales, a company focused on representing industry-leading suppliers to OEMs in the RV and Marine markets. Working as both a lead and co-inventor, Wade acquired three patents with the company. Wade began contract work with Dragonfly Energy in 2018 prior to fully joining the company as a Director of Outside Sales and Business Development in 2021, and now serving as Chief Revenue Officer of the company. During his time with Dragonfly Energy, Seaburg has helped grow the company’s OEM business and relationships exponentially, including being instrumental in successfully getting the company recognized as a “Five Rivet Supplier” with the iconic brand – Airstream RV. His work and strong B2B relationships also propelled the growth of the partnership between Dragonfly Energy and Keystone RV—where the two companies transformed the way an entire industry looked at battery power for RVs. Wade continues to prove Dragonfly’s ability to successfully serve high-volume OEM in various markets. Seaburg’s diverse skillset has led him to continually gain clear understanding of needs across industries and then to reach productive resolutions for all parties involved, including valued customers and stakeholders. As a valued leader, Wade has built a talented and experienced team around him at Dragonfly Energy as he continues to develop integral business relationships and new opportunities.

DFE Headshot - Nicole Harvey

NICOLE HARVEY

Ms. Harvey serves as Dragonfly’s Chief Legal Officer, Compliance Officer and Corporate Secretary. In those roles she oversees corporate law, corporate governance, government relations, intellectual property, risk management, and regulatory compliance for the organization. Ms. Harvey crafted her practice as an associate at Jones Vargas, and then as the principle and managing attorney of Harvey Law Firm, a Nevada boutique. She served as senior counsel for Corix Group of Companies as well as regulatory compliance manager for Harley-Davidson Financial Services. Nicole earned a bachelor’s degree in economics from the University of Nevada, Reno, and her Juris Doctorate at Arizona State University Sandra Day O’Connor College of Law (Order of Barristers) and is licensed to practice in Nevada. She is a Certified Regulatory Compliance Manager through the American Bankers Association. Ms. Harvey is involved in her local community, having served as acting facilitator for 3 Degrees Networking, director of Disability Resources, program director of Nevada Council of the Society for Human Resources Management, committee member of Nevada System of Higher Education Chancellor’s Diversity Roundtable, and chair of Northern Nevada Human Resources Association for the Carson area. Ms. Harvey is a frequent speaker on numerous topics, including human resources and employment law, regulatory compliance, and constitutional law. She is the author of “I Hope You Die Laughing: A Beginner’s Guide to Estate Planning” and is the fourth generation of her family to call northern Nevada home. She enjoys the outdoors, the history and culture of Nevada.

DFE Headshot - Tyler Bourns

TYLER BOURNS

Chief Marketing Officer, Tyler Bourns, leads the creative charge at Dragonfly Energy. With over 15 years spent producing story-rich, award-winning content for global brands, Tyler has received much recognition throughout his career. Today, he draws on his deep reserves of hands-on knowledge to push the envelope of strategic marketing at Dragonfly Energy. Tyler’s segue into full-time marketing is preceded by outstanding work in content creation with a strong focus on powerful storytelling and authenticity. His experience in video production and marketing extends over 12 years with the ownership and operation of the successful and award-winning video production company Bourns Productions Inc. In 2018 he was awarded the AAF Reno Ad Person of the Year alongside the region’s most respected advertising leaders. A three-time Emmy Award Winner, he has produced and filmed thought-leading content for Panasonic, GE Energy and Terrasmart, among many others. Tyler is no stranger to an international audience; he went on to produce an extensive library of video and photo content for the legendary rock band Whitesnake. In addition, he produced, wrote and directed an internationally distributed feature film, “Desert Shadows,” starring Mitch Pillegi (X-Files, Sons of Anarchy) and produced several worldwide acclaimed short films, two of which screened at the prestigious Cannes Film Festival. His role as Director of Photography on many of these film projects has helped develop his bold and thorough eye for big ideas and strong narratives. Community service has always been important to Tyler. He served on the Under30CEO Board of Directors in Reno for two years, encouraging, collaborating and training young business leaders in the community. Tyler has also served on the Board of Directors for the Cordillera International Film Festival since its inception in 2018. This festival secured its status as a FilmFreeway Top 100 Film Festival, a rare achievement for a festival less than five years old at the time. For over 6 years, through his video production company, Bourns Productions, Tyler helped Dragonfly Energy’s Battle Born Batteries brand grow to be one of the most respected and popular Deep Cycle Lithium-ion products on the market today. In 2021, Tyler joined Dragonfly Energy full time. Drawing on his hard-earned wealth of on-the-ground insight in production, Tyler strives to apply the same narrative-driven approach to marketing that brought him both recognition and fulfillment in the world of content creation. Steered by a strategy of creative authenticity, he brings a dynamic, experience-informed leadership style to Dragonfly Energy.

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVENTEEN THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, TD MEDIA LLC  FOR A ONE DAY DFLI AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Source 1: https://www.barchart.com/stocks/quotes/DFLI/price-history/historical

Source 2: https://energysectorreport.com/wp-content/uploads/sites/33/2023/03/Black-gold-for-the-green-economy_-initiating-coverage-of-ENVX-BUY-20-PT-and-DFLI-BUY-15-PT-1.pdf
Source 3: https://finviz.com/quote.ashx?t=DFLI&p=d
Source 4: https://www.sec.gov/ix?doc=/Archives/edgar/data/1847986/000110465922110688/dfli-20220630xs1.htm
Source 5: https://dragonflyenergy.com/about-us/#team
Source 6: https://waya.media/wp-content/uploads/sites/3/2023/01/UAE-1.jpg
Source 7: https://www.powermag.com/new-technologies-new-sites-supporting-growth-of-energy-storage/
Source 8: https://www.globenewswire.com/en/news-release/2022/04/06/2417212/0/en/Energy-Storage-Systems-Market-Size-to-Surpass-US-435-32-Bn-by-2030.html
Source 9: https://dragonflyenergy.com/the-brand/
Source 10: https://schrts.co/vQAfCsfF
Source 11: https://www.benzinga.com/news/22/11/29782274/chardan-capital-initiates-coverage-on-dragonfly-energy-hldgs-with-buy-rating-announces-price-target
Source 12: https://www.sofi.com/learn/content/understanding-low-float-stocks/
Source 13: https://www.youtube.com/watch?v=0IyGdITtMqE
Source 14: https://www.youtube.com/watch?v=-NfiWXMAEeA&t=129s
Source 15: https://www.youtube.com/watch?v=TLrufQ_2vL0&t=232s
Source 16: https://www.youtube.com/watch?v=QHndyhbAqtQ
Source 17: https://www.youtube.com/watch?v=V3t7HXDzHYI
Source 18: https://www.youtube.com/watch?v=6LELAR2vVQQ
Source 19: https://www.youtube.com/watch?v=goO1tWFhmDE
Source 20: https://energysectorreport.com/wp-content/uploads/sites/33/2023/03/2022.11.17_Stifel_Initiating-coverage-of-Dragonfly-Energy-with-a-Buy-rating-and-12-target-price-1.pdf

Categories
Report

(Nasdaq: NMTC) Profile

(PRNewsfoto/NeuroOne Medical Technologies Corporation)

OUR NEW PROFILE IS:  (NASDAQ: NMTC)

STRATEGIC PARTNERSHIP WITH ZIMMER BIOMET (NYSE:ZBH, ~$27B MKT CAP) TO EXCLUSIVELY COMMERCIALIZE AND DISTRIBUTE EVO® DIAGNOSTIC ELECTRODES; ACCELERATED PAYMENT OF $3.5 MILLION RECEIVED IN AUGUST 2022

NMTC HAS NO DEBT OUTSTANDING AS OF MARCH 31, 2023

NEUROONE® SUCCESSFULLY COMPLETES INITIAL ANIMAL IMPLANT OF NOVEL THIN FILM PADDLE LEAD FOR SPINAL CORD STIMULATION

PRODUCT REVENUE WAS $466,000 IN THE FISCAL SECOND QUARTER 2023, COMPARED TO PRODUCT REVENUE OF $37,000 IN THE FISCAL SECOND QUARTER 2022. FOR THE FIRST SIX MONTHS OF FISCAL 2023, PRODUCT REVENUE WAS $581,000, COMPARED TO $70,000 FOR THE SAME PERIOD IN FISCAL 2022. COLLABORATION REVENUE WAS $1.46 MILLION IN THE FIRST SIX MONTHS OF FISCAL 2023, COMPARED TO COLLABORATION REVENUE OF $6,000 IN THE FIRST SIX MONTHS OF FISCAL 2022

NEUROONE® ANNOUNCES FIRST CLINICAL CASE USING EVO® SEEG ELECTRODE

CHECK OUT THE INVESTOR PRESENTATION HERE

CHECK OUT THE COMPANY FACT SHEET HERE

______________________________________

Hello Everyone,

We have another biotech profile that we want you to put on your radar heading into Mondays session.

This one is sitting just above a buck right now but is known for big multi-session swings.

Pull up NMTC Immediately. 

NMTC is a medical technology company focused on the development and commercialization of a minimally invasive and high-definition/high-precision electrode technology platform used for acute diagnostics and chronic treatment across a wide range of neurologic conditions including epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. NeuroOne’s electrodes offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions such as EEG recording and tissue ablation and/or chronic stimulation. In addition to NeuroOne’s FDA-cleared EVO® diagnostic electrodes, a combination recording and radiofrequency (RF) ablation technology, OneRF®, is currently under development as the Company’s first therapeutic device. Other research and development programs include revolutionary new thin-film-based (chronic) electrodes for spinal cord stimulation (SCS) and deep brain stimulation (DBS), and the potential application of the Company’s technology for artificial intelligence and machine learning.

NEUROONE® ANNOUNCES FIRST CLINICAL CASE USING EVO® SEEG ELECTRODE IN ROBOTIC NEUROSURGERY

Evo sEEG electrode used with Zimmer Biomet’s ROSA One® Brain duringprocedure at Cleveland Clinic

EDEN PRAIRIE, Minn., May 17, 2023 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the first clinical case using the Evo® sEEG electrode in robotic neurosurgery. Performed by Dr. William Bingaman at Cleveland Clinic, the procedure was the first to utilize NeuroOne’s Evo sEEG electrode, exclusively marketed in the U.S. by Zimmer Biomet, with Zimmer Biomet’s ROSA One® Brain, a robotic platform that assists surgeons in planning and performing complex minimally invasive neurosurgical procedures.

Dave Rosa, CEO of NeuroOne, commented, “This clinical case utilizing our minimally invasive and high-definition electrode technology with ROSA One Brain is a major milestone in NeuroOne’s partnership with Zimmer Biomet. Now that Zimmer Biomet has commenced U.S. distribution of our Evo sEEG electrodes, this case study confirms the synergistic use of our product with Zimmer Biomet’s robotics platform which was the foundation of our interest to partner with Zimmer Biomet.”

The Evo sEEG electrode technology offers stereoelectroencephalography recording, brain stimulation and future development of ablation solutions targeted for patients suffering from multiple neurological conditions. In October 2022, NeuroOne received FDA clearance to market its Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.

NEUROONE® REPORTS SECOND QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal second quarter 2023 ended March 31, 2023.

Fiscal Second Quarter 2023 and Recent Business Updates

Evo® sEEG:

  • Announced the commercial launch of the Evo sEEG electrode product line in the United States with exclusive distribution partner Zimmer Biomet. The new technology potentially provides NeuroOne with a new revenue stream.
  • The first clinical case using the Evo® sEEG electrode was performed at the Mayo Clinic using a stereotactic frame system. Another procedure using the Evo® sEEG electrode in robotic neurosurgery was performed at a different medical facility. This procedure was the first to utilize NeuroOne’s Evo sEEG electrode with Zimmer Biomet’s ROSA One® Brain, a robotic platform that assists surgeons in planning and performing complex yet minimally invasive neurosurgical procedures.
  • Fulfilled five shipments of sEEG product to Zimmer Biomet in preparation for launch.
  • Completed initial training for the sEEG product line to select Zimmer Biomet sales personnel.
  • Presented the Evo sEEG system alongside Zimmer Biomet at the American Association of Neurological Surgeons (AANS) annual meeting.

OneRF™Ablation:

  • Successfully completed usability testing for OneRF with 15 neurosurgeons.
  • Successfully completed execution of internal device verification and validation protocols for the final OneRF Ablation System.

Spinal Cord Stimulation Program:

  • Successfully completed an initial animal implant of novel thin film paddle leads for spinal cord stimulation (SCS). The devices are intended for the treatment of patients with chronic back pain due to multiple failed back surgery syndrome, intractable low back, and leg pain. A percutaneous (through a needle) delivery system for paddle leads is also under development and has been successfully bench-tested.

Drug Delivery Program:

  • Successfully completed feasibility bench top testing of first drug delivery and recording system prototype.

Other Updates:

  • Expanded IP portfolio with new U.S. patent titled “Improved Neural Depth Probes and Related Systems and Methods” focused on a layered thin film neural depth electrode. The electrode could have potential applications in a wide variety of neurological procedures for both diagnostic and therapeutic use.
  • Expanded management team with the appointment of Anthony Millar as Vice-President of Operations.
  • Oral presentation delivered at the North American Neuromodulation Society (NANS) annual meeting titled “Electrochemical Characterization of the First FDA-Cleared Thin-Film Electrodes for Recording and Stimulation of Brain Activity.”

Dave Rosa, CEO of NeuroOne, commented, “We were excited to officially announce the commercial release of our Evo sEEG electrode and look forward to a successful launch with Zimmer Biomet. In addition, we continued to make critical progress with the OneRF ablation system design verification testing and remain on track to submit a 510(k) to FDA for OneRF in the second calendar quarter of 2023. We made meaningful progress with our spinal cord stimulation program, as well as our recording and drug delivery system. We also filled a key executive role and are excited to have Anthony Millar join our team as our VP of Operations.”

Upcoming Targeted Milestones

Evo sEEG:

  • Successful market launch of Evo sEEG system.
  • Expand sales training of the sEEG product line to Zimmer personnel.

OneRF:

  • Complete design verification and validation testing for OneRF confirming that the full feature system meets its design specifications and is fully functional.
  • Submit a 510(k) application to the FDA for OneRF ablation system in the second quarter of calendar year 2023.
  • Initiate transfer of OneRF to production activities.
  • Perform in vivo animal study with six neurosurgeons utilizing the complete OneRF ablation system.
  • Presentation of OneRF® Ablation System preclinical study at Neurological Disorders Summit (NDS-2023) Italy, June 2023.

SCS Program:

  • Complete bench top testing of percutaneous implantation of thin film paddle electrode in spinal cord model by a physician.
  • Complete first animal study to assess biocompatibility of NeuroOne’s thin film electrode in the spinal cord.

Drug Delivery Program:

  • Complete testing of drug delivery and recordings in a small animal model.

Fiscal Second Quarter 2023 Financial Results

Product revenue was $466,000 in the fiscal second quarter 2023, compared to product revenue of $37,000 in the fiscal second quarter 2022. For the first six months of fiscal 2023, product revenue was $581,000, compared to $70,000 for the same period in fiscal 2022. Collaboration revenue was $1.46 million in the first six months of fiscal 2023, compared to collaboration revenue of $6,000 in the first six months of fiscal 2022. Collaboration revenue was derived from the Zimmer Development Agreement and represents the portion of the exclusivity and milestone fee payments eligible for revenue recognition during the respective periods.

Total operating expenses in the fiscal second quarter 2023 were $3.5 million, compared with $3.0 million in the same period of the prior fiscal year. Research and Development expense in the fiscal second quarter 2023 was $1.7 million compared with $1.2 million in the same period of fiscal 2022. Selling General and Administrative expense in the fiscal second quarter 2023 was $1.8 million compared with $1.8 million in the prior year period. For the first six months of fiscal 2023, total operating expenses were $6.8 million, compared with $5.8 million in the same period of the prior fiscal year. R&D expense in the first six months of fiscal 2023 was $3.3 million compared with $2.3 million in the same period of fiscal 2022. SG&A expense in the first six months of fiscal 2023 was $3.5 million compared with $3.6 million in the prior year period.

Net loss was $3.5 million for the fiscal second quarter 2023, compared to a net loss of $3.1 million in the prior year period. Net loss for the first six months of fiscal 2023 was $5.3 million compared with $5.9 million in the same period of fiscal 2022.

As of March 31, 2023, the Company had cash, cash equivalents, and short-term investments of $4.6 million, compared to $11.1 million as of September 30, 2022. The Company had working capital of $4.8 million as of March 31, 2023, compared to working capital of $9.1 million as of September 30, 2022.

The Company had no debt outstanding as of March 31, 2023.

NEUROONE® SUCCESSFULLY COMPLETES INITIAL ANIMAL IMPLANT OF NOVEL THIN FILM PADDLE LEAD FOR SPINAL CORD STIMULATION

Company is also developing a percutaneous (through a needle) delivery system for paddle leads

EDEN PRAIRIE, Minn., March 16, 2023 /PRNewswire/ — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the successful completion of an initial animal implant of its novel thin film paddle leads for spinal cord stimulation. The devices are intended for the treatment of patients with chronic back pain due to multiple failed back surgery syndrome, intractable low back and leg pain.

The study evaluated the feasibility of implanting a variety of sizes and shapes of ultra-thin paddle leads in a sheep model. A mini laminectomy surgical approach was used to gain access to the epidural space for device placement. All devices were easily advanced to the target location in under one minute. A competitive silicone-based lead was also placed for comparison purposes. The NeuroOne lead fit comfortably in the epidural space and the veterinary surgeon reported no concerns regarding the placement of the lead.

These results demonstrated feasibility for placement of a thin film paddle lead intended to treat chronic back pain due to multiple failed back surgeries. More testing will be completed to optimize the design and placement. The Company is also developing a percutaneous (through a needle) paddle lead placement system which would eliminate the need for an incision in the patient’s back. The preliminary bench top testing for this percutaneous approach has also been successfully completed.

Dave Rosa, CEO of NeuroOne, commented, “This represents a major milestone for the Company as we continue our development of innovative devices that provide therapeutic properties coupled with recording capabilities. The market opportunity for spinal cord stimulation is large and growing. We believe our technology can fill a market need for improved patient outcomes due in part to its potential ability to place a paddle device through a needle, provide a larger stimulation surface area of the spinal cord, better conformability with the tissue and improve battery life of devices, reducing the frequency of patient’s need to recharge or replace the battery.”

Evo® Cortical ElectrodeNeuroOne offers a breakthrough thin-film electrode for the diagnosis of various neurological conditions. Evo’s high- definition, minimally invasive technology delivers major advantages over the limitations of legacy silicone-based electrodes, hampered by the lack of innovation and progress in electrode technology, that are still widely used today.o Over 7 times thinner and 8 times lighter than comparable silicone electrodes used in legacy products. o Flexibility, thinness, and reduced weight facilitates potential for minimally invasive placement.o Reduced inflammation as compared to silicon-based legacy electrodes based on published testing by Mayo.Evo cortical electrode technology has received 510(k) clearance from the FDA for recording, monitoring, and stimulating brain tissue for up to 30 days.

Evo® sEEG ElectrodeThe Evo sEEG electrode technology offers stereoelectrocencephalography recording, spinal cord stimulation, brain stimulation and ablation solutions. The first clinical case using the Evo sEEG electrode was recently performed by Dr. Robert Gross at Emory University for intraoperative brain mapping at the subsurface level of the brain.The sEEG electrode has received FDA 510(k) clearance from the FDA for use of less than 24 hours. A 510(k) for Evo sEEG electrode technology for up to 30 day use has been submitted to the FDA.
 

Brain Monitoring – Understanding What Allows Us To Sense, Move, Think And Feel

Neurons

86 BILLION NEURONS

Neurons communicate through electrical and chemical signals. The specific properties of the neurons composing a brain area and their connections with neurons in other brain areas, define the function of a brain area (e.g. language, vision, movement).

Monitoring Neural Activity

THEY CAN RECORD ELECTRICAL SIGNALS

There are different ways to record and monitor neural activity. Their solution is to provide electrodes that are placed on top of or within the brain and capture the activity of a group of neurons located underneath/around each contact. The signals recorded are called intracranial electroencephalogram (iEEG) or electrocorticography (ECoG) signals. The shape, amplitude and frequency of these electrical signals provide a readout of the activity of that brain area.

Monitoring Neurological Disorders

Neurological diseases may be associated with disturbances in neural activity and connectivity between brain areas. The changes in the shape, amplitude and frequency of recorded electrical signals may be used to identify areas with altered activity.

Epilepsy

Epilepsy is the disease associated with spontaneously recurring seizures. A seizure is a sudden, uncontrolled electrical disturbance in the brain. It can cause changes in behavior, movements or feelings, and in levels of consciousness. There are different types of seizures and their characterization and classification helps guide the treatment.

There are more than twenty seven FDA-approved drugs for the treatment of seizures. However, in ~1/3 of the patient’s medication fails to control their seizures. These patients are candidates for surgical options.

Evo® Cortical Electrode

Cortical or subdural electrodes are used in electrocorticography (ECoG) or intracranial electroencephalography (iEEG) surgeries to monitor, record and stimulate the surface of the brain for up to 30 days. The company’s Evo cortical electrode portfolio consists of various contact configurations of strip and grid electrodes. (Rx only)

image

The Evo Advantage 

Decreased Immunological Response – The Evo Electrode is over 7 times thinner than a silicone electrode. The flexibility and reduced volume should reduce pain and edema.

The Evo’s polyimide substrate has properties like increased flexibility, reduced volume, and decreased immunological response, which should reduce signal artifacts.

Single Tail Design – The single thin tail design allows the implanted electrode tail to be tunneled through one incision which should reduce infection risk and procedure time.

Reduced Cable Management – A disposable cable assembly is sent with each Evo Electrode as an electrode kit, removing the need to source the correct cables for each electrode being used in surgery. Also, hospital resources are freed from the management of sterilizing and storing individual electrode cable assemblies.

image

How NeuroOne’s Thin Film Electrode Technology is Different

In comparison to currently available technologies, our electrodes are manufactured with polyimide thin film. Our electrodes are designed to reduce trauma to the brain by allowing a less invasive implant due to the flexibility, thinness and reduced weight of the electrode.

Furthermore, the potential to significantly increase the resolution of brain recordings may enable the usage of powerful computing techniques, such as machine learning and artificial intelligence.

Caution: US Federal law restricts this device to sell by or on the order of a physician

Two FDA-Cleared Devices and Counting 

Are you beginning to understand that NeuroOne is not just “another” MedTech company? In fact, their Evo Cortical and sEEG Electrodes are both FDA approved!

What they are doing right now has incredible implications for the future of the medical industry.

So much so that the technologies below could be commonplace and in wide use across the globe.

image

Evo® Cortical Electrode* (less than 30-day use)

NeuroOne offers a thin-film electrode for the diagnosis of various neurological conditions. Evo’s high- definition, minimally invasive technology delivers major advantages over the limitations of legacy silicone-based electrodes, hampered by the lack of innovation and progress in electrode technology, that are still widely used today.

• 7 times thinner and 8 times lighter than typical silicone electrodes1 • Reduced artifact and improved signal quality2
• Reduced inflammation based on published testing by Mayo Clinic3

Evo® sEEG Electrode* (less than 30-day use)

The Evo sEEG electrode technology offers stereoelectroencephalography recording, spinal cord stimulation, brain stimulation and ablation solutions. The first clinical case using the Evo sEEG electrode was performed intraoperatively by Dr. Robert Gross at Emory University for brain mapping at the subsurface level of the brain.

• Designed to be less invasive – reduced risk of brain plunge, may require fewer brain insertions • Improved signal quality vs. other devices1
• Proven implant accuracy1
• Automated manufacturing, precise and consistent quality1

*Caution U.S. Federal law restricts this device to sale by, or on the order of, a physician.

1NeuroOne data on file 2Bower R., et al. December 2017. Multi-Resolution intracranial EEG rodent recording system. (Abst. 2.062) 2017. American Epilepsy Society 3Worrell, G. et. al. December 2019. Commercial Scale Production of Thin-Film electrode arrays for Clinical Intracranial EEG. (Abst. 1.154), 2019. American Epilepsy Society)

OneRFTM Therapeutic Ablation Electrode System

OneRF is a developing technology that utilizes existing implanted sEEG diagnostic electrodes for RF ablation in nervous (brain) tissue to create tissue lesion(s). It is designed to be a safer and less expensive combination electrode, intended to improve patient outcomes, reduce procedures and overall treatment cost.

NEUROONE® ANNOUNCES FIRST CLINICAL CASE USING EVO® SEEG ELECTRODE

Evo sEEG electrodes used for brain mapping in epilepsy surgery

EDEN PRAIRIE, Minn., May 10, 2023 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that its first clinical case using the Evo® sEEG electrode was performed by Dr. Jamie Van Gompel at Mayo Clinic. Using a non-robotic stereotactic frame system, Evo electrodes were implanted successfully and met the Company’s product performance objectives.

Dave Rosa, CEO of NeuroOne, commented, “We would like to thank Dr. Van Gompel and his surgical team at Mayo for this ‘first in the world’ opportunity. We are ecstatic with the initial performance of our Evo sEEG electrodes which confirmed the results of many years of testing on the device. While we previously used the device intraoperatively, this was the first clinical case that was cleared by the FDA for less than 30 day use. We look forward to continued success with the launch of the technology as we continue the roll out of the technology through our distribution partner, Zimmer Biomet.”

NeuroOne provides a full line of electrode technology to address an estimated worldwide market of $100 million for patients requiring diagnostic brain mapping procedures. Epilepsy mapping procedures primarily utilize sEEG electrodes due to their less invasive insertion procedure, but less than 5% of people with drug-resistant epilepsy who are surgical candidates receive diagnostic procedures using sEEGs. NeuroOne believes there is a significant opportunity to expand market adoption of sEEG technology with broad U.S. distribution of its Evo product line.

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

MAJOR CATALYSTS

  • Disruptive next-generation diagnostic electrodes advancing a new era in neuroscience; foundational technology initially developed in collaboration with Mayo Clinic, a shareholder of the Company.
  • Strategic partnership with Zimmer Biomet (NYSE:ZBH, ~$27B mkt cap) to exclusively commercialize and distribute EVO® diagnostic electrodes; accelerated payment of $3.5 million received in August 2022.
  • Potential to penetrate large disease populations including epilepsy, Parkinson’s disease, and spinal cord stimulation, with total addressable markets of $1+ billion, $5+ billion, and $10+ billion, respectively.
  • Multi-billion market opportunity for combination devices; potential for technology adaptation and entry into AI and machine learning markets.
  • Platform technology with licensing potential for applications in urinary incontinence, pain management, hypertension, depression, and other related neurological disorders.
  • Ample capital resources to support upcoming commercial and development catalysts including the commercial launch of the Evo sEEG diagnostic line, and further development of OneRF and a thin-film-based SCS electrode system.
  • Leadership with deep expertise in medical device technology, marketing, and business development; world-class board of directors; esteemed scientific and physician advisory boards.

NEUROONE® ANNOUNCES $3.5 MILLION ACCELERATED MILESTONE PAYMENT FROM ZIMMER BIOMET FOR EVO® SEEG ELECTRODE

Amendment provides Zimmer Biomet with 350,000 warrants with exercise price of $3.00 per share

EDEN PRAIRIE, Minn., Aug. 3, 2022 /PRNewswire/ — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the Company entered into an amendment to its Exclusive Development and Distribution Agreement with Zimmer Biomet, Inc. (“Zimmer”) that will provide the Company with a $3.5 million accelerated payment within 10 business days which relates to certain milestone payments.  In addition, Zimmer Biomet will receive a Warrant to purchase 350,000 shares of the Company’s common stock, with an exercise price of $3.00 per share.

Dave Rosa, Chief Executive Officer of NeuroOne, states, “I want to thank Zimmer for all their support to date and their confidence in our business, technology and future endeavors. This agreement accomplishes multiple objectives for NeuroOne, most importantly by providing additional capital to our balance sheet in the short-term without the need for a highly dilutive financing, and further reinforcing our ongoing partnership with Zimmer.”

Brian Hatcher, President of the Trauma, CMFT, Foot and Ankle Division of Zimmer said, “We look forward to continuing the relationship with NeuroOne as we advance our mission to alleviate pain and improve the quality of life for people around the world.” Under the Exclusive Development and Distribution Agreement signed by both parties in July 2020, Zimmer Biomet has exclusive global distribution rights to distribute the Company’s Cortical and sEEG diagnostic electrode technology.

NEWS

MAY 17, 2023 09:00AM

NEUROONE® ANNOUNCES FIRST CLINICAL CASE USING EVO® SEEG ELECTRODE IN ROBOTIC NEUROSURGERY

MAY 11, 2023 04:00PM

NEUROONE® REPORTS SECOND QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

MAY 11, 2023 12:17PM

NEUROONE® TO REPORT SECOND QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 11

MAY 10, 2023 09:00AM

NEUROONE® ANNOUNCES FIRST CLINICAL CASE USING EVO® SEEG ELECTRODE

MAY 05, 2023 03:08PM

NEUROONE REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

MAY 05, 2023 09:00AM

NEUROONE® TO PRESENT AT THE SIDOTI MICRO-CAP VIRTUAL CONFERENCE ON MAY 10

MAY 02, 2023 09:00AM

NEUROONE® ANNOUNCES U.S. COMMERCIAL LAUNCH OF EVO® SEEG ELECTRODES

APR 27, 2023 04:00PM

NEUROONE REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

MAR 16, 2023 07:30AM

NEUROONE® SUCCESSFULLY COMPLETES INITIAL ANIMAL IMPLANT OF NOVEL THIN FILM PADDLE LEAD FOR SPINAL CORD STIMULATION

MAR 09, 2023 09:00AM

NEUROONE® TO PARTICIPATE IN THE 35TH ANNUAL ROTH CONFERENCE

MAR 07, 2023 07:30AM

NEUROONE® AWARDED U.S. PATENT COVERING NOVEL AND PROPRIETARY THIN FILM ELECTRODE PLATFORM

FEB 14, 2023 04:00PM

NEUROONE® REPORTS FIRST QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

FEB 09, 2023 09:00AM

NEUROONE® TO REPORT FIRST QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON FEBRUARY 14

JAN 30, 2023 09:00AM

NEUROONE® ISSUES LETTER TO SHAREHOLDERS

DEC 22, 2022 09:00AM

NEUROONE® REPORTS FISCAL FOURTH QUARTER AND FULL FISCAL YEAR 2022 FINANCIAL RESULTS

DEC 13, 2022 04:00PM

NEUROONE® TO HOST FISCAL FOURTH QUARTER CORPORATE UPDATE

DEC 08, 2022 09:00AM

NEUROONE® TO REPORT FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON DECEMBER 13

DEC 06, 2022 09:00AM

NEUROONE® SUCCESSFULLY COMPLETES FEASIBILITY STUDY WITH ITS ONERF™ ABLATION SYSTEM

NOV 30, 2022 09:00AM

NEUROONE® SHIPS INITIAL ZIMMER BIOMET ORDER FOR ITS EVO® SEEG SYSTEM FOR LESS THAN 30 DAY USE

NOV 22, 2022 09:00AM

NEUROONE® TO RING NASDAQ STOCK MARKET CLOSING BELL ON NOVEMBER 22

NOV 21, 2022 11:00AM

NEUROONE® CEO DAVE ROSA FEATURED ON FOX BUSINESS NETWORKS MORNINGS WITH MARIA

OCT 25, 2022 09:00AM

NEUROONE® RECEIVES FDA 510(K) CLEARANCE TO MARKET ITS EVO® SEEG SYSTEM FOR LESS THAN 30 DAY USE

SEP 22, 2022 09:00AM

NEUROONE REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

MANAGMENT

DAVE ROSA

President & Chief Executive Officer

Mr. Rosa is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early-stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.

RON MCCLURG

Chief Financial Officer

Mr. McClurg has over 30 years of financial leadership experience with private and public companies. Prior to joining NeuroOne, Mr. McClurg was VP – Finance & Administration and Chief Financial Officer of Incisive Surgical, Inc., a privately-held medical device manufacturer, and Chief Financial Officer and Treasurer of Wavecrest Corporation, a privately-held manufacturer of electronic test instruments for the semiconductor industry. Mr. McClurg also served as Chief Financial Officer for several publicly-held companies, including Video Sentry Corporation, Insignia Systems, Inc., and Orthomet, Inc. Currently, he serves as a director for a privately held company. He began his career in public accounting with Ernst & Young, where he earned his CPA certificate. He holds a Bachelor of Business Administration degree in accounting from the University of Wisconsin – Eau Claire.

MARK CHRISTIANSON

Co-Founder, Business Development Director, Medical Sales Liaison

In excess of 15 years of executive sales, sales management, marketing, and project management experience with development stage companies. Prior to NeuroOne, Mr. Christianson held the positions of North American Sales Manager for Cortec Corporation, a manufacturer of specialty chemical products, and Regional Sales Manager for PMT Corporation, a leading manufacturer of products for neurosurgery, orthopedics and plastic surgery. He holds an accounting degree from Augsburg College.

STEVE MERTENS

Chief Technology Officer

Prior to joining NeuroOne, Mertens was Sr. Vice President of R&D and Operations at Nuvaira, a privately held lung denervation company developing minimally invasive products for obstructive lung diseases. Before that, Mertens was a Senior Vice President of Research and Development for Boston Scientific, where he guided a wide range of technologies through product development for the cardiology, electrophysiology, and peripheral vascular markets.

Mertens began his medical device career working in engineering, quality control, and manufacturing roles at SciMed Life Sciences. Mertens holds a Bachelor of Science degree in Chemical Engineering from the University of Minnesota and a master’s degree in Business Administration from the University of St. Thomas.

CAMILO DIAZ-BOTIA

Director of Electrode Development

Dr. Camilo Diaz-Botia is a highly experienced neural engineer whose work has focused on the development of technologies for bidirectional communication with the nervous system. He has authored and co-authored multiple peer reviewed scientific articles published in journals including Journal of Neural Engineering, Neuron, and Lab-on-a-Chip.

Most recently, Dr. Diaz-Botia worked for Neuralink where he led and mentored the process engineering team to deliver projects with unique microfabrication processes. Under his direction, the team built and designed novel processes for integration of thin film neural probes with brain machine interface systems.

Dr. Diaz-Botia earned a B.S. in Electrical Engineering from Universidad Nacional de Colombia and a Ph.D. in Bioengineering from the joint program at the University of California Berkeley and the University of California San Francisco. During his graduate studies, he conducted research on microfabricated thin film neural interfaces for chronic implants developing electrocorticography arrays with silicon carbide, a material suitable for long-term performance in harsh environments, and electrode arrays for minimally invasive subcortical recordings.

CHAD WILHELMY

Vice President of Quality Control and Regulatory Affairs

Chad Wilhelmy joined NeuroOne with 20 years of medical device experience developing, implementing, and leading quality management systems. Prior to joining NeuroOne, he held top leadership roles at HLT Medical as the Vice President of Quality and at Sunshine Heart as the Senior Director of Quality. He has driven quality strategies from early-stage development to commercial distribution with both the FDA and Notified Body. Chad earned a Bachelor of Science degree from the University of Wisconsin – Stout in Engineering Technology with an emphasis in Quality.

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, SICA MEDIA LLC  FOR A ONE DAY NMTC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: COEP) Profile

OUR NEW PROFILE IS:  (NASDAQ: COEP)

COEPTIS THERAPEUTICS SIGNS AGREEMENT TO ACQUIRE ALLOGENEIC IMMUNO-ONCOLOGY NK PLATFORM IN PHASE 1 CLINICAL TRIALS FROM DEVERRA THERAPEUTICS

COEPTIS THERAPEUTICS SECURES EXCLUSIVE RIGHTS TO NEGOTIATE TO ACQUIRE TRANSFORMATIONAL CELL THERAPY PLATFORM TO ENABLE POTENT COMBINATORIAL IMMUNO-ONCOLOGY TREATMENT STRATEGIES

COEPTIS THERAPEUTICS ENTERS INTO EXCLUSIVE OPTION AGREEMENT WITH UNIVERSITY OF PITTSBURGH FOR RIGHTS TO CAR-T TECHNOLOGIES DESIGNED TO TARGET MULTIPLE CANCER INDICATIONS, INCLUDING HEMATOLOGIC AND SOLID TUMORS


______________________________

Hello Everyone,

We have another profile that we want to put on your radar for tomorrow’s session.

We have had some recent success profiling small cap biotechs in recent months.

This is a company that has seen activity pick up pretty significantly over the past 3 sessions with no recent news to speak of.

Pull up COEP immediately.

This one almost doubled from late April to mid May on fairly light interest.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh(SNAP-CAR), and the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis’ business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA.

MAJOR CATALYSTS

👉Potential acquisition of VyGen-Bio would strengthen their oncology pipeline by obtaining exclusive, worldwide ownership rights to GEAR™ Platform

👉Focused on SNAP-CAR T Cells, a Platform Technology Being Developed to be Combined with Tagged, Tumor-Specific Antibodies to Potentially Target Many Different Tumor      Types.

👉Exclusive Rights to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies.

👉SNAP-CAR Technology Highlighted in Peer-Reviewed Article in Translational Medicine Journal.

👉Research Agreement with the University of Pittsburgh to Expand Pre-Clinical Development of SNAP-CAR T Cells Targeting HER2-Positive Cancers.

👉Collaboration with IQVIA, a Global Contract Research Organization, to Identify Target Indications and Initiate IND-Enabling Activities.

👉CAR T Cell Therapy Market is Expected to Reach $20.56 Billion by 2029 from $1.96 Billion in 2021.

$COEP NASDAQ

Coeptis Therapeutics, Inc. has entered into an exclusive license agreement with the University of Pittsburgh for certain intellectual property rights to technologies developed within research laboratories at the University of Pittsburgh. Chimeric antigen receptors (CARs) are artificial T cell receptors that re-target T cells to specifically recognize and kill tumor cells. The licensing agreement involves a CAR T cell therapy platform called “SNAP CAR” designed to be a universal therapeutic in the treatment of various types of cancer. The SNAP-CAR T cell therapy is currently in preclinical development.

Through the company’s subsidiary, Coeptis Pharmaceuticals, they have entered into co-development agreements with VyGen-Bio, led by its team of leading medical researchers at the Karolinska Institutet (KI) based in Stockholm, Sweden, to jointly develop novel natural killer cell-based therapeutics and related diagnostics with an initial focus on the urgent need to improve treatments for cancers that over-express the CD38 protein (CD38+).

COEP‘s Scientific Collaboration

Coeptis is collaborating with researchers from the University of Pittsburgh and contracted a prominent Clinical Research Organization (CRO) to begin developing the SNAP-CAR T cell therapy with the goal to pursue clinical trials. Coeptis has been assigned the worldwide development and commercialization rights to the licensed technology in the field of human treatment of cancer with antibody or antibody fragments using SNAP-CAR T cell technology.

VyGen-Bio is a discovery-stage, cell-based immunotherapy company focused on the development of transformational technology platforms: GEAR-NK, modified natural killer cell-based therapeutics (NK cells), optimized to be co-administered with targeted antibodies; and, GEAR Diagnostic, a companion diagnostic being developed to select patient populations most likely to benefit from targeted antibody therapies.

CAR T And SNAP-CAR Strategy

The Importance Of CAR T Cell Therapy – Chimeric antigen receptor (CAR) therapy is a new treatment for cancer in which a patient’s T cells (a type of immune cell) are genetically engineered to recognize cancer cells to target and destroy them. Cells are extracted from the patient and then genetically engineered to make the CAR and are re-introduced back into the patient. Currently approved CAR T therapies are revolutionizing the treatment of many blood cancers including B cell leukemias and lymphomas by targeting specific proteins found on these cancers, and there is hope in treating additional cancers including solid tumors by having them recognize new targets.

What is SNAP-CAR And How Does It Target Certain Cancers? – Coeptis has licensed a CAR T cell therapy platform called “SNAP-CAR” to be a universal therapeutic. The SNAP-CAR technology is in preclinical development at the University of Pittsburgh. Instead of directly binding to a target on the tumor cell, the CAR T cells are co-administered with one or more antibody adaptors that bind to the tumor cells and are fitted with a chemical group that irreversibly connects them to the SNAP-CAR on the therapeutic cells via a covalent bond. A covalent bond is the highest affinity bond possible, thus this binding is expected to translate to highly potent therapeutic activity.

SNAP-CAR, A Highly Programmable Therapeutic Platform –Pre-clinical studies in mice have demonstrated that by targeting tumors via antibody adaptor molecules, the SNAP-CAR therapy provides a highly programmable therapeutic platform that may present several potential advantages over standard CAR T treatments.

Immunotherapy Challenges

Reducing potential toxicity: The therapeutic activity of the SNAP-CAR T cells can be controlled by the antibody dose, which we envision would allow clinicians to potentially mitigate toxicity from over-activity. We also envision that the immune response against cancer may also be boosted in patients with additional doses of the tagged tumor-specific antibody.

The Goal

Lowering the chance for cancer relapse: Relapse from CAR T cell therapy which often results from the loss or down-regulation of the targeted protein on the cancer, can potentially be avoided by combining SNAP-CAR T cells with antibodies targeting multiple antigens at once.

A Novel Approach

Targeting new cancers: SNAP-CAR T cells are a platform technology that is being developed to be co-administered with tagged, tumor-specific antibodies to potentially target many different tumor types, including hematological malignancies and solid tumors.

GEAR-NK (CD38) Strategy

GEAR-NK (CD38) – The company’s science stems from the premise that certain cancer therapies for CD38+ tumors can be enhanced to minimize off-target effects while harnessing the therapeutic impact of NK cells. CD38 is a multifunctional transmembrane glycoprotein that is abnormally overexpressed in a variety of tumor types and is associated with cancer progression.

Immunotherapies, specifically anti-CD38 monoclonal antibodies (mAbs) target the CD38+ cancer cells, but also kill other important innate immune effector cells such as CD38+NK cells that recognize and destroy cancer cells, or virus-infected cells.

How Does CD38 Play An Important Role In Targeting Certain Cancers? – CD38 is a protein receptor overexpressed on certain cancers including hematological malignancies and solid tumors. With the development of anti-CD38 monoclonal antibody therapies (mAbs) designed to bind to CD38 antigen to generate immune-mediated killing, survival outcomes for CD38+ cancers have significantly improved. However, despite the potential benefit of anti-CD38 mAbs, cancers such as multiple myeloma are still considered to be incurable.

Immunotherapy Challenges

Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.

The Goal

To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with CD38 targeting therapies, and thus allowing for complementary tumor killing and immune surveillance.

A Novel Combinatorial Approach

Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible.

COEPTIS THERAPEUTICS SIGNS AGREEMENT TO ACQUIRE ALLOGENEIC IMMUNO-ONCOLOGY NK PLATFORM IN PHASE 1 CLINICAL TRIALS FROM DEVERRA THERAPEUTICS

Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML) and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors

Clinical data from AML Clinical Trial Expected during 2H 2023

$COEP Opening Bell

WEXFORD, Pa. , April 18, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has entered into a binding term sheet with Deverra Therapeutics, Inc. (“Deverra Therapeutics”) pursuant to which it has obtained an exclusive right, until August 31, 2023, to negotiate towards the acquisition or license of assets from Deverra Therapeutics related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. Deverra Therapeutics is currently advancing clinical programs investigating these technologies in relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) and patients hospitalized with respiratory viral infections.

The transaction, if finalized, would provide Coeptis with, among other assets, exclusive rights to two FDA approved Investigational New Drug (IND) applications and two Phase 1 clinical trials (NCT04901416, NCT04900454) investigating infusion of DVX201, an unmodified natural killer (NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies and viral infections. In addition, Coeptis would gain access to a highly scalable allogeneic cellular immunotherapy platform that is being developed to generate and deliver off-the-shelf (no HLA matching), cost effective, on demand cell therapies to a broad patient population. Deverra expects phase I clinical trial data from its AML study to be complete during 2H 2023.

Additionally, subject to the successful negotiation and completion of any proposed transaction, Deverra Therapeutics’ current Scientific Founder, Chief Scientific Officer and EVP, Research & Development, Colleen Delaney, MD, would be expected to assume the position of Chief Scientific and Medical Officer at Coeptis Therapeutics. Dr. Delaney is a world-renowned expert in cell and gene therapy research with more than 20 years’ experience in the translation of scientific discovery to clinical practice, including all aspects of cell therapy product development.

“This transaction would greatly expand Coeptis’ technology portfolio by incorporation of a cutting-edge allogeneic cell therapy platform with extensive safety and clinical data and align itself with leading experts in the field of cell and gene therapy,” said Dave Mehalick, President and CEO of Coeptis Therapeutics. Mr. Mehalick continued, “The addition of these clinical and pre-clinical immune effector cell programs would significantly diversify our R&D capabilities and bring a clinical pipeline with multiple novel approaches to combination cellular immunotherapy approaches, not yet achieved by others. Importantly, the substantial capabilities of the allogeneic cell therapy platform would open new pathways for Coeptis to consider expanding its cell-based therapies beyond autologous CAR T. We are excited about the possibility of exploring the application of both the SNAP-CAR and GEAR technologies to allogeneic, off-the-shelf immune effector cells. The NK and macrophage (MAC) immune effector cell generation from Deverra’s platform combined with Coeptis’ target specific CARs has the potential to result in development of allogeneic NK and MAC cell therapies.”

Dr. Delaney stated: “Deverra’s allogeneic cell therapy platform has been in use clinically since 2006, and we have generated significant clinical and safety data since that time. This platform has been shown to provide extreme flexibility and optionality in the generation and modification of multiple distinct immune effector cell types from a single platform. We are excited about the prospect of bringing together our established allogeneic cell platform with the novel targets and technologies from Coeptis to generate first-in-class allogeneic cell therapies to treat a wide range of life-threatening disorders in a cost effective and clinically accessible way.”

The proposed transaction is subject to confirmatory due diligence, negotiation and execution of definitive documentation based on agreed terms and other closing conditions, including third party approvals, as well as a right of first refusal in place that a third party possesses and will have a right to exercise. There can be no assurance that the parties will reach a definitive agreement related to the proposed acquisition or license of assets or that, even if any such agreement is reached, any such transaction will be successfully consummated.

About Deverra Therapeutics

Deverra Therapeutics is a privately held clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf (no matching required) cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. Deverra is the only company with a proprietary and clinically proven stem cell expansion technology that also serves as starting material for generation of multiple fully functional immune effector cells that can also be engineered to be potent killers of cancer cells. Deverra was a pioneer developing universal non-HLA matched allogeneic and off-the-shelf cell therapies that have been utilized in multiple clinical trials with no safety concerns.

COEPTIS THERAPEUTICS SECURES EXCLUSIVE RIGHTS TO NEGOTIATE TO ACQUIRE TRANSFORMATIONAL CELL THERAPY PLATFORM TO ENABLE POTENT COMBINATORIAL IMMUNO-ONCOLOGY TREATMENT STRATEGIES

Potential acquisition of VyGen-Bio would strengthen Coeptis’ oncology pipeline by obtaining exclusive, worldwide ownership rights to GEAR™ Platform and companion diagnostic technologies

WEXFORD, Pa., March 29, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has obtained the exclusive right to negotiate towards the acquisition of VyGen-Bio, Inc. or its assets. Coeptis intends to immediately commence its due diligence review of VyGen-Bio’s assets, including its IP and knowhow related to rights to GEAR™ cell therapy and companion diagnostic platforms, and, depending on the results of its due diligence analysis, turn to negotiation of definitive deal documents. VyGen-Bio’s product candidates and platforms were discovered by scientists at the world-renowned Karolinska Institutet in Stockholm, Sweden, including Dr. Arnika Wagner, who is expected to play a key collaborative development role for Coeptis as the Company builds its capabilities to develop treatments for cancer and gains technologies to develop additional cell and gene therapies.

This transaction, if finalized, would expand upon Coeptis’ collaboration with VyGen-Bio, which is currently focused on CD38-GEAR-NK, a natural killer (NK) cell therapy for the treatment of CD38+ cancers with an initial focus on multiple myeloma, and CD38-Diagnostic, an in vitro diagnostic tool being developed to help identify cancer patients who may be appropriate candidates for anti-CD38 mAb therapy.

In the event a transaction is consummated, Coeptis would then be in a position to advance the development of various GEAR-engineered cells, including NK cells, T cells, and hematopoietic stem cells, and to pursue development of GEAR-engineered cells for use in combination with mAbs that target a potentially wide range of receptor targets. Additional development options that would be explored could include therapeutic modalities where the antigen-specificity of mAbs is used, such as CAR-T and bispecific antibodies for the treatment of a broad range of hematologic malignancies and solid tumors.

“We believe that the acquisition of VyGen-Bio’s GEAR Platform would represent a significant inflection point in the growth of Coeptis and our strategy to be a leader in the development of ‘next generation’ cell therapy technologies for cancer and other diseases,” said Dave Mehalick, President and CEO of Coeptis Therapeutics. “Our vision for GEAR is bold and ambitious, as we believe this novel cell engineering approach protects the integrity, fitness and function of the cell while importantly shielding it from destruction by co-administered mAbs. We believe the GEAR platform offers the potential to not only improve existing cancer therapies, but further expand the use of existing therapies in new indications.”

“If we are able to successfully consummate an acquisition transaction, we plan to initially focus on advancing the first GEAR candidate, CD38-GEAR-NK, to the clinic for the treatment of multiple myeloma and to concurrently engage in business development activities to expand the GEAR Platform into new cell therapy products via potential co-development and/or licensing partnerships,” Mehalick added.

GEAR was discovered by scientists at the Karolinska Institutet (KI), including Evren Alici M.D., Ph.D., Hans-Gustaf Ljunggren M.D., Ph.D., and Arnika Kathleen Wagner Ph.D. Drs. Alici, Ljunggren, and Wagner are founding members of VyGen-Bio and will continue to contribute in the development of the technology platforms as members of Coeptis’ Scientific Advisory Board. Drs. Ljunggren and Alici are managing directors of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI and funded by Sweden’s innovations agency, Vinnova. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine.

“GEAR-NK cells, and ultimately all GEAR-engineered cells, are being designed to potentially decrease side-effects associated with certain mAb therapies and potentially reduce or eliminate the ‘on-target-off-tumor’ effect. As a Coeptis’ SAB member, I look forward to collaborating in the development of these technologies, which may have widespread applicability in cancer and beyond,” stated GEAR co-inventor, Dr. Wagner.

About VyGen-Bio™, Inc.

VyGen-Bio is a discovery-stage, cell-based immunotherapy company focused on the development of potentially transformational technology platforms. GEAR-NK is a modified NK cell-based therapeutic being designed to be co-administered with targeted antibodies. The Company is also developing companion diagnostics designed to potentially identify patient populations that may be most likely to benefit from targeted antibody therapies. Headquartered in Tampa, Florida on the campus of the H. Lee Moffitt Cancer Center, VyGen-Bio is a majority-owned subsidiary of Vycellix, Inc. (www.Vycellix.com). The Company’s platforms were discovered by scientists at Karolinska Institutet (KI), Stockholm, Sweden that collaborate with VyGen-Bio. Additionally, VyGen-Bio is a Partner in “NextGenNK”, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI and funded by Sweden’s innovations agency, Vinnova. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine.

NEWS

MANAGEMENT

LEADERSHIP TEAM

Management has demonstrated a track record of acquiring and developing novel therapies.

 Dave Mehalick

DAVE MEHALICK

CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER

Mr. Mehalick is a successful executive with a career spanning over 30 years across a variety of industries including life sciences, technology, financial services, military contracting, entertainment, and consumer products. His career has allowed him deep immersion into all facets of executive management notably mergers and acquisitions, corporate finance, C- Suite management, product development and licensing, partnerships, product commercialization, and corporate communications. Mr. Mehalick has assisted and managed several organizations towards successful investor monetization across all aspects of company evolution resulting in billions of dollars in transactions and financings. Currently, Mr. Mehalick is our Chairman, Chief Executive Officer and President, and one of our co-founders. He has been involved in several companies in a variety of positions and functions prior to Coeptis spanning many different industries. Mr. Mehalick began his career in the financial services industry in the wealth management area before transitioning to investment banking in the early 2000’s. He held positions of Vice President and Senior Vice President at multiple firms notably First Union Capital Markets, Gruntal and Co. and Ferris Baker Watts. He then began working earnestly with companies to assist them in all aspects of growth. He was a founding partner in American Defense Systems, a military contractor designing lightweight antiballistic armor and hardening systems for transportation and solid structures. After procuring several military contracts, the company grew revenues to a point that they became public on the AMEX stock exchange. Throughout his career Mr. Mehalick was involved in numerous similar situations either in a management or consultant role to allow strong returns for shareholders via acquisitions or public strategies.

Brian Cogley

BRIAN COGLEY

CHIEF FINANCIAL OFFICER

Brian Cogley is a senior-level financial executive with 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing. Prior to joining Coeptis Therapeutics, Mr. Cogley was a Senior Manager in the Accounting Advisory practice at CFGI, LLC., where he served pharmaceutical and financial services clients in technical accounting implementations and execution. In this role, he led financial operations for client companies and successfully executed various financial projects while performing multiple interim management roles. Formerly, Mr. Cogley worked as the Vice President of Finance & Accounting at NexTier Bank, after holding previous roles as Global Cash Manager, Senior Accountant, Financial Analyst and Senior Audit Associate across the finance industry, including at KPMG, a “Big 4” accounting firm. In Mr. Cogley’s varied career experience, he developed expertise in financial planning, reporting and variance analysis, as well as in asset and liability management, handling cash, investments, derivatives and debt portfolios for efficient use of company funds. A forward-thinker with problem-solving skills and enthusiasm, Mr. Cogley’s leadership of teams has resulted in innovative thinking and tangible results. Mr. Cogley holds a bachelor’s degree in accounting and a Master of Business Administration with a concentration in finance from Duquesne University.

Christine Sheehy

CHRISTINE SHEEHY

VP OF COMPLIANCE AND CORPORATE SECRETARY

Christine Sheehy is a pharmaceutical business leader with over 25 years of experience, including globally commercializing drug products and working in development of targeted therapeutics including cell and gene therapies. Ms. Sheehy was Senior Vice-President of Operations for Kadmon Pharmaceuticals, leading the global supply chain, distribution, and IT organizations. She was a founding employee of start-up pharmaceutical company Three Rivers Pharmaceuticals, which was acquired by Kadmon Pharmaceuticals in 2010. During that time, she launched branded and generic products in the U.S., leading the operational business. Globally, Ms. Sheehy has executed international supply and distribution partnerships in Europe and Asia. Prior to Three Rivers Pharmaceuticals, Ms. Sheehy held various roles ranging from business and finance consulting to financial management. Strategically minded, with a strong ability to understand all aspects of the business, her leadership skills have been developed by working substantially in start-ups and early-stage companies. Additionally, over the past 15 years Ms. Sheehy has held board of director and advisory positions for multiple industry organizations, and she holds a bachelor’s degree in accounting from Penn State University.­­­­

Dan Yerace

DAN YERACE

DIRECTOR AND VICE PRESIDENT OF OPERATIONS

Dan Yerace is a co-founder of Coeptis Pharmaceuticals and serves as the Vice President of Operations. Mr. Yerace has over ten years of experience in the pharmaceutical industry and is a key strategist responsible for supply chain management, business development, portfolio management, and corporate strategy. Mr. Yerace has broad operational experience and has held leadership positions in procurement, global supply chain management, operations, and business development for small private firms and fortune 500 multi-national corporations. Prior to joining Coeptis, Mr. Yerace served as Senior Director of Global Supply Chain and Commercial Business Development for Kadmon Pharmaceuticals. Mr. Yerace holds a bachelor’s degree in economics, and a masters of business administration from Waynesburg University.

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, KING TIDE MEDIA LLC  FOR A ONE DAY COEP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: GNPX) Profile

OUR NEW PROFILE IS:   (NASDAQ: GNPX)

_____________________________________________________________

GNPX HAS ALREADY RECEIVED FAST TRACK DESIGNATION FOR ACCLAIM 2

GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO ADVANCE TO PHASE 2 EXPANSION PORTION OF ACCLAIM-1 CLINICAL TRIAL OF REQORSA® IN COMBINATION WITH TAGRISSO® IN ADVANCED NON-SMALL CELL LUNG CANCER 

INDEPENDENT RESEARCHERS FIND THAT TUSC2, THE GENE DELIVERED BY GENPREX’S REQORSA®, FUNCTIONS AS A NOVEL TUMOR SUPPRESSOR FOR GLIOBLASTOMA

GENPREX COLLABORATORS REPORT POSITIVE PRECLINICAL DATA WITH NPRL2 GENE THERAPY UTILIZING NON-VIRAL ONCOPREX® NANOPARTICLE DELIVERY SYSTEM IN NON-SMALL CELL LUNG CANCER AT THE 2023 AACR ANNUAL MEETING

CHECK OUT THE INVESTOR PRESENTATION HERE

_______________________________________________

Hello Everyone,

We have another profile for you to research for Friday’s session.

This is a company you are definitely going to want to research immediately.

Pull up GNPX right away.

This one looks like it is moving north with some steam as it has been seeing interest pick up with a close at the HOD, also making a new 30 day high.

TAKE A LOOK AT THE 10 DAY CHART.  NOTICE HOW IT RECENTLY EXPLODED OFF OF THE LOWS WHEN IT SAW SOME PROFIT TAKING AFTER A BIG MOVE AND IS MOVING NORTH.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.

Rodney Varner, CEO of Austin-based biotech company Genprex, stands at the podium during the closing bell ceremony for the Nasdaq exchange in 2018 following the company's initial public offering of stock. [Photo courtesy Genprex]

Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.

Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans.

ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body.

The Company’s lead product candidate, REQORSA™ is being evaluated as a treatment for non-small cell lung cancer (NSCLC) (with each of these clinical programs receiving a Fast Track Designation from the Food and Drug Administration) and for small cell lung cancer.

Genprex’s diabetes gene therapy approach consists of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas.

In models of Type 1 diabetes, the genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.

In Type 2 diabetes, where autoimmunity is not at play, it is believed that exhausted beta cells are also rejuvenated and replenished.

Research And Development Pipeline

GNPX Email Image 1.0

CATALYSTS

– Addressing unmet medical need in large markets through the buildout of a robust pipeline of new drug candidates and drug combinations.

– Leveraging a gene therapy platform; Genprex’s non-viral ONCOPREX® Nanoparticle Delivery System is designed to deliver a variety of therapeutic genes to fight multiple types of cancer.

– REQORSATM immunogene therapy, the first systemically delivered gene therapy used for cancer in humans, can be combined with top-selling cancer drugs and may improve their benefits.

– Genprex has demonstrated clinical achievement with REQORSA in two clinical trials, showing a favorable safety profile and evidence of efficacy in lung cancer.

– GPX-002, Genprex’s diabetes gene therapy, works to transform alpha cells in the pancreas into insulin producing beta-like cells. A Phase 1 clinical trial could be the first-ever gene therapy tested in humans for diabetes.

– Advancing novel gene therapies in diseases with large markets and unmet needs.

– Two NSCLC trials currently enrolling; both with FDA Fast Track Designations.

– World class academic partners.

GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO ADVANCE TO PHASE 2 EXPANSION PORTION OF ACCLAIM-1 CLINICAL TRIAL OF REQORSA® IN COMBINATION WITH TAGRISSO® IN ADVANCED NON-SMALL CELL LUNG CANCER 

TAKE A LOOK AT THE CHART.  NOTICE HOW IT RECENTLY EXPLODED OFF OF THE LOWS AND IS MOVING NORTH.

CLINICAL TRIALS

ONC-001

EVALUATING THE SAFETY OF REQORSA® IMMUNOGENE THERAPY AS A MONOTHERAPY (COMPLETED)

A Phase 1 dose escalation trial was conducted at The University of Texas MD Anderson Cancer Center evaluating the systemic, intravenous delivery of REQORSA® (TUSC2/FUS1) as a monotherapy in stage IV recurrent, metastatic lung cancer patients. The primary objective of this Phase 1 trial was to assess the toxicity of REQORSA administered systemically and intravenously, to determine the maximum tolerated dose, or MTD, and to determine a recommended Phase 2 dose of REQORSA alone.

THE FIRST SYSTEMICALLY DELIVERED GENE THERAPY USED FOR CANCER IN HUMANS

The study showed for the first time that a tumor suppressor gene can be delivered systemically, intravenously and selectively to a patient’s cancer cells using a systemic nanoparticle vector. Although this trial was not designed to show changes in outcomes, a halt in cancer growth was observed in a number of patients. REQORSA was well tolerated with tumor responses noted in lung primary and metastatic cancers in the liver, pancreas, and lymph nodes. In addition, pre- and post-treatment patient biopsies demonstrated that intravenous REQORSA selectively and preferentially targeted patients’ cancer cells.

Metabolic Tumor Response in a Metastatic Lung Cancer Subject

This subject survived after subsequent therapy more than seven years after the final treatment with REQORSA, to our knowledge, without evidence of cancer progression in the responding sites.

ONC-002

COMBINING REQORSA® IMMUNOGENE THERAPY WITH TARCEVA (ERLOTINIB)

PHASE 1 PORTION COMPLETED; PHASE 2 PORTION NO LONGER ENROLLING DUE TO OUR CHANGE OF FOCUS TO CONDUCT ACCLAIM-1

A Phase 1/2 clinical trial evaluated REQORSA® in combination with Tarceva® in stage IIIB/IV lung cancer patients without an activating EGFR mutation and in patients with an activating EGFR mutation whose cancer has progressed on Tarceva therapy.  Patients without the EGFR mutation represent the vast majority of lung cancer patients. However, such patients generally are not candidates for Tarceva therapy.


In the Phase 2 trial combining REQORSA with Tarceva, subjects received REQORSA in combination with Tarceva every 21 days until the occurrence of progressive disease (PD), unacceptable toxicity, withdrawal of consent, or study treatment discontinuation for other reasons, whichever occurred first. We believe that the results from the Phase 2 trial are encouraging. Out of 10 patients, 9 had received 2 or more cycles and were therefore evaluable for response. Four patients had tumor regression. The median duration of response is three months. The disease control rate (CR+PR+SD > 8weeks) was 78%, which substantially exceeds the 7% response rate (with no CRs) and 58% disease control rate reported for the LUX-Lung 1 trial, a clinical trial of Gilotrif (afatinib) in a comparable group of patients.

REQORSA + Tarceva Combination: Phase 2 data in subjects with or without EGFR mutationsACCLAIM-1 
COMBINING REQORSA™ IMMUNOGENE THERAPY WITH TAGRISSO (OSIMERTINIB)Preliminary analysis of the interim data from the Phase 2 portion of our ONC-002 trial supported our belief that REQORSA™ may provide medical benefit in several subpopulations of NSCLC patients for which there is an unmet medical need, and may provide pathways for accelerated approval by the U.S. Food and Drug Administration, or FDA. Data from our clinical trials, along with our preclinical data, provided the basis for our application for a Fast Track Designation, which was granted by FDA on January 14, 2020.In granting our Fast Track Designation, the FDA found that REQORSA may provide a benefit over existing therapies for patients whose tumors progress on AstraZeneca’s Tagrisso. The FDA Fast Track Designation is for use of REQORSA in combination with TKI Tagrisso for the treatment of NSCLC patients with EGFR mutations whose tumors progressed after treatment with Tagrisso. We believe that the Fast Track Designation provides a clearly defined pathway toward FDA approval of the combination of REQORSA with Tagrisso.We initiated the Acclaim-1 clinical trial in June 2021, a Phase 1/2 clinical trial of REQORSA combined with Tagrisso. To learn more about Acclaim-1, please visit ClinicalTrials.gov.To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our TUSC2 Bibliography page.

COMBINING REQORSA™ IMMUNOGENE THERAPY WITH KEYTRUDA (PEMBROLIZUMAB)
Researchers at MD Anderson Cancer Center have conducted preclinical studies evaluating REQORSA™ in combination with anti-PD1 checkpoint inhibitors, including Merck’s Keytruda.Positive and encouraging data indicate that REQORSA is synergistic with immunotherapies.In April 2019, we reported that our collaborators at MD Anderson presented positive preclinical data for the combination of TUSC2 with pembrolizumab, demonstrating that TUSC2 combined with checkpoint blockade was more effective than checkpoint blockade alone in increasing the survival of mice with human immune cells, that had metastatic lung cancer.In November 2019, we reported that our collaborators at MD Anderson presented positive preclinical data for the combination of TUSC2, pembrolizumab and chemotherapy for the treatment of some of the most resistant metastatic lung cancers. This study found that the combination of TUSC2 increases the effectiveness of pembrolizumab and chemotherapy, and thus, may improve on first-line standard of care for lung cancer.In May 2020, we entered into a worldwide, exclusive license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson for the use of TUSC2 in combination with immunotherapies, including Keytruda, and also for the use of TUSC2 in a three-drug combination of TUSC2, immunotherapy and chemotherapy.In December 2021, we received Fast Track Designation from the FDA for use of REQORSA in combination with the checkpoint inhibitor Keytruda for the treatment of advanced NSCLC patients whose tumors progressed after treatment with Keytruda.In March 2022, we opened the Acclaim-2 clinical trial for patient enrollment, a Phase 1/2 clinical trial of REQORSA combined with Keytruda. To learn more about Acclaim-2, please visit ClinicalTrials.gov.To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our TUSC2 Bibliography page.
DIA-001 STUDYING GPX-002 IN DIABETIC MICE
Researchers at the University of Pittsburgh have conducted preclinical studies evaluating GPX-002 in diabetic mice models. In vivo mice studies have found that GPX-002 restored normal blood glucose levels for an extended period of time, typically around four months. The duration of restored blood glucose levels in mice could translate to decades in humans.These researchers are continuing to conduct preclinical studies in diabetic primates. Once sufficient preclinical data has been generated, we expect to begin a Phase 1 clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes.To learn more about scientific evidence and studies supporting GPX-002 and the Pdx1/MafA genes, please refer to our Pdx1/MafA Bibliography page.
ONCOLOGY COMBINATION TREATMENT APPROACH
Our oncology program uses a modern combinational treatment approach to fight cancer, utilizing our lead drug candidate, REQORSA™ immunogene therapy and our unique, proprietary, non-viral ONCOPREX® nanoparticle delivery system combined with approved targeted therapies and immunotherapies. This enables us to offer hope to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them.
ONCOLOGY COMBINATION TREATMENT APPROACH
Our research indicates that when REQORSA, our lead drug candidate for non-small cell lung cancer (NSCLC), is combined with targeted therapies such as Tarceva (erlotinib) or Tagrisso (osimertinib) or with immunotherapies such as Opdivo (nivolumab) or Keytruda (pembrolizumab), REQORSA is synergistic with those drugs, meaning that the combination is more effective than either drug alone. We believe that by combining REQORSA with targeted therapies and immunotherapies, we can extend the benefit of these approved lung cancer drugs into the large majority of patients who do not now benefit from them, either because the patients’ tumors do not have the molecular profiles that indicate effectiveness of those drugs, or because the patients have developed resistance to those drugs after receiving them for some period of time.To learn more about our combination trials utilizing our oncology combination treatment approach, refer to our 
Pipeline and Clinical Trials pages.
TARGETED THERAPIEST
argeted therapies work by targeting the cancer or disease’s specific gene, protein or tissue that contributes to the disease while sparing normal tissue. Unfortunately, targeted therapies require patients to have an activating genetic mutation specific to the drug. In NSCLC, the vast majority of lung cancer patients do not have the genetic mutations that qualify them for targeted therapies, such as the EGFR or ALK gene. In addition, the few patients who do have the genetic mutation qualifying them to receive targeted therapies are likely to develop resistance to these drugs over time.In January 2020, we received a United States FDA Fast Track Designation for use of REQORSA in combination with EGFR inhibitor Tagrisso for the treatment of NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. The median length of time that patients are treated with Tagrisso before their tumors progress is approximately eighteen (18) months.
IMMUNOTHERAPIES
Immunotherapy is a type of treatment that helps the immune system fight disease. Biomarker testing can help determine if high levels of PD-1/PD-L1 proteins are detected in the patient, signifying that the body’s immune system is not working to fight cancer or disease as it should. These patients could qualify for approved immunotherapies, however, not all patients benefit from immunotherapies.Genprex is conducting preclinical studies to evaluate REQORSA in combination with checkpoint inhibitors. Preclinical data indicate that Genprex’s lead drug candidate is synergistic with checkpoint inhibitors, such as Merck’s Keytruda, meaning that the combination of drugs may be more effective than checkpoint inhibitors alone. Preclinical data also indicates that a three-drug combination of a checkpoint inhibitor, chemotherapy, and REQORSA may be more effective than the two-drug combination of a checkpoint inhibitor and chemotherapy.
MARKET OPPORTUNITY
AstraZeneca’s Tagrisso had more than $4 billion in worldwide gross sales in 2020, and Tagrisso is AstraZeneca’s highest grossing product. Given Genprex’s Fast Track Designation and Tagrisso’s status as the current standard of care in EGFR-mutated NSCLC, we have prioritized the clinical development of REQORSA in combination with Tagrisso. We believe this regulatory pathway positions us well in the $17.9 billion global lung cancer market, especially given the advantages of our Fast Track Designation status.Merck’s Keytruda generated more than $14 billion in worldwide sales in 2020, and Keytruda is Merck’s highest grossing product. Keytruda is the standard of care in non-EGFR mutated NSCLC. Genprex plans to initiate a Phase I/II clinical trial evaluating REQORSA in combination with pembrolizumab.
CANCER

Cancer is a complex disease that can start in any site in the body when a tissue grows out of control and inhibits the body’s normal functioning. At the cell level, cancer often involves the dysregulation of multiple genes and cellular pathways, leading to the cell’s inability to maintain proper cellular functions. Re-establishing or blocking these pathways can be done through many therapeutic approaches, including gene therapy. More general information about cancer can be found at The American Cancer Society.
LUNG CANCER
Genprex’s oncology program is focused on developing new treatments for cancer. Our initial therapeutic target is lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).According to the World Health Organization in 2020, lung cancer was the leading cause of cancer deaths worldwide, causing more deaths than colorectal, breast, liver, or stomach cancers. In 2020, there were more than 2 million new lung cancer cases and 1.8 million deaths from lung cancer worldwide. In the United States, according to the American Cancer Society, it is estimated that in 2022 there will be more than 236,000 new cases of lung cancer and more than 130,000 deaths from this disease. NSCLC represents 84% of all lung cancers and the five-year survival rate for patients with NSCLC with distant spread is 7 percent. SCLC represents about 13% of lung cancer patients and the five-year survival rate for patients with SCLC with distant spread is 3 percent. With limited benefit from current therapies, we believe there is a significant unmet medical need for new treatments for NSCLC and SCLC in the United States and globally, and we believe REQORSA may be suitable for the majority of lung cancer patients.
DIABETES
Our diabetes gene therapy candidate, GPX-002, is being developed for the treatment of diabetes.According to the U.S. Center for Disease Control, 37 million Americans, or approximately 11% of the population, have diabetes. It is also believed that more than 96 million Americans have prediabetes, which represents approximately 38% of the U.S. population. The prevalence of this chronic disease is continuing to rise.Chronic diabetes conditions include Type 1 diabetes and Type 2 diabetes, both of which lead to excess sugar in the blood and can cause serious health problems. Left untreated, high blood sugar levels can damage eyes, kidneys, nerves, and the heart, and can also lead to coma and death.

TECHNOLOGY

REQORSA® IMMUNOGENE THERAPY

THE FIRST SYSTEMICALLY DELIVERED GENE THERAPY USED FOR CANCER IN HUMANS

Our lead product candidate, REQORSA®  immunogene therapy (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC), uses the company’s unique, proprietary ONCOPREX® Nanoparticle Delivery System, which we believe is the first systemic gene therapy delivery platform used for cancer in humans. In 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso® (osimertinib) in late-stage NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track Designation for REQORSA in combination with Merck & Co’s Keytruda® (pembrolizumab) in late-stage NSCLC patients whose disease progressed after treatment with Keytruda.

The active ingredient in our lead product candidate, REQORSA, is the TUSC2 gene, a tumor suppressor gene.

REQORSA consists of the TUSC2 gene encapsulated in a nanoparticle made from lipid molecules with a positive electrical charge. REQORSA is injected intravenously and can specifically target cancer cells, which generally have a negative electrical charge. Once REQORSA is taken up into a cancer cell, the TUSC2 gene is expressed into a protein that is capable of restoring certain defective functions arising in the cancer cell. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance.

We believe that REQORSA, unlike other gene therapies, which either need to be delivered directly into tumors or require cells to be removed from the body, re-engineered and then reinserted into the body, is the first systemic gene therapy used for cancer in humans.

OVERCOMING DRUG RESISTANCE

REQORSA is a pan-kinase inhibitor shown to simultaneously inhibit the EGFR and AKT oncogenic kinase pathways in vitro and in vivo. Once the cancer cell takes up the nanoparticle containing TUSC2, it is reprogrammed to die. Resistance to targeted drugs and checkpoint inhibitors develop through activation of alternate bypass pathways. For example, when PD-1 is blocked, the TIM-3 checkpoint is up-regulated. We believe that REQORSA’s multimodal activity will block emerging bypass pathways, reducing the probability that drug resistance develops.

To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our Clinical Trials and TUSC2 Bibliographypages.

GPX-002

DIABETES GENE THERAPY

GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies. GPX-002 was developed by researchers at the University of Pittsburgh. Diabetic mice studies have shown that GPX-002 restored normal blood glucose levels for an extended period of time, which could translate to decades in humans. This gene therapy could not only become a new treatment option for millions of diabetes patients who need insulin replacement therapy, but it holds the potential to provide long-term effectiveness, or may even be a cure, for diabetic patients.

The diabetes gene therapy, GPX-002, is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. The genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.

Image source: Osipovich, Anna & Magnuson, Mark. (2018). Alpha to Beta Cell Reprogramming: Stepping toward a New Treatment for Diabetes. Cell Stem Cell. 22. 12-13. 10.1016/j.stem.2017.12.012.

Diabetic mice studies show that the gene therapy restored normal blood glucose levels for an extended period of time, typically around four months. The duration of restored blood glucose levels in mice could translate to decades in humans.

The diabetes gene therapy was developed by Dr. George Gittes, a researcher at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, where preclinical research is ongoing. GPX-002 has been tested in vivo in mice and nonhuman primates. Once sufficient preclinical data has been generated, we expect to begin a Phase I clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes.

To learn more about scientific evidence and studies supporting GPX-002 and the Pdx1/MafA genes, please refer to our Clinical Trials and Pdx1/MafA Bibliography pages.

ONCOPREX® NANOPARTICLE DELIVERY SYSTEM

THE FIRST SYSTEMIC GENE THERAPY DELIVERY PLATFORM USED IN HUMANS FOR CANCER

Our oncology drug development program utilizes our unique, proprietary non-viral ONCOPREX Nanoparticle Delivery System, which we believe is the first systemic gene therapy delivery platform used for cancer in humans. This platform, originally developed through collaborative research between the University of Texas MD Anderson Cancer Center and the National Institutes of Health, has been optimized to work with our initial product candidate, REQORSA® immunogene therapy.

DESIGNED TO DELIVER CANCER-FIGHTING GENES SYSTEMICALLY

The ONCOPREX platform has been designed and optimized to deliver cancer-fighting genes into the patient’s body systemically. Using this system, we encapsulate plasmids that express tumor suppressor genes within lipid nanoparticles and intravenously administer the encapsulated plasmids which are taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in the tumor cells. Our nanoparticles are non-immunogenic, allowing repetitive therapeutic dosing and have been clinically shown to deliver molecular kinase inhibitors effectively.

OPTIMIZED PARTICLE SIZE

Our systemic, nanoparticle, non-viral delivery system, which is being used in our clinical trials for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is designed to be small enough to cross tight barriers in the lungs but large enough to avoid accumulation in the liver, spleen and kidney. The nanoparticles have been shown to be taken up by tumor cells after REQORSA administration at up to 33 times the rate they are taken up by normal cells. The cationic charge of the lipid nanoparticles targets cancer cells, which facilitates endocytosis. Once inside the cancer cell, the TUSC2 gene activates signaling pathways that result in cell destruction or apoptosis.

ENHANCED SAFETY AND EFFICACY DESIGN

We have administered REQORSA to more than 50 patients in Phase 1 and 2 clinical trials using our systemic, proprietary, non-viral delivery system.

A Phase 1 clinical trial showed that systemic, intravenous therapy using the ONCOPREX Nanoparticle Delivery System was shown to selectively and preferentially target primary and metastatic tumor cells, resulting in clinically significant anticancer activity. The nanoparticles are non-immunogenic, allowing repetitive therapeutic dosing and providing extended half-life in the circulation.

Our earlier clinical trials have also shown that the ONCOPREX Nanoparticle Delivery System is well tolerated in humans and can safely deliver high therapeutic doses. We believe the ONC-001 clinical trial was the first systemic gene therapy clinical trial using a nanoparticle delivery system to deliver a tumor suppressor gene.

GENPREX COLLABORATORS REPORT POSITIVE PRECLINICAL DATA WITH NPRL2 GENE THERAPY UTILIZING NON-VIRAL ONCOPREX® NANOPARTICLE DELIVERY SYSTEM IN NON-SMALL CELL LUNG CANCER AT THE 2023 AACR ANNUAL MEETING

APRIL 19, 2023

NPRL2 Gene Therapy Induces Effective Anti-Tumor Activity in Non-Small Cell Lung Cancer Pembrolizumab Resistant Tumors in a Humanized Mouse Model

Provides Preclinical Validation of the ONCOPREX® Nanoparticle Delivery System with a Second Tumor Suppressor Gene

AUSTIN, Texas — (April 19, 2023) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for the NPRL2 gene (also known as the TUSC4 gene). The studies used the Company’s non-viral ONCOPREX® Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (NSCLC) humanized mouse models and were presented at the 2023 American Association of Cancer Research (AACR) annual meeting, which took place from April 14-18, 2023 in Orlando, Florida.

“We are pleased to have these positive data that support the therapeutic potential of our non-viral delivery system, which is being used in our current REQORSA® clinical oncology programs, presented before some of the world’s leading cancer researchers,” said Rodney Varner, President and Chief Executive Officer at Genprex. “The use of the ONCOPREX® Nanoparticle Delivery System to deliver the NPRL2 tumor suppressor gene positions Genprex to expand our clinical pipeline with a new drug candidate.”

“The preclinical data also provide further evidence that the ONCOPREX® Nanoparticle Delivery System has the ability to be successful using genes other than the TUSC2 gene that we are already using in clinical trials with REQORSA®,” stated Varner. “These compelling outcomes give us further confidence in the potentially broad-based application of our non-viral delivery system, which may provide a multitude of potential pipeline opportunities in the future.”

Genprex’s ONCOPREX® Nanoparticle Delivery System, is a novel non-viral approach utilizing lipid nanoparticles to deliver tumor suppressor genes that have been deleted during the course of cancer development. The platform allows for the intravenous delivery of various tumor suppressor genes, and potentially other genes, to achieve a therapeutic affect without the risk of toxicity often associated with viral delivery systems.

Featured Genprex-supported posters presented at AACR 2023 include:

Event: Americal Association of Cancer Research (AACR) Annual Meeting

Session Category: Immunology

Session Title: Combination Immunotherapies 2

Location: Section 22

Session Date and Time: Tuesday, April 18 from 1:30-5:00 p.m. ET

Title: “NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human NSCLC in a humanizedmouse model”

Presenters: Jack A. Roth, MD, The University of Texas MD Anderson Cancer Center

Poster Board Number: 23

Abstract Presentation Number: 5120

The abstract entitled, “NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (NSCLC) in a humanized mouse model,” is available on the AACR website. The presentation reported results from this study, which investigated the antitumor immune responses to NPRL2 gene therapy on anti-PD1 resistant KRAS/STK11 mutant NSCLC in a humanized mouse model. In the study, humanized mice were treated with NPRL2 gene therapy, immunotherapy pembrolizumab (Keytruda®), or the combination. A dramatic antitumor effect was mediated by NPRL2 treatment, whereas pembrolizumab was ineffective. A significant antitumor effect was also found in non-humanized NSG mice, although the antitumor effect was greater in humanized mice, suggesting that the immune response played a role in inducing antitumor activity.

The study data suggest that NPRL2 gene therapy induces antitumor activity on KRAS/STK11 mutant anti-PD1 resistant tumors through DC mediated antigen presentation and cytotoxic immune cell activation.

A KRAS mutation occurs in approximately 25% of patients with NSCLC, and one study found that KRAS/STK11 combination mutations were found in approximately 6.5% of NSCLC patients.

“These data are encouraging because they not only validate Genprex’s non-viral oncology platform to deliver a variety of tumor suppressor genes, but they also provide further evidence of the important role that tumor suppressor genes play in cancer, particularly NSCLC,” said Mark Berger, MD, Chief Medical Officer at Genprex. “KRAS is the most frequent oncogene mutated in NSCLC, and KRAS mutations are often associated with resistance to drug therapy[i]. Targeting KRAS/STK11 mutant NSCLC with the NPRL2 gene, and potentially with anti-PD1 as well, may provide therapeutic potential for this group of lung cancer patients.”

Genprex currently has three clinical trials evaluating the Company’s lead drug candidate, REQORSA® Immunogene Therapy (quaratusugene ozeplasmid) in lung cancer. The Acclaim-1 clinical trial, which received FDA Fast Track Designation, is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA in combination with Tagrisso® (osimertinib) in patients with late-stage NSCLC with activating epidermal growth factor receptor (“EGFR”) mutations whose disease progressed after treatment with Tagrisso. The Acclaim-2 clinical trial, which received FDA Fast Track Designation, is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA in combination with Keytruda® (pembrolizumab) in patients with late-stage NSCLC whose disease progressed after treatment with Keytruda. The Acclaim-3 clinical trial, expected to open for enrollment by the end of the third quarter of 2023, is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA in combination with Tecentriq® (atezolizumab) in patients with extensive-stage small-cell lung cancer (SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as an initial treatment.

INDEPENDENT RESEARCHERS FIND THAT TUSC2, THE GENE DELIVERED BY GENPREX’S REQORSA®, FUNCTIONS AS A NOVEL TUMOR SUPPRESSOR FOR GLIOBLASTOMA

APRIL 18, 2023

Pre-clinical study results show TUSC2 overexpression reduces colony formation, neurosphere formation and promotes apoptosis in vitro, and suppresses tumor growth in vivo

Study adds to the growing body of research examining TUSC2 as a target for multiple other cancers

TUSC2 is the tumor suppressor gene used in the Company’s lead drug candidate, REQORSA® (quaratusugene ozeplasmid)

AUSTIN, Texas — (April 18, 2023) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that independent researchers recently presented preclinical data on the tumor suppressor gene, TUSC2, reporting that it functions as a novel tumor suppressor for glioblastoma. TUSC2 is the tumor suppressor gene that is reexpressed in tumors using REQORSA® Therapy treatment, Genprex’s lead drug candidate. Genprex has no affiliation with these researchers.

The independent researchers presented their abstract, titled, “Investigating TUSC2 for its tumor suppressive functions in glioblastoma and its role in gliomagenesis,” at the 2023 American Association for Cancer Research Annual Meeting on April 17. The abstract reports TUSC2 protein expression, but not mRNA expression, to be significantly decreased in glioblastoma as compared to normal brain. TUSC2 protein is destabilized in glioblastoma due to polyubiquitination by E3 ligase, neural precursor cell-expressed developmentally downregulated gene 4 (NEDD4), and degradation by the proteasome. The researchers determined that NEDD4 targets TUSC2 on lysine residue K71.

The researchers also reported that TUSC2 overexpression reduced colony formation and neurosphere formation and promoted apoptosis of glioblastoma cells in vitro, and suppressed tumor growth in vivo. Further, glioblastoma cells with CRISPR-mediated knockout (KO) of TUSC2 were highly aggressive in vitro and in vivo, demonstrating the role of TUSC2 as a novel tumor suppressor for glioblastoma.

In the study, researchers performed immunoprecipitation-mass spectrometry analysis to identify TUSC2-interacting proteins in both normal human astrocytes and glioblastoma cell lines. Results showed 95 and 88 TUSC2-interacting proteins in astrocytes and glioblastoma cell lines respectively, and 27 proteins were found to interact with TUSC2 in both astrocytes and glioblastoma.

“This research supports the growing body of studies evaluating TUSC2 as a target in oncology, and potentially an effective treatment, for many types of cancer,” said Rodney Varner, Chairman, President and Chief Executive Officer of Genprex. “We are encouraged by the increasing number of research institutions and independent researchers producing positive data on TUSC2, which provide additional support for REQORSA® and its therapeutic potential against cancers.”

REQORSA® Therapy is currently in development for the treatment of non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). REQORSA® consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (the Company’s ONCOPREX® Nanoparticle Delivery System) with a positive electrical charge. REQORSA® is injected intravenously and specifically targets cancer cells, taking advantage of leaky tumor vascularity, increased tumor pinocytosis, and attraction of positively charged lipid nanoparticles to negatively charged cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue.

According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers. More than 13,000 Americans were expected to receive a glioblastoma diagnosis in 2022. Glioblastoma accounts for 49.1 percent of all primary malignant brain tumors. There have only been five drugs and one device ever approved by the U.S. Food and Drug Adminstration for the treatment of glioblastoma.

Other independent researchers and studies have found that TUSC2 therapy may benefit other types of cancer, including head and neck, breast (including triple-negative breast cancer), renal cell (kidney), thyroid, and soft tissue sarcoma, as well as NSCLC and SCLC. For more information and additional studies supporting TUSC2, please refer to our Bibliography Page.

NEWS

GENPREX PUBLISHES POSITIVE CLINICAL DATA FROM PHASE 1 PORTION OF ACCLAIM-1 CLINICAL TRIAL EVALUATING REQORSA® IMMUNOGENE THERAPY IN NON-SMALL CELL LUNG CANCER AT THE 2023 ASCO ANNUAL MEETING

MAY 25, 2023

Results Show Combination of REQORSA® and Tagrisso® was Well Tolerated at All Three Dose Levels of Phase 1 Trial with Encouraging Evidence of Efficacy Observed

Read More


GENPREX UNVEILS NEW VIDEO FEATURING CHIEF MEDICAL OFFICER DISCUSSING POSITIVE PRECLINICAL DATA WITH NPRL2 GENE THERAPY UTILIZING NON-VIRAL ONCOPREX® NANOPARTICLE DELIVERY SYSTEM

MAY 23, 2023

Chief Medical Officer Provides Overview of Preclinical Data Recently Presented at the 2023 American Association of Cancer Research (AACR) annual meeting

Read More


GENPREX TO PARTICIPATE AND PRESENT AT UPCOMING MAY INDUSTRY AND INVESTOR CONFERENCES 

MAY 8, 2023

Presentations to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More

GENPREX COLLABORATORS REPORT POSITIVE PRECLINICAL DATA WITH NPRL2 GENE THERAPY UTILIZING NON-VIRAL ONCOPREX® NANOPARTICLE DELIVERY SYSTEM IN NON-SMALL CELL LUNG CANCER AT THE 2023 AACR ANNUAL MEETING

APRIL 19, 2023

Provides Preclinical Validation of the ONCOPREX® Nanoparticle Delivery System with a Second Tumor Suppressor Gene

Read More


INDEPENDENT RESEARCHERS FIND THAT TUSC2, THE GENE DELIVERED BY GENPREX’S REQORSA®, FUNCTIONS AS A NOVEL TUMOR SUPPRESSOR FOR GLIOBLASTOMA

APRIL 18, 2023

Pre-clinical study results show TUSC2 overexpression reduces colony formation, neurosphere formation and promotes apoptosis in vitro, and suppresses tumor growth in vivo

Read More


GENPREX CEO COMMENDS FDA’S INITIATIVE TO ACCELERATE APPROVAL PROCESS FOR GENE THERAPIES

MARCH 23, 2023

Genprex is advancing its novel gene therapies for large patient populations with cancer and diabetes who currently have limited treatment options

Read More


GENPREX TO PRESENT AT BIOPROCESSING SUMMIT CONFERENCE

MARCH 13, 2023

Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies

Read More


GENPREX TO PARTICIPATE IN MARCH INVESTOR AND INDUSTRY CONFERENCES 

MARCH 8, 2023

Company to Showcase its Innovate Gene Therapy Programs in Oncology and Diabetes

Read More


GENPREX, INC. ANNOUNCES $4 MILLION REGISTERED DIRECT OFFERING WITH A SINGLE, HEALTHCARE-FOCUSED INSTITUTIONAL INVESTOR

FEBRUARY 27, 2023

The gross proceeds from the offering are expected to be approximately $4 million, before deducting placement agent fees and other estimated offering expenses.

Read More


GENPREX ANNOUNCES GROUNDBREAKING DATA FROM NON-HUMAN PRIMATE STUDY EVALUATING NOVEL GENE THERAPY TO TREAT TYPE 1 DIABETES AT 16TH ANNUAL INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES & TREATMENT FOR DIABETES 2023

FEBRUARY 23, 2023

Results show statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance compared to baseline

Read More


GENPREX SIGNS EXCLUSIVE LICENSE TO ADDITIONAL DIABETES TECHNOLOGY WITH THE UNIVERSITY OF PITTSBURGH

JANUARY 5, 2023

Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Millions of Patients Around the World with Type 1 or Type 2 Diabetes

Read More


GENPREX ANNOUNCES SELECTION OF PRECLINICAL DATA FOR ORAL PRESENTATION AT 16TH INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES & TREATMENTS FOR DIABETES 

JANUARY 4, 2023

Exciting Data from University of Pittsburgh Researchers in Non Human Primates that Underpins Genprex’s Gene Therapy Program in Diabetes to be Showcased

Read More

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

DECEMBER 15, 2022

Technology for modulating autoimmunity expands intellectual property portfolio

Read More


GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO PROCEED TO FINAL COHORT IN ACCLAIM-1 PHASE 1 DOSE ESCALATION TRIAL OF REQORSA® IN COMBINATION WITH TAGRISSO® IN ADVANCED NON-SMALL CELL LUNG CANCER

DECEMBER 14, 2022

Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer

Read More


MANAGEMENT

Check out the management team here: https://www.genprex.com/about/company-management/

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, SICA MEDIA LLC  FOR A ONE DAY GNPX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.